CINXE.COM

<!DOCTYPE html> <html class="client-nojs vector-feature-language-in-header-enabled vector-feature-language-in-main-page-header-disabled vector-feature-sticky-header-disabled vector-feature-page-tools-pinned-disabled vector-feature-toc-pinned-clientpref-1 vector-feature-main-menu-pinned-disabled vector-feature-limited-width-clientpref-1 vector-feature-limited-width-content-enabled vector-feature-custom-font-size-clientpref-1 vector-feature-appearance-pinned-clientpref-1 vector-feature-night-mode-enabled skin-theme-clientpref-day vector-toc-available" lang="en" dir="ltr"> <head> <meta charset="UTF-8"> <title>Elagolix - Wikipedia</title> <script>(function(){var className="client-js vector-feature-language-in-header-enabled vector-feature-language-in-main-page-header-disabled vector-feature-sticky-header-disabled vector-feature-page-tools-pinned-disabled vector-feature-toc-pinned-clientpref-1 vector-feature-main-menu-pinned-disabled vector-feature-limited-width-clientpref-1 vector-feature-limited-width-content-enabled vector-feature-custom-font-size-clientpref-1 vector-feature-appearance-pinned-clientpref-1 vector-feature-night-mode-enabled skin-theme-clientpref-day vector-toc-available";var cookie=document.cookie.match(/(?:^|; )enwikimwclientpreferences=([^;]+)/);if(cookie){cookie[1].split('%2C').forEach(function(pref){className=className.replace(new RegExp('(^| )'+pref.replace(/-clientpref-\w+$|[^\w-]+/g,'')+'-clientpref-\\w+( |$)'),'$1'+pref+'$2');});}document.documentElement.className=className;}());RLCONF={"wgBreakFrames":false,"wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"dmy", "wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgRequestId":"7fbd7157-a0a1-4c14-9fc0-5118106c8e7f","wgCanonicalNamespace":"","wgCanonicalSpecialPageName":false,"wgNamespaceNumber":0,"wgPageName":"Elagolix","wgTitle":"Elagolix","wgCurRevisionId":1257903058,"wgRevisionId":1257903058,"wgArticleId":48187627,"wgIsArticle":true,"wgIsRedirect":false,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Webarchive template wayback links","Articles with short description","Short description matches Wikidata","ECHA InfoCard ID from Wikidata","Multiple chemicals in Infobox drug","Chemicals using indexlabels","Chemical articles with multiple CAS registry numbers","Articles containing unverified chemical infoboxes","All articles with unsourced statements","Articles with unsourced statements from February 2019","Articles containing potentially dated statements from November 2018", "All articles containing potentially dated statements","Drugs developed by AbbVie","Amines","CYP3A4 inducers","Ethers","Fluoroarenes","GnRH antagonists","Lactams","Pyrimidinediones","Trifluoromethyl compounds","Triketones","Uracil derivatives"],"wgPageViewLanguage":"en","wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgRelevantPageName":"Elagolix","wgRelevantArticleId":48187627,"wgIsProbablyEditable":true,"wgRelevantPageIsProbablyEditable":true,"wgRestrictionEdit":[],"wgRestrictionMove":[],"wgNoticeProject":"wikipedia","wgCiteReferencePreviewsActive":false,"wgFlaggedRevsParams":{"tags":{"status":{"levels":1}}},"wgMediaViewerOnClick":true,"wgMediaViewerEnabledByDefault":true,"wgPopupsFlags":0,"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","pageVariantFallbacks":"en"},"wgMFDisplayWikibaseDescriptions":{"search":true,"watchlist":true,"tagline":false,"nearby":true},"wgWMESchemaEditAttemptStepOversample":false,"wgWMEPageLength":70000, "wgRelatedArticlesCompat":[],"wgCentralAuthMobileDomain":false,"wgEditSubmitButtonLabelPublish":true,"wgULSPosition":"interlanguage","wgULSisCompactLinksEnabled":false,"wgVector2022LanguageInHeader":true,"wgULSisLanguageSelectorEmpty":false,"wgWikibaseItemId":"Q21098999","wgCheckUserClientHintsHeadersJsApi":["brands","architecture","bitness","fullVersionList","mobile","model","platform","platformVersion"],"GEHomepageSuggestedEditsEnableTopics":true,"wgGETopicsMatchModeEnabled":false,"wgGEStructuredTaskRejectionReasonTextInputEnabled":false,"wgGELevelingUpEnabledForUser":false};RLSTATE={"ext.globalCssJs.user.styles":"ready","site.styles":"ready","user.styles":"ready","ext.globalCssJs.user":"ready","user":"ready","user.options":"loading","ext.cite.styles":"ready","skins.vector.search.codex.styles":"ready","skins.vector.styles":"ready","skins.vector.icons":"ready","jquery.makeCollapsible.styles":"ready","ext.wikimediamessages.styles":"ready", "ext.visualEditor.desktopArticleTarget.noscript":"ready","ext.uls.interlanguage":"ready","wikibase.client.init":"ready","ext.wikimediaBadges":"ready"};RLPAGEMODULES=["ext.cite.ux-enhancements","mediawiki.page.media","site","mediawiki.page.ready","jquery.makeCollapsible","mediawiki.toc","skins.vector.js","ext.centralNotice.geoIP","ext.centralNotice.startUp","ext.gadget.ReferenceTooltips","ext.gadget.switcher","ext.urlShortener.toolbar","ext.centralauth.centralautologin","mmv.bootstrap","ext.popups","ext.visualEditor.desktopArticleTarget.init","ext.visualEditor.targetLoader","ext.echo.centralauth","ext.eventLogging","ext.wikimediaEvents","ext.navigationTiming","ext.uls.interface","ext.cx.eventlogging.campaigns","ext.cx.uls.quick.actions","wikibase.client.vector-2022","ext.checkUser.clientHints","ext.growthExperiments.SuggestedEditSession","wikibase.sidebar.tracking"];</script> <script>(RLQ=window.RLQ||[]).push(function(){mw.loader.impl(function(){return["user.options@12s5i",function($,jQuery,require,module){mw.user.tokens.set({"patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"}); }];});});</script> <link rel="stylesheet" href="/w/load.php?lang=en&modules=ext.cite.styles%7Cext.uls.interlanguage%7Cext.visualEditor.desktopArticleTarget.noscript%7Cext.wikimediaBadges%7Cext.wikimediamessages.styles%7Cjquery.makeCollapsible.styles%7Cskins.vector.icons%2Cstyles%7Cskins.vector.search.codex.styles%7Cwikibase.client.init&only=styles&skin=vector-2022"> <script async="" src="/w/load.php?lang=en&modules=startup&only=scripts&raw=1&skin=vector-2022"></script> <meta name="ResourceLoaderDynamicStyles" content=""> <link rel="stylesheet" href="/w/load.php?lang=en&modules=site.styles&only=styles&skin=vector-2022"> <meta name="generator" content="MediaWiki 1.44.0-wmf.4"> <meta name="referrer" content="origin"> <meta name="referrer" content="origin-when-cross-origin"> <meta name="robots" content="max-image-preview:standard"> <meta name="format-detection" content="telephone=no"> <meta property="og:image" content="https://upload.wikimedia.org/wikipedia/commons/thumb/6/67/Elagolix.svg/1200px-Elagolix.svg.png"> <meta property="og:image:width" content="1200"> <meta property="og:image:height" content="907"> <meta property="og:image" content="https://upload.wikimedia.org/wikipedia/commons/thumb/6/67/Elagolix.svg/800px-Elagolix.svg.png"> <meta property="og:image:width" content="800"> <meta property="og:image:height" content="605"> <meta property="og:image" content="https://upload.wikimedia.org/wikipedia/commons/thumb/6/67/Elagolix.svg/640px-Elagolix.svg.png"> <meta property="og:image:width" content="640"> <meta property="og:image:height" content="484"> <meta name="viewport" content="width=1120"> <meta property="og:title" content="Elagolix - Wikipedia"> <meta property="og:type" content="website"> <link rel="preconnect" href="//upload.wikimedia.org"> <link rel="alternate" media="only screen and (max-width: 640px)" href="//en.m.wikipedia.org/wiki/Elagolix"> <link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Elagolix&action=edit"> <link rel="apple-touch-icon" href="/static/apple-touch/wikipedia.png"> <link rel="icon" href="/static/favicon/wikipedia.ico"> <link rel="search" type="application/opensearchdescription+xml" href="/w/rest.php/v1/search" title="Wikipedia (en)"> <link rel="EditURI" type="application/rsd+xml" href="//en.wikipedia.org/w/api.php?action=rsd"> <link rel="canonical" href="https://en.wikipedia.org/wiki/Elagolix"> <link rel="license" href="https://creativecommons.org/licenses/by-sa/4.0/deed.en"> <link rel="alternate" type="application/atom+xml" title="Wikipedia Atom feed" href="/w/index.php?title=Special:RecentChanges&feed=atom"> <link rel="dns-prefetch" href="//meta.wikimedia.org" /> <link rel="dns-prefetch" href="//login.wikimedia.org"> </head> <body class="skin--responsive skin-vector skin-vector-search-vue mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject mw-editable page-Elagolix rootpage-Elagolix skin-vector-2022 action-view"><a class="mw-jump-link" href="#bodyContent">Jump to content</a> <div class="vector-header-container"> <header class="vector-header mw-header"> <div class="vector-header-start"> <nav class="vector-main-menu-landmark" aria-label="Site"> <div id="vector-main-menu-dropdown" class="vector-dropdown vector-main-menu-dropdown vector-button-flush-left vector-button-flush-right" > <input type="checkbox" id="vector-main-menu-dropdown-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-main-menu-dropdown" class="vector-dropdown-checkbox " aria-label="Main menu" > <label id="vector-main-menu-dropdown-label" for="vector-main-menu-dropdown-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only " aria-hidden="true" > Main menu </label> <div class="vector-dropdown-content"> <div id="vector-main-menu-unpinned-container" class="vector-unpinned-container"> <div id="vector-main-menu" class="vector-main-menu vector-pinnable-element"> <div class="vector-pinnable-header vector-main-menu-pinnable-header vector-pinnable-header-unpinned" data-feature-name="main-menu-pinned" data-pinnable-element-id="vector-main-menu" data-pinned-container-id="vector-main-menu-pinned-container" data-unpinned-container-id="vector-main-menu-unpinned-container" > <div class="vector-pinnable-header-label">Main menu</div> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-pin-button" data-event-name="pinnable-header.vector-main-menu.pin">move to sidebar</button> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-unpin-button" data-event-name="pinnable-header.vector-main-menu.unpin">hide</button> </div> <div id="p-navigation" class="vector-menu mw-portlet mw-portlet-navigation" > <div class="vector-menu-heading"> Navigation </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="n-mainpage-description" class="mw-list-item"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z">Main page</a></li><li id="n-contents" class="mw-list-item"><a href="/wiki/Wikipedia:Contents" title="Guides to browsing Wikipedia">Contents</a></li><li id="n-currentevents" class="mw-list-item"><a href="/wiki/Portal:Current_events" title="Articles related to current events">Current events</a></li><li id="n-randompage" class="mw-list-item"><a href="/wiki/Special:Random" title="Visit a randomly selected article [x]" accesskey="x">Random article</a></li><li id="n-aboutsite" class="mw-list-item"><a href="/wiki/Wikipedia:About" title="Learn about Wikipedia and how it works">About Wikipedia</a></li><li id="n-contactpage" class="mw-list-item"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us" title="How to contact Wikipedia">Contact us</a></li> </ul> </div> </div> <div id="p-interaction" class="vector-menu mw-portlet mw-portlet-interaction" > <div class="vector-menu-heading"> Contribute </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="n-help" class="mw-list-item"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia">Help</a></li><li id="n-introduction" class="mw-list-item"><a href="/wiki/Help:Introduction" title="Learn how to edit Wikipedia">Learn to edit</a></li><li id="n-portal" class="mw-list-item"><a href="/wiki/Wikipedia:Community_portal" title="The hub for editors">Community portal</a></li><li id="n-recentchanges" class="mw-list-item"><a href="/wiki/Special:RecentChanges" title="A list of recent changes to Wikipedia [r]" accesskey="r">Recent changes</a></li><li id="n-upload" class="mw-list-item"><a href="/wiki/Wikipedia:File_upload_wizard" title="Add images or other media for use on Wikipedia">Upload file</a></li> </ul> </div> </div> </div> </div> </div> </div> </nav> <a href="/wiki/Main_Page" class="mw-logo"> <img class="mw-logo-icon" src="/static/images/icons/wikipedia.png" alt="" aria-hidden="true" height="50" width="50"> <img class="mw-logo-wordmark" alt="Wikipedia" src="/static/images/mobile/copyright/wikipedia-wordmark-en.svg" style="width: 7.5em; height: 1.125em;"> <img class="mw-logo-tagline" alt="The Free Encyclopedia" src="/static/images/mobile/copyright/wikipedia-tagline-en.svg" width="117" height="13" style="width: 7.3125em; height: 0.8125em;"> </a> </div> <div class="vector-header-end"> <div id="p-search" role="search" class="vector-search-box-vue vector-search-box-collapses vector-search-box-show-thumbnail vector-search-box-auto-expand-width vector-search-box"> <a href="/wiki/Special:Search" class="cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only search-toggle" title="Search Wikipedia [f]" accesskey="f"> Search </a> <div class="vector-typeahead-search-container"> <div class="cdx-typeahead-search cdx-typeahead-search--show-thumbnail cdx-typeahead-search--auto-expand-width"> <form action="/w/index.php" id="searchform" class="cdx-search-input cdx-search-input--has-end-button"> <div id="simpleSearch" class="cdx-search-input__input-wrapper" data-search-loc="header-moved"> <div class="cdx-text-input cdx-text-input--has-start-icon"> <input class="cdx-text-input__input" type="search" name="search" placeholder="Search Wikipedia" aria-label="Search Wikipedia" autocapitalize="sentences" title="Search Wikipedia [f]" accesskey="f" id="searchInput" > </div> <input type="hidden" name="title" value="Special:Search"> </div> <button class="cdx-button cdx-search-input__end-button">Search</button> </form> </div> </div> </div> <nav class="vector-user-links vector-user-links-wide" aria-label="Personal tools"> <div class="vector-user-links-main"> <div id="p-vector-user-menu-preferences" class="vector-menu mw-portlet emptyPortlet" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> </ul> </div> </div> <div id="p-vector-user-menu-userpage" class="vector-menu mw-portlet emptyPortlet" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> </ul> </div> </div> <nav class="vector-appearance-landmark" aria-label="Appearance"> <div id="vector-appearance-dropdown" class="vector-dropdown " title="Change the appearance of the page's font size, width, and color" > <input type="checkbox" id="vector-appearance-dropdown-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-appearance-dropdown" class="vector-dropdown-checkbox " aria-label="Appearance" > <label id="vector-appearance-dropdown-label" for="vector-appearance-dropdown-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only " aria-hidden="true" > Appearance </label> <div class="vector-dropdown-content"> <div id="vector-appearance-unpinned-container" class="vector-unpinned-container"> </div> </div> </div> </nav> <div id="p-vector-user-menu-notifications" class="vector-menu mw-portlet emptyPortlet" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> </ul> </div> </div> <div id="p-vector-user-menu-overflow" class="vector-menu mw-portlet" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="pt-sitesupport-2" class="user-links-collapsible-item mw-list-item user-links-collapsible-item"><a data-mw="interface" href="https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&utm_medium=sidebar&utm_campaign=C13_en.wikipedia.org&uselang=en" class="">Donate</a> </li> <li id="pt-createaccount-2" class="user-links-collapsible-item mw-list-item user-links-collapsible-item"><a data-mw="interface" href="/w/index.php?title=Special:CreateAccount&returnto=Elagolix" title="You are encouraged to create an account and log in; however, it is not mandatory" class="">Create account</a> </li> <li id="pt-login-2" class="user-links-collapsible-item mw-list-item user-links-collapsible-item"><a data-mw="interface" href="/w/index.php?title=Special:UserLogin&returnto=Elagolix" title="You're encouraged to log in; however, it's not mandatory. [o]" accesskey="o" class="">Log in</a> </li> </ul> </div> </div> </div> <div id="vector-user-links-dropdown" class="vector-dropdown vector-user-menu vector-button-flush-right vector-user-menu-logged-out" title="Log in and more options" > <input type="checkbox" id="vector-user-links-dropdown-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-user-links-dropdown" class="vector-dropdown-checkbox " aria-label="Personal tools" > <label id="vector-user-links-dropdown-label" for="vector-user-links-dropdown-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only " aria-hidden="true" > Personal tools </label> <div class="vector-dropdown-content"> <div id="p-personal" class="vector-menu mw-portlet mw-portlet-personal user-links-collapsible-item" title="User menu" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="pt-sitesupport" class="user-links-collapsible-item mw-list-item"><a href="https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&utm_medium=sidebar&utm_campaign=C13_en.wikipedia.org&uselang=en">Donate</a></li><li id="pt-createaccount" class="user-links-collapsible-item mw-list-item"><a href="/w/index.php?title=Special:CreateAccount&returnto=Elagolix" title="You are encouraged to create an account and log in; however, it is not mandatory"> Create account</a></li><li id="pt-login" class="user-links-collapsible-item mw-list-item"><a href="/w/index.php?title=Special:UserLogin&returnto=Elagolix" title="You're encouraged to log in; however, it's not mandatory. [o]" accesskey="o"> Log in</a></li> </ul> </div> </div> <div id="p-user-menu-anon-editor" class="vector-menu mw-portlet mw-portlet-user-menu-anon-editor" > <div class="vector-menu-heading"> Pages for logged out editors <a href="/wiki/Help:Introduction" aria-label="Learn more about editing">learn more</a> </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="pt-anoncontribs" class="mw-list-item"><a href="/wiki/Special:MyContributions" title="A list of edits made from this IP address [y]" accesskey="y">Contributions</a></li><li id="pt-anontalk" class="mw-list-item"><a href="/wiki/Special:MyTalk" title="Discussion about edits from this IP address [n]" accesskey="n">Talk</a></li> </ul> </div> </div> </div> </div> </nav> </div> </header> </div> <div class="mw-page-container"> <div class="mw-page-container-inner"> <div class="vector-sitenotice-container"> <div id="siteNotice"></div> </div> <div class="vector-column-start"> <div class="vector-main-menu-container"> <div id="mw-navigation"> <nav id="mw-panel" class="vector-main-menu-landmark" aria-label="Site"> <div id="vector-main-menu-pinned-container" class="vector-pinned-container"> </div> </nav> </div> </div> <div class="vector-sticky-pinned-container"> <nav id="mw-panel-toc" aria-label="Contents" data-event-name="ui.sidebar-toc" class="mw-table-of-contents-container vector-toc-landmark"> <div id="vector-toc-pinned-container" class="vector-pinned-container"> <div id="vector-toc" class="vector-toc vector-pinnable-element"> <div class="vector-pinnable-header vector-toc-pinnable-header vector-pinnable-header-pinned" data-feature-name="toc-pinned" data-pinnable-element-id="vector-toc" > <h2 class="vector-pinnable-header-label">Contents</h2> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-pin-button" data-event-name="pinnable-header.vector-toc.pin">move to sidebar</button> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-unpin-button" data-event-name="pinnable-header.vector-toc.unpin">hide</button> </div> <ul class="vector-toc-contents" id="mw-panel-toc-list"> <li id="toc-mw-content-text" class="vector-toc-list-item vector-toc-level-1"> <a href="#" class="vector-toc-link"> <div class="vector-toc-text">(Top)</div> </a> </li> <li id="toc-Medical_uses" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Medical_uses"> <div class="vector-toc-text"> 1 Medical uses </div> </a> <button aria-controls="toc-Medical_uses-sublist" class="cdx-button cdx-button--weight-quiet cdx-button--icon-only vector-toc-toggle"> Toggle Medical uses subsection </button> <ul id="toc-Medical_uses-sublist" class="vector-toc-list"> <li id="toc-Available_forms" class="vector-toc-list-item vector-toc-level-2"> <a class="vector-toc-link" href="#Available_forms"> <div class="vector-toc-text"> 1.1 Available forms </div> </a> <ul id="toc-Available_forms-sublist" class="vector-toc-list"> </ul> </li> </ul> </li> <li id="toc-Contraindications" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Contraindications"> <div class="vector-toc-text"> 2 Contraindications </div> </a> <ul id="toc-Contraindications-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Side_effects" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Side_effects"> <div class="vector-toc-text"> 3 Side effects </div> </a> <ul id="toc-Side_effects-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Overdose" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Overdose"> <div class="vector-toc-text"> 4 Overdose </div> </a> <ul id="toc-Overdose-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Interactions" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Interactions"> <div class="vector-toc-text"> 5 Interactions </div> </a> <ul id="toc-Interactions-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Pharmacology" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Pharmacology"> <div class="vector-toc-text"> 6 Pharmacology </div> </a> <button aria-controls="toc-Pharmacology-sublist" class="cdx-button cdx-button--weight-quiet cdx-button--icon-only vector-toc-toggle"> Toggle Pharmacology subsection </button> <ul id="toc-Pharmacology-sublist" class="vector-toc-list"> <li id="toc-Pharmacodynamics" class="vector-toc-list-item vector-toc-level-2"> <a class="vector-toc-link" href="#Pharmacodynamics"> <div class="vector-toc-text"> 6.1 Pharmacodynamics </div> </a> <ul id="toc-Pharmacodynamics-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Pharmacokinetics" class="vector-toc-list-item vector-toc-level-2"> <a class="vector-toc-link" href="#Pharmacokinetics"> <div class="vector-toc-text"> 6.2 Pharmacokinetics </div> </a> <ul id="toc-Pharmacokinetics-sublist" class="vector-toc-list"> </ul> </li> </ul> </li> <li id="toc-Chemistry" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Chemistry"> <div class="vector-toc-text"> 7 Chemistry </div> </a> <ul id="toc-Chemistry-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-History" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#History"> <div class="vector-toc-text"> 8 History </div> </a> <ul id="toc-History-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Society_and_culture" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Society_and_culture"> <div class="vector-toc-text"> 9 Society and culture </div> </a> <button aria-controls="toc-Society_and_culture-sublist" class="cdx-button cdx-button--weight-quiet cdx-button--icon-only vector-toc-toggle"> Toggle Society and culture subsection </button> <ul id="toc-Society_and_culture-sublist" class="vector-toc-list"> <li id="toc-Generic_names" class="vector-toc-list-item vector-toc-level-2"> <a class="vector-toc-link" href="#Generic_names"> <div class="vector-toc-text"> 9.1 Generic names </div> </a> <ul id="toc-Generic_names-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Brand_names" class="vector-toc-list-item vector-toc-level-2"> <a class="vector-toc-link" href="#Brand_names"> <div class="vector-toc-text"> 9.2 Brand names </div> </a> <ul id="toc-Brand_names-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Availability" class="vector-toc-list-item vector-toc-level-2"> <a class="vector-toc-link" href="#Availability"> <div class="vector-toc-text"> 9.3 Availability </div> </a> <ul id="toc-Availability-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Economics" class="vector-toc-list-item vector-toc-level-2"> <a class="vector-toc-link" href="#Economics"> <div class="vector-toc-text"> 9.4 Economics </div> </a> <ul id="toc-Economics-sublist" class="vector-toc-list"> </ul> </li> </ul> </li> <li id="toc-Research" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Research"> <div class="vector-toc-text"> 10 Research </div> </a> <ul id="toc-Research-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-References" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#References"> <div class="vector-toc-text"> 11 References </div> </a> <ul id="toc-References-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Further_reading" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Further_reading"> <div class="vector-toc-text"> 12 Further reading </div> </a> <ul id="toc-Further_reading-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-External_links" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#External_links"> <div class="vector-toc-text"> 13 External links </div> </a> <ul id="toc-External_links-sublist" class="vector-toc-list"> </ul> </li> </ul> </div> </div> </nav> </div> </div> <div class="mw-content-container"> <main id="content" class="mw-body"> <header class="mw-body-header vector-page-titlebar"> <nav aria-label="Contents" class="vector-toc-landmark"> <div id="vector-page-titlebar-toc" class="vector-dropdown vector-page-titlebar-toc vector-button-flush-left" > <input type="checkbox" id="vector-page-titlebar-toc-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-page-titlebar-toc" class="vector-dropdown-checkbox " aria-label="Toggle the table of contents" > <label id="vector-page-titlebar-toc-label" for="vector-page-titlebar-toc-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only " aria-hidden="true" > Toggle the table of contents </label> <div class="vector-dropdown-content"> <div id="vector-page-titlebar-toc-unpinned-container" class="vector-unpinned-container"> </div> </div> </div> </nav> <h1 id="firstHeading" class="firstHeading mw-first-heading">Elagolix</h1> <div id="p-lang-btn" class="vector-dropdown mw-portlet mw-portlet-lang" > <input type="checkbox" id="p-lang-btn-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-p-lang-btn" class="vector-dropdown-checkbox mw-interlanguage-selector" aria-label="Go to an article in another language. Available in 2 languages" > <label id="p-lang-btn-label" for="p-lang-btn-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--action-progressive mw-portlet-lang-heading-2" aria-hidden="true" > 2 languages </label> <div class="vector-dropdown-content"> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li class="interlanguage-link interwiki-fr mw-list-item"><a href="https://fr.wikipedia.org/wiki/Elagolix" title="Elagolix – French" lang="fr" hreflang="fr" data-title="Elagolix" data-language-autonym="Français" data-language-local-name="French" class="interlanguage-link-target">Français</a></li><li class="interlanguage-link interwiki-tr mw-list-item"><a href="https://tr.wikipedia.org/wiki/Elagoliks" title="Elagoliks – Turkish" lang="tr" hreflang="tr" data-title="Elagoliks" data-language-autonym="Türkçe" data-language-local-name="Turkish" class="interlanguage-link-target">Türkçe</a></li> </ul> <div class="after-portlet after-portlet-lang"><a href="https://www.wikidata.org/wiki/Special:EntityPage/Q21098999#sitelinks-wikipedia" title="Edit interlanguage links" class="wbc-editpage">Edit links</a></div> </div> </div> </div> </header> <div class="vector-page-toolbar"> <div class="vector-page-toolbar-container"> <div id="left-navigation"> <nav aria-label="Namespaces"> <div id="p-associated-pages" class="vector-menu vector-menu-tabs mw-portlet mw-portlet-associated-pages" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="ca-nstab-main" class="selected vector-tab-noicon mw-list-item"><a href="/wiki/Elagolix" title="View the content page [c]" accesskey="c">Article</a></li><li id="ca-talk" class="vector-tab-noicon mw-list-item"><a href="/wiki/Talk:Elagolix" rel="discussion" title="Discuss improvements to the content page [t]" accesskey="t">Talk</a></li> </ul> </div> </div> <div id="vector-variants-dropdown" class="vector-dropdown emptyPortlet" > <input type="checkbox" id="vector-variants-dropdown-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-variants-dropdown" class="vector-dropdown-checkbox " aria-label="Change language variant" > <label id="vector-variants-dropdown-label" for="vector-variants-dropdown-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet" aria-hidden="true" >English </label> <div class="vector-dropdown-content"> <div id="p-variants" class="vector-menu mw-portlet mw-portlet-variants emptyPortlet" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> </ul> </div> </div> </div> </div> </nav> </div> <div id="right-navigation" class="vector-collapsible"> <nav aria-label="Views"> <div id="p-views" class="vector-menu vector-menu-tabs mw-portlet mw-portlet-views" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="ca-view" class="selected vector-tab-noicon mw-list-item"><a href="/wiki/Elagolix">Read</a></li><li id="ca-edit" class="vector-tab-noicon mw-list-item"><a href="/w/index.php?title=Elagolix&action=edit" title="Edit this page [e]" accesskey="e">Edit</a></li><li id="ca-history" class="vector-tab-noicon mw-list-item"><a href="/w/index.php?title=Elagolix&action=history" title="Past revisions of this page [h]" accesskey="h">View history</a></li> </ul> </div> </div> </nav> <nav class="vector-page-tools-landmark" aria-label="Page tools"> <div id="vector-page-tools-dropdown" class="vector-dropdown vector-page-tools-dropdown" > <input type="checkbox" id="vector-page-tools-dropdown-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-page-tools-dropdown" class="vector-dropdown-checkbox " aria-label="Tools" > <label id="vector-page-tools-dropdown-label" for="vector-page-tools-dropdown-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet" aria-hidden="true" >Tools </label> <div class="vector-dropdown-content"> <div id="vector-page-tools-unpinned-container" class="vector-unpinned-container"> <div id="vector-page-tools" class="vector-page-tools vector-pinnable-element"> <div class="vector-pinnable-header vector-page-tools-pinnable-header vector-pinnable-header-unpinned" data-feature-name="page-tools-pinned" data-pinnable-element-id="vector-page-tools" data-pinned-container-id="vector-page-tools-pinned-container" data-unpinned-container-id="vector-page-tools-unpinned-container" > <div class="vector-pinnable-header-label">Tools</div> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-pin-button" data-event-name="pinnable-header.vector-page-tools.pin">move to sidebar</button> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-unpin-button" data-event-name="pinnable-header.vector-page-tools.unpin">hide</button> </div> <div id="p-cactions" class="vector-menu mw-portlet mw-portlet-cactions emptyPortlet vector-has-collapsible-items" title="More options" > <div class="vector-menu-heading"> Actions </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="ca-more-view" class="selected vector-more-collapsible-item mw-list-item"><a href="/wiki/Elagolix">Read</a></li><li id="ca-more-edit" class="vector-more-collapsible-item mw-list-item"><a href="/w/index.php?title=Elagolix&action=edit" title="Edit this page [e]" accesskey="e">Edit</a></li><li id="ca-more-history" class="vector-more-collapsible-item mw-list-item"><a href="/w/index.php?title=Elagolix&action=history">View history</a></li> </ul> </div> </div> <div id="p-tb" class="vector-menu mw-portlet mw-portlet-tb" > <div class="vector-menu-heading"> General </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="t-whatlinkshere" class="mw-list-item"><a href="/wiki/Special:WhatLinksHere/Elagolix" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j">What links here</a></li><li id="t-recentchangeslinked" class="mw-list-item"><a href="/wiki/Special:RecentChangesLinked/Elagolix" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</a></li><li id="t-upload" class="mw-list-item"><a href="/wiki/Wikipedia:File_Upload_Wizard" title="Upload files [u]" accesskey="u">Upload file</a></li><li id="t-specialpages" class="mw-list-item"><a href="/wiki/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q">Special pages</a></li><li id="t-permalink" class="mw-list-item"><a href="/w/index.php?title=Elagolix&oldid=1257903058" title="Permanent link to this revision of this page">Permanent link</a></li><li id="t-info" class="mw-list-item"><a href="/w/index.php?title=Elagolix&action=info" title="More information about this page">Page information</a></li><li id="t-cite" class="mw-list-item"><a href="/w/index.php?title=Special:CiteThisPage&page=Elagolix&id=1257903058&wpFormIdentifier=titleform" title="Information on how to cite this page">Cite this page</a></li><li id="t-urlshortener" class="mw-list-item"><a href="/w/index.php?title=Special:UrlShortener&url=https%3A%2F%2Fen.wikipedia.org%2Fwiki%2FElagolix">Get shortened URL</a></li><li id="t-urlshortener-qrcode" class="mw-list-item"><a href="/w/index.php?title=Special:QrCode&url=https%3A%2F%2Fen.wikipedia.org%2Fwiki%2FElagolix">Download QR code</a></li> </ul> </div> </div> <div id="p-coll-print_export" class="vector-menu mw-portlet mw-portlet-coll-print_export" > <div class="vector-menu-heading"> Print/export </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="coll-download-as-rl" class="mw-list-item"><a href="/w/index.php?title=Special:DownloadAsPdf&page=Elagolix&action=show-download-screen" title="Download this page as a PDF file">Download as PDF</a></li><li id="t-print" class="mw-list-item"><a href="/w/index.php?title=Elagolix&printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</a></li> </ul> </div> </div> <div id="p-wikibase-otherprojects" class="vector-menu mw-portlet mw-portlet-wikibase-otherprojects" > <div class="vector-menu-heading"> In other projects </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li class="wb-otherproject-link wb-otherproject-commons mw-list-item"><a href="https://commons.wikimedia.org/wiki/Category:Elagolix" hreflang="en">Wikimedia Commons</a></li><li id="t-wikibase" class="wb-otherproject-link wb-otherproject-wikibase-dataitem mw-list-item"><a href="https://www.wikidata.org/wiki/Special:EntityPage/Q21098999" title="Structured data on this page hosted by Wikidata [g]" accesskey="g">Wikidata item</a></li> </ul> </div> </div> </div> </div> </div> </div> </nav> </div> </div> </div> <div class="vector-column-end"> <div class="vector-sticky-pinned-container"> <nav class="vector-page-tools-landmark" aria-label="Page tools"> <div id="vector-page-tools-pinned-container" class="vector-pinned-container"> </div> </nav> <nav class="vector-appearance-landmark" aria-label="Appearance"> <div id="vector-appearance-pinned-container" class="vector-pinned-container"> <div id="vector-appearance" class="vector-appearance vector-pinnable-element"> <div class="vector-pinnable-header vector-appearance-pinnable-header vector-pinnable-header-pinned" data-feature-name="appearance-pinned" data-pinnable-element-id="vector-appearance" data-pinned-container-id="vector-appearance-pinned-container" data-unpinned-container-id="vector-appearance-unpinned-container" > <div class="vector-pinnable-header-label">Appearance</div> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-pin-button" data-event-name="pinnable-header.vector-appearance.pin">move to sidebar</button> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-unpin-button" data-event-name="pinnable-header.vector-appearance.unpin">hide</button> </div> </div> </div> </nav> </div> </div> <div id="bodyContent" class="vector-body" aria-labelledby="firstHeading" data-mw-ve-target-container> <div class="vector-body-before-content"> <div class="mw-indicators"> </div> <div id="siteSub" class="noprint">From Wikipedia, the free encyclopedia</div> </div> <div id="contentSub"><div id="mw-content-subtitle"></div></div> <div id="mw-content-text" class="mw-body-content"><div class="mw-content-ltr mw-parser-output" lang="en" dir="ltr"><div class="shortdescription nomobile noexcerpt noprint searchaux" style="display:none">Chemical compound</div> <style data-mw-deduplicate="TemplateStyles:r1257001546">.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}@media screen{html.skin-theme-clientpref-night .mw-parser-output .infobox-full-data:not(.notheme)>div:not(.notheme)[style]{background:#1f1f23!important;color:#f8f9fa}}@media screen and (prefers-color-scheme:dark){html.skin-theme-clientpref-os .mw-parser-output .infobox-full-data:not(.notheme) div:not(.notheme){background:#1f1f23!important;color:#f8f9fa}}@media(min-width:640px){body.skin--responsive .mw-parser-output .infobox-table{display:table!important}body.skin--responsive .mw-parser-output .infobox-table>caption{display:table-caption!important}body.skin--responsive .mw-parser-output .infobox-table>tbody{display:table-row-group}body.skin--responsive .mw-parser-output .infobox-table tr{display:table-row!important}body.skin--responsive .mw-parser-output .infobox-table th,body.skin--responsive .mw-parser-output .infobox-table td{padding-left:inherit;padding-right:inherit}}</style><table class="infobox" style="border-spacing:2px;"><caption class="infobox-title">Elagolix</caption><tbody><tr><td colspan="2" class="infobox-image notheme" style="background-color: #f8f9fa;"><a href="/wiki/File:Elagolix.svg" class="mw-file-description"><img src="//upload.wikimedia.org/wikipedia/commons/thumb/6/67/Elagolix.svg/250px-Elagolix.svg.png" decoding="async" width="250" height="189" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/6/67/Elagolix.svg/375px-Elagolix.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/67/Elagolix.svg/500px-Elagolix.svg.png 2x" data-file-width="512" data-file-height="387" /></a></td></tr><tr><td colspan="2" class="infobox-image notheme" style="background-color: #f8f9fa;"><a href="/wiki/File:Elagolix_molecule_ball.png" class="mw-file-description"><img src="//upload.wikimedia.org/wikipedia/commons/thumb/d/d9/Elagolix_molecule_ball.png/250px-Elagolix_molecule_ball.png" decoding="async" width="250" height="248" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/d/d9/Elagolix_molecule_ball.png/375px-Elagolix_molecule_ball.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/d/d9/Elagolix_molecule_ball.png/500px-Elagolix_molecule_ball.png 2x" data-file-width="2000" data-file-height="1980" /></a></td></tr><tr><th colspan="2" class="infobox-header" style="background:#ddd">Clinical data</th></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;">Pronunciation</th><td class="infobox-data"><a href="/wiki/Help:IPA/English" title="Help:IPA/English">/ˌɛləˈɡoʊlɪks/</a> <a href="/wiki/Help:Pronunciation_respelling_key" title="Help:Pronunciation respelling key">EL-ə-GOH-liks</a> </td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Drug_nomenclature#Trade_names" title="Drug nomenclature">Trade names</a></th><td class="infobox-data">Orilissa, Oriahnn</td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;">Other names</th><td class="infobox-data">NBI-56418, ABT-620</td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/American_Society_of_Health-System_Pharmacists" title="American Society of Health-System Pharmacists">AHFS</a>/<a href="/wiki/Drugs.com" title="Drugs.com">Drugs.com</a></th><td class="infobox-data"><a rel="nofollow" class="external text" href="https://www.drugs.com/monograph/elagolix-sodium.html">Monograph</a></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/MedlinePlus" title="MedlinePlus">MedlinePlus</a></th><td class="infobox-data"><a rel="nofollow" class="external text" href="https://medlineplus.gov/druginfo/meds/a618044.html">a618044</a></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Regulation_of_therapeutic_goods" title="Regulation of therapeutic goods">License data</a></th><td class="infobox-data"><style data-mw-deduplicate="TemplateStyles:r1126788409">.mw-parser-output .plainlist ol,.mw-parser-output .plainlist ul{line-height:inherit;list-style:none;margin:0;padding:0}.mw-parser-output .plainlist ol li,.mw-parser-output .plainlist ul li{margin-bottom:0}</style><div class="plainlist"> <ul><li><abbr class="country-name" title="United States">US</abbr> <a href="/wiki/DailyMed" title="DailyMed">DailyMed</a>: <a rel="nofollow" class="external text" href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Elagolix">Elagolix</a></li></ul></div> </td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Pregnancy_category" title="Pregnancy category">Pregnancy category</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"> <ul><li>Contraindicated</li></ul> </div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Route_of_administration" title="Route of administration">Routes of administration</a></th><td class="infobox-data"><a href="/wiki/Oral_administration" title="Oral administration">By mouth</a><a href="#cite_note-Orilissa_FDA_Label-1">[1]</a></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Drug_class" title="Drug class">Drug class</a></th><td class="infobox-data"><a href="/wiki/GnRH_antagonist" class="mw-redirect" title="GnRH antagonist">GnRH antagonist</a></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Anatomical_Therapeutic_Chemical_Classification_System" title="Anatomical Therapeutic Chemical Classification System">ATC code</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li><a href="/wiki/ATC_code_H01" title="ATC code H01">H01CC03</a> (<a rel="nofollow" class="external text" href="https://www.whocc.no/atc_ddd_index/?code=H01CC03">WHO</a>) </li></ul></div></td></tr><tr><th colspan="2" class="infobox-header" style="background:#ddd">Legal status</th></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Regulation_of_therapeutic_goods" title="Regulation of therapeutic goods">Legal status</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"> <ul><li><abbr class="country-name" title="Canada">CA</abbr>: <a href="/wiki/Prescription_drug" title="Prescription drug"> ℞-only</a><a href="#cite_note-Orilissa_CA_PI-2">[2]</a><a href="#cite_note-OrillisaLabelCa-3">[3]</a></li> <li><abbr class="country-name" title="United States">US</abbr>: <a href="/wiki/Prescription_drug" title="Prescription drug">℞-only</a><a href="#cite_note-Orilissa_FDA_Label-1">[1]</a></li></ul></div> </td></tr><tr><th colspan="2" class="infobox-header" style="background:#ddd"><a href="/wiki/Pharmacokinetics" title="Pharmacokinetics">Pharmacokinetic</a> data</th></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Bioavailability" title="Bioavailability">Bioavailability</a></th><td class="infobox-data">Low (5.8% in rats, 11% in monkeys; no human data)<a href="#cite_note-pmid29232843-4">[4]</a></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Plasma_protein_binding" title="Plasma protein binding">Protein binding</a></th><td class="infobox-data">80%<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Drug_metabolism" title="Drug metabolism">Metabolism</a></th><td class="infobox-data"><a href="/wiki/Liver" title="Liver">Liver</a> (<a href="/wiki/CYP3A" title="CYP3A">CYP3A</a>)<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Biological_half-life" title="Biological half-life">Elimination half-life</a></th><td class="infobox-data">Typical: 4–6 hours<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Single dose: 2.4–6.3 hrs<a href="#cite_note-pmid19033369-5">[5]</a><a href="#cite_note-EzzatiCarr2015-6">[6]</a> Continuous: 2.2–10.8 hours<a href="#cite_note-pmid19033369-5">[5]</a></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Excretion" title="Excretion">Excretion</a></th><td class="infobox-data"><a href="/wiki/Urine" title="Urine">Urine</a>: <3%<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> <a href="/wiki/Feces" title="Feces">Feces</a>: 90%<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a></td></tr><tr><th colspan="2" class="infobox-header" style="background:#ddd">Identifiers</th></tr><tr><td colspan="2" class="infobox-full-data"><div class="collapsible-list mw-collapsible mw-collapsed" style="text-align: left;"> <div style="line-height: 1.6em; font-weight: bold;"><div><a href="/wiki/IUPAC_nomenclature_of_chemistry" title="IUPAC nomenclature of chemistry">IUPAC name</a></div></div> <ul class="mw-collapsible-content" style="margin-top: 0; margin-bottom: 0; line-height: inherit; list-style: none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em;"><li style="line-height: inherit; margin: 0"><div style="font-size: 97%;">4-[[(1R)-2-[5-(2-Fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoic acid</div></li></ul> </div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/CAS_Registry_Number" title="CAS Registry Number">CAS Number</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li><a rel="nofollow" class="external text" href="https://commonchemistry.cas.org/detail?cas_rn=834153-87-6">834153-87-6</a> <img alt="check" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png" decoding="async" width="7" height="7" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/11px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png 2x" data-file-width="600" data-file-height="600" />Y</li><li>Sodium salt: <a rel="nofollow" class="external text" href="https://commonchemistry.cas.org/detail?cas_rn=832720-36-2">832720-36-2</a> <img alt="check" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png" decoding="async" width="7" height="7" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/11px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png 2x" data-file-width="600" data-file-height="600" />Y</li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/PubChem#CID" title="PubChem">PubChem</a> <abbr title="Compound ID">CID</abbr></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li><a rel="nofollow" class="external text" href="https://pubchem.ncbi.nlm.nih.gov/compound/11250647">11250647</a></li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Guide_to_Pharmacology" title="Guide to Pharmacology">IUPHAR/BPS</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li><a rel="nofollow" class="external text" href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8362">8362</a></li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/DrugBank" title="DrugBank">DrugBank</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li><a rel="nofollow" class="external text" href="https://www.drugbank.ca/drugs/DB11979">DB11979</a></li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/ChemSpider" title="ChemSpider">ChemSpider</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li><a rel="nofollow" class="external text" href="https://www.chemspider.com/Chemical-Structure.9425680.html">9425680</a></li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Unique_Ingredient_Identifier" title="Unique Ingredient Identifier">UNII</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li><a rel="nofollow" class="external text" href="https://precision.fda.gov/uniisearch/srs/unii/5B2546MB5Z">5B2546MB5Z</a></li><li>Sodium salt: <a rel="nofollow" class="external text" href="https://precision.fda.gov/uniisearch/srs/unii/5948VUI423">5948VUI423</a> <img alt="check" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png" decoding="async" width="7" height="7" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/11px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png 2x" data-file-width="600" data-file-height="600" />Y</li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/KEGG" title="KEGG">KEGG</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li><a rel="nofollow" class="external text" href="https://www.kegg.jp/entry/D09335">D09335</a></li><li>Sodium salt: <a rel="nofollow" class="external text" href="https://www.kegg.jp/entry/D09336">D09336</a></li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/ChEBI" title="ChEBI">ChEBI</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li><a rel="nofollow" class="external text" href="https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:177453">CHEBI:177453</a></li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/ChEMBL" title="ChEMBL">ChEMBL</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li><a rel="nofollow" class="external text" href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1208155">ChEMBL1208155</a></li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Protein_Data_Bank" title="Protein Data Bank">PDB ligand</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li>F5O (<a rel="nofollow" class="external text" href="https://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=F5O">PDBe</a>, <a rel="nofollow" class="external text" href="https://www.rcsb.org/ligand/F5O">RCSB PDB</a>)</li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/CompTox_Chemicals_Dashboard" title="CompTox Chemicals Dashboard">CompTox Dashboard</a> (<abbr title="U.S. Environmental Protection Agency">EPA</abbr>)</th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li><a rel="nofollow" class="external text" href="https://comptox.epa.gov/dashboard/chemical/details/DTXSID40232348">DTXSID40232348</a> <a href="https://www.wikidata.org/wiki/Q21098999#P3117" title="Edit this at Wikidata"><img alt="Edit this at Wikidata" src="//upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png" decoding="async" width="10" height="10" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/15px-OOjs_UI_icon_edit-ltr-progressive.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/20px-OOjs_UI_icon_edit-ltr-progressive.svg.png 2x" data-file-width="20" data-file-height="20" /></a></li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/ECHA_InfoCard" class="mw-redirect" title="ECHA InfoCard">ECHA InfoCard</a></th><td class="infobox-data"><a rel="nofollow" class="external text" href="https://echa.europa.eu/substance-information/-/substanceinfo/100.259.758">100.259.758</a> <a href="https://www.wikidata.org/wiki/Q21098999#P2566" title="Edit this at Wikidata"><img alt="Edit this at Wikidata" src="//upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png" decoding="async" width="10" height="10" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/15px-OOjs_UI_icon_edit-ltr-progressive.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/20px-OOjs_UI_icon_edit-ltr-progressive.svg.png 2x" data-file-width="20" data-file-height="20" /></a></td></tr><tr><th colspan="2" class="infobox-header" style="background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Chemical_formula" title="Chemical formula">Formula</a></th><td class="infobox-data">C32H30F5N3O5</td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Molar_mass" title="Molar mass">Molar mass</a></th><td class="infobox-data">631.600 g·mol−1</td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;">3D model (<a href="/wiki/JSmol" class="mw-redirect" title="JSmol">JSmol</a>)</th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li><a rel="nofollow" class="external text" href="https://chemapps.stolaf.edu/jmol/jmol.php?model=COc1cccc%28-c2c%28C%29n%28Cc3c%28F%29cccc3C%28F%29%28F%29F%29c%28%3DO%29n%28C%5BC%40H%5D%28NCCCC%28%3DO%29O%29c3ccccc3%29c2%3DO%29c1F">Interactive image</a></li></ul></div></td></tr><tr><td colspan="2" class="infobox-full-data"><div class="collapsible-list mw-collapsible mw-collapsed" style="text-align: left;"> <div style="line-height: 1.6em; font-weight: bold;"><div><a href="/wiki/Simplified_molecular-input_line-entry_system" class="mw-redirect" title="Simplified molecular-input line-entry system">SMILES</a></div></div> <ul class="mw-collapsible-content" style="margin-top: 0; margin-bottom: 0; line-height: inherit; list-style: none; margin-left: 0; word-break:break-all;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:97%; line-height:120%;">COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F</div></li></ul> </div></td></tr><tr><td colspan="2" class="infobox-full-data"><div class="collapsible-list mw-collapsible mw-collapsed" style="text-align: left;"> <div style="line-height: 1.6em; font-weight: bold;"><div><a href="/wiki/International_Chemical_Identifier" title="International Chemical Identifier">InChI</a></div></div> <ul class="mw-collapsible-content" style="margin-top: 0; margin-bottom: 0; line-height: inherit; list-style: none; margin-left: 0; word-break:break-all;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:97%; line-height:120%;">InChI=1S/C32H30F5N3O5/c1-19-28(21-11-6-14-26(45-2)29(21)34)30(43)40(18-25(20-9-4-3-5-10-20)38-16-8-15-27(41)42)31(44)39(19)17-22-23(32(35,36)37)12-7-13-24(22)33/h3-7,9-14,25,38H,8,15-18H2,1-2H3,(H,41,42)/t25-/m0/s1</div></li><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:97%; line-height:120%;">Key:HEAUOKZIVMZVQL-VWLOTQADSA-N</div></li></ul> </div></td></tr></tbody></table> Elagolix, sold under the brand name Orilissa, is a <a href="/wiki/Gonadotropin-releasing_hormone_antagonist" title="Gonadotropin-releasing hormone antagonist">gonadotropin-releasing hormone antagonist</a> (GnRH antagonist) medication which is used in the treatment of <a href="/wiki/Pain" title="Pain">pain</a> associated with <a href="/wiki/Endometriosis" title="Endometriosis">endometriosis</a> in women.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a><a href="#cite_note-Orilissa_CA_PI-2">[2]</a><a href="#cite_note-OrillisaLabelCa-3">[3]</a><a href="#cite_note-pmid30194661-7">[7]</a><a href="#cite_note-EzzatiCarr2015-6">[6]</a><a href="#cite_note-pmid29232843-4">[4]</a><a href="#cite_note-pmid29559388-8">[8]</a><a href="#cite_note-AdisInsight-9">[9]</a> It is also under development for the treatment of <a href="/wiki/Uterine_fibroid" title="Uterine fibroid">uterine fibroids</a> and <a href="/wiki/Menorrhagia" class="mw-redirect" title="Menorrhagia">heavy menstrual bleeding</a> in women.<a href="#cite_note-AdisInsight-9">[9]</a> The medication was under investigation for the treatment of <a href="/wiki/Prostate_cancer" title="Prostate cancer">prostate cancer</a> and <a href="/wiki/Benign_prostatic_hyperplasia" title="Benign prostatic hyperplasia">enlarged prostate</a> in men as well, but development for these conditions was discontinued.<a href="#cite_note-AdisInsight-9">[9]</a> Elagolix is taken <a href="/wiki/Oral_administration" title="Oral administration">by mouth</a> once or twice per day.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a><a href="#cite_note-AdisInsight-9">[9]</a> It can be taken for up to 6 to 24 months, depending on the dosage.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> <a href="/wiki/Side_effect" title="Side effect">Side effects</a> of elagolix include <a href="/wiki/Menopausal_symptoms" class="mw-redirect" title="Menopausal symptoms">menopausal-like symptoms</a> such as <a href="/wiki/Hot_flash" title="Hot flash">hot flashes</a>, <a href="/wiki/Night_sweat" class="mw-redirect" title="Night sweat">night sweats</a>, <a href="/wiki/Insomnia" title="Insomnia">insomnia</a>, <a href="/wiki/Amenorrhea" title="Amenorrhea">amenorrhea</a>, <a href="/wiki/Mood_(psychology)" title="Mood (psychology)">mood</a> changes, <a href="/wiki/Anxiety" title="Anxiety">anxiety</a>, and decreased <a href="/wiki/Bone_mineral_density" class="mw-redirect" title="Bone mineral density">bone density</a>, among others.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Elagolix is a GnRH antagonist, or an <a href="/wiki/Receptor_antagonist" title="Receptor antagonist">antagonist</a> of the <a href="/wiki/Gonadotropin-releasing_hormone_receptor" title="Gonadotropin-releasing hormone receptor">gonadotropin-releasing hormone receptor</a> (GnRHR), the <a href="/wiki/Biological_target" title="Biological target">biological target</a> of the <a href="/wiki/Hypothalamus" title="Hypothalamus">hypothalamic</a> <a href="/wiki/Hormone" title="Hormone">hormone</a> <a href="/wiki/Gonadotropin-releasing_hormone" title="Gonadotropin-releasing hormone">gonadotropin-releasing hormone</a> (GnRH).<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> By blocking the GnRHR, it dose-dependently suppresses the <a href="/wiki/Gonad" title="Gonad">gonadal</a> <a href="/wiki/Biosynthesis" title="Biosynthesis">production</a> and hence circulating levels of <a href="/wiki/Sex_hormone" title="Sex hormone">sex hormones</a> such as <a href="/wiki/Estradiol" title="Estradiol">estradiol</a>, <a href="/wiki/Progesterone" title="Progesterone">progesterone</a>, and <a href="/wiki/Testosterone" title="Testosterone">testosterone</a>.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Elagolix is a short-acting GnRH antagonist, and can be used to achieve either partial or more substantial suppression of sex hormone levels.<a href="#cite_note-pmid29559388-8">[8]</a> Reduced <a href="/wiki/Estrogen" title="Estrogen">estrogen</a> levels in the <a href="/wiki/Endometrium" title="Endometrium">endometrium</a> are responsible for the <a href="/wiki/Efficacy" title="Efficacy">efficacy</a> of elagolix in the treatment of endometriosis.<a href="#cite_note-pmid29559388-8">[8]</a> Elagolix was first described in 2008 and was approved for medical use in July 2018.<a href="#cite_note-pmid19006286-10">[10]</a><a href="#cite_note-AdisInsight-9">[9]</a> It has been described as a "second-generation" <a href="/wiki/GnRH_modulator" class="mw-redirect" title="GnRH modulator">GnRH modulator</a> due to its <a href="/wiki/Non-peptide" class="mw-redirect" title="Non-peptide">non-peptide</a> and <a href="/wiki/Small-molecule" class="mw-redirect" title="Small-molecule">small-molecule</a> nature and its <a href="/wiki/Oral_administration" title="Oral administration">oral activity</a>.<a href="#cite_note-EzzatiCarr2015-6">[6]</a><a href="#cite_note-AdisInsight-9">[9]</a> Unlike <a href="/wiki/GnRH_agonist" class="mw-redirect" title="GnRH agonist">GnRH agonists</a> and older <a href="/wiki/GnRH_antagonist" class="mw-redirect" title="GnRH antagonist">GnRH antagonists</a>, which are <a href="/wiki/Peptide" title="Peptide">peptides</a> and first-generation GnRH modulators, elagolix is not a <a href="/wiki/GnRH_analogue" class="mw-redirect" title="GnRH analogue">GnRH analogue</a> as it is not structurally related to GnRH.<a href="#cite_note-EzzatiCarr2015-6">[6]</a><a href="#cite_note-AdisInsight-9">[9]</a> Elagolix was the first second-generation and orally active GnRH modulator to be introduced for medical use.<a href="#cite_note-AdisInsight-9">[9]</a> The introduction of elagolix in the United States and <a href="/wiki/Canada" title="Canada">Canada</a> was followed by that of <a href="/wiki/Relugolix" title="Relugolix">relugolix</a> (brand name Relumina), the next second-generation GnRH antagonist, in <a href="/wiki/Japan" title="Japan">Japan</a> in January 2019.<a href="#cite_note-AdisInsight-Relugolix-11">[11]</a> The U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA) considers it to be a <a href="/wiki/First-in-class_medication" title="First-in-class medication">first-in-class medication</a>.<a href="#cite_note-12">[12]</a> <meta property="mw:PageProp/toc" /> <div class="mw-heading mw-heading2"><h2 id="Medical_uses">Medical uses</h2>[<a href="/w/index.php?title=Elagolix&action=edit&section=1" title="Edit section: Medical uses">edit</a>]</div> Elagolix is used in the treatment of moderate to severe <a href="/wiki/Pain" title="Pain">pain</a> associated with <a href="/wiki/Endometriosis" title="Endometriosis">endometriosis</a> in <a href="/wiki/Premenopause" class="mw-redirect" title="Premenopause">premenopausal</a> women.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Endometriosis is a condition in which the <a href="/wiki/Endometrium" title="Endometrium">endometrium</a>, the inner lining of the <a href="/wiki/Uterus" title="Uterus">uterus</a>, grows outside of the uterus into surrounding <a href="/wiki/Tissue_(biology)" title="Tissue (biology)">tissues</a> and causes <a href="/wiki/Symptom" class="mw-redirect" title="Symptom">symptoms</a> such as <a href="/wiki/Pelvic_pain" title="Pelvic pain">pelvic pain</a> and <a href="/wiki/Infertility" title="Infertility">infertility</a>.<a href="#cite_note-pmid20574791-13">[13]</a> Around 10% of women may be affected by endometriosis.<a href="#cite_note-pmid20574791-13">[13]</a> Elagolix significantly decreases symptoms of <a href="/wiki/Dysmenorrhea" title="Dysmenorrhea">dysmenorrhea</a> (menstrual pelvic pain), non-<a href="/wiki/Menstrual_cycle" title="Menstrual cycle">menstrual</a> <a href="/wiki/Pelvic_pain" title="Pelvic pain">pelvic pain</a>, and <a href="/wiki/Dyspareunia" title="Dyspareunia">dyspareunia</a> (pain during <a href="/wiki/Sexual_intercourse" title="Sexual intercourse">sexual intercourse</a>) in women with endometriosis.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a><a href="#cite_note-UPI2018-14">[14]</a><a href="#cite_note-pmid28525302-15">[15]</a><a href="#cite_note-pmid29889764-16">[16]</a> The medication is used at a lower dosage of 150 mg once per day or at a higher dosage of 200 mg twice per day, depending on the severity of symptoms.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a><a href="#cite_note-UPI2018-14">[14]</a> The effectiveness of elagolix in the treatment of symptoms of endometriosis was demonstrated in the 6-month Elaris Endometriosis I and II (EM-I and EM-II) <a href="/wiki/Phases_of_clinical_research#Phase_III" title="Phases of clinical research">phase III</a> <a href="/wiki/Clinical_trial" title="Clinical trial">clinical trials</a>.<a href="#cite_note-pmid29559388-8">[8]</a><a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> In Elaris EM-I, the percentage of women who had a clinical response with respect to dysmenorrhea was 46.4% in the lower-dose elagolix group and 75.8% in the higher-dose elagolix group, as compared with 19.6% in the placebo group; in Elaris EM-II, the corresponding percentages were 43.4% and 72.4%, as compared with 22.7% (P < 0.001 for all comparisons).<a href="#cite_note-pmid28525302-15">[15]</a> In Elaris EM-I, the percentage of women who had a clinical response with respect to non-menstrual pelvic pain was 50.4% in the lower-dose elagolix group and 54.5% in the higher-dose elagolix group, as compared with 36.5% in the placebo group (P < 0.001 for all comparisons); in Elaris EM-II, the corresponding percentages were 49.8% and 57.8%, as compared with 36.5% (P = 0.003 and P < 0.001, respectively).<a href="#cite_note-pmid28525302-15">[15]</a> The reductions in symptoms of endometriosis with elagolix resulted in an improved <a href="/wiki/Quality_of_life" title="Quality of life">quality of life</a>.<a href="#cite_note-pmid29559388-8">[8]</a><a href="#cite_note-pmid29889764-16">[16]</a> The duration of use of elagolix in the treatment of endometriosis should be limited due to a progressive risk of <a href="/wiki/Osteoporosis" title="Osteoporosis">bone loss</a>, and the lowest effective dosage should be used.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Elagolix can be used for up to 24 months at the 150 mg once per day dosage and for up to 6 months at the 200 mg twice per day dosage.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Because of its relatively short <a href="/wiki/Duration_of_action" class="mw-redirect" title="Duration of action">duration</a>, elagolix should be taken at approximately the same time each day.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> In the case of twice-daily administration, elagolix should be taken at approximate 12-hour intervals, for instance once in the morning and once at night.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> It can be taken with or without <a href="/wiki/Food" title="Food">food</a>.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Elagolix is approved only for the treatment of endometriosis.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Other approved and off-label uses of GnRH antagonists in general are the same as those of GnRHR <a href="/wiki/Downregulation_and_upregulation" title="Downregulation and upregulation">desensitization</a> therapy with GnRH agonists such as <a href="/wiki/Leuprorelin" title="Leuprorelin">leuprorelin</a>, and include uterine fibroids and <a href="/wiki/Breast_cancer" title="Breast cancer">breast cancer</a> in premenopausal women, <a href="/wiki/Prostate_cancer" title="Prostate cancer">prostate cancer</a> in men, <a href="/wiki/Precocious_puberty" title="Precocious puberty">precocious puberty</a> in children, and <a href="/wiki/Transgender_hormone_therapy" class="mw-redirect" title="Transgender hormone therapy">hormone therapy</a> in <a href="/wiki/Transgender" title="Transgender">transgender</a> adolescents and adults, among others.<a href="#cite_note-pmid11734258-17">[17]</a><a href="#cite_note-pmid19509099-18">[18]</a> <div class="mw-heading mw-heading3"><h3 id="Available_forms">Available forms</h3>[<a href="/w/index.php?title=Elagolix&action=edit&section=2" title="Edit section: Available forms">edit</a>]</div> Elagolix is available in the form of Orilissa 150 and 200 mg <a href="/wiki/Oral_administration" title="Oral administration">oral</a> <a href="/wiki/Tablet_(pharmacy)" title="Tablet (pharmacy)">tablets</a>.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> The 150 mg tablets are light pink, oblong, and film-coated with "EL 150" debossed on one side, while the 200 mg tablets are light orange, oblong, and film-coated with "EL 200" debossed on one side.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> The <a href="/wiki/Excipient" title="Excipient">inactive ingredients</a> in the tablets include <a href="/wiki/Mannitol" title="Mannitol">mannitol</a>, <a href="/wiki/Sodium_carbonate_monohydrate" class="mw-redirect" title="Sodium carbonate monohydrate">sodium carbonate monohydrate</a>, <a href="/wiki/Pregelatinized_starch" class="mw-redirect" title="Pregelatinized starch">pregelatinized starch</a>, <a href="/wiki/Povidone" class="mw-redirect" title="Povidone">povidone</a>, <a href="/wiki/Magnesium_stearate" title="Magnesium stearate">magnesium stearate</a>, <a href="/wiki/Polyvinyl_alcohol" title="Polyvinyl alcohol">polyvinyl alcohol</a>, <a href="/wiki/Titanium_dioxide" title="Titanium dioxide">titanium dioxide</a>, <a href="/wiki/Polyethylene_glycol" title="Polyethylene glycol">polyethylene glycol</a>, <a href="/wiki/Talc" title="Talc">talc</a>, and a distinct <a href="/wiki/Color_additive" class="mw-redirect" title="Color additive">color additive</a> (<a href="/wiki/Carmine_high_tint" class="mw-redirect" title="Carmine high tint">carmine high tint</a> in the 150 mg tablets and <a href="/wiki/Iron_oxide_red" title="Iron oxide red">iron oxide red</a> in the 200 mg tablets).<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> <div class="mw-heading mw-heading2"><h2 id="Contraindications">Contraindications</h2>[<a href="/w/index.php?title=Elagolix&action=edit&section=3" title="Edit section: Contraindications">edit</a>]</div> <a href="/wiki/Contraindication" title="Contraindication">Contraindications</a> of elagolix include <a href="/wiki/Pregnancy" title="Pregnancy">pregnancy</a>, known <a href="/wiki/Osteoporosis" title="Osteoporosis">osteoporosis</a>, severe <a href="/wiki/Hepatic_impairment" class="mw-redirect" title="Hepatic impairment">hepatic impairment</a>, and concomitant use with strong <a href="/wiki/Organic_anion-transporting_polypeptide" class="mw-redirect" title="Organic anion-transporting polypeptide">organic anion-transporting polypeptide</a> (OATP) <a href="/wiki/SLCO1B1" class="mw-redirect" title="SLCO1B1">1B1</a> <a href="/wiki/Transporter_blocker" class="mw-redirect" title="Transporter blocker">inhibitors</a> such as <a href="/wiki/Ciclosporin" title="Ciclosporin">ciclosporin</a> and <a href="/wiki/Gemfibrozil" title="Gemfibrozil">gemfibrozil</a>.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Elagolix may increase the risk of <a href="/wiki/Miscarriage" title="Miscarriage">miscarriage</a> in early pregnancy.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Women should avoid pregnancy while taking elagolix, for instance by using <a href="/wiki/Birth_control" title="Birth control">birth control</a>, and should discontinue the medication if they become or wish to become pregnant.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Elagolix should not be used in women with osteoporosis because it may increase the risk of further <a href="/wiki/Osteoporosis" title="Osteoporosis">bone loss</a>.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Severe hepatic impairment is associated with 7-fold increased exposure to elagolix, which may increase the risk of bone loss.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> In women with moderate hepatic impairment, which is associated with 3-fold increased exposure to elagolix, the medication at 200 mg twice per day should not be used, while 150 mg once per day should be used for no more than 6 months.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> OATP1B1 inhibitors are likely to greatly increase exposure to elagolix similarly to moderate to severe hepatic impairment.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> <a href="/wiki/Combined_birth_control" class="mw-redirect" title="Combined birth control">Combined birth control</a> is not contraindicated with elagolix, but because of the <a href="/wiki/Estrogen_(medication)" title="Estrogen (medication)">estrogen</a> component, is expected to decrease the effectiveness of elagolix in the treatment of endometriosis, and hence is not recommended.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Other forms of birth control, such as non-hormonal birth control, can be used instead.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Elagolix is not contraindicated in women who are <a href="/wiki/Breastfeeding" title="Breastfeeding">breastfeeding</a>, but it is unknown whether the medication is <a href="/wiki/Excretion" title="Excretion">excreted</a> in <a href="/wiki/Breast_milk" title="Breast milk">breast milk</a> or if it has adverse effects on <a href="/wiki/Lactation" title="Lactation">milk production</a> or the <a href="/wiki/Breastfeeding" title="Breastfeeding">breastfed</a> child.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> The use of elagolix in women who are breastfeeding should be considered carefully, weighing both benefits and risks.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> <div class="mw-heading mw-heading2"><h2 id="Side_effects">Side effects</h2>[<a href="/w/index.php?title=Elagolix&action=edit&section=4" title="Edit section: Side effects">edit</a>]</div> <table class="wikitable floatright"> <caption>Side effects of elagolix in clinical trials (mostly ≥5% incidence)<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a><a href="#cite_note-Orilissa_Canada_Label-19">[19]</a><a href="#cite_note-Orilissa-AbbVie-Leaflet-20">[20]</a> </caption> <tbody><tr> <th>Side effect </th> <th>150 mg <abbr title="quaque die (once per day)">q.d.</abbr> [n=475] (%) </th> <th>200 mg <abbr title="bis in die (twice per day)">b.i.d.</abbr> [n=477] (%) </th> <th>Placebo [n=734] (%) </th></tr> <tr> <td><a href="/wiki/Hot_flash" title="Hot flash">Hot flashes</a>/<a href="/wiki/Night_sweat" class="mw-redirect" title="Night sweat">night sweats</a> </td> <td>23–24 </td> <td>45–46 </td> <td>9 </td></tr> <tr> <td><a href="/wiki/Amenorrhea" title="Amenorrhea">Amenorrhea</a> </td> <td>4; 6–17 </td> <td>7; 13–57 </td> <td><1 </td></tr> <tr> <td><a href="/wiki/Headache" title="Headache">Headaches</a> </td> <td>17 </td> <td>20 </td> <td>12 </td></tr> <tr> <td><a href="/wiki/Nausea" title="Nausea">Nausea</a> </td> <td>11 </td> <td>16 </td> <td>13 </td></tr> <tr> <td><a href="/wiki/Mood_swing" title="Mood swing">Mood changes/swings</a> </td> <td>6 </td> <td>5 </td> <td>3 </td></tr> <tr> <td><a href="/wiki/Anxiety" title="Anxiety">Anxiety</a> </td> <td>3 </td> <td>5 </td> <td>3 </td></tr> <tr> <td><a href="/wiki/Depression_(mood)" title="Depression (mood)">Depressive symptoms</a> </td> <td>3 </td> <td>6 </td> <td>2 </td></tr> <tr> <td><a href="/wiki/Insomnia" title="Insomnia">Insomnia</a> </td> <td>6 </td> <td>9 </td> <td>3 </td></tr> <tr> <td><a href="/wiki/Upper_respiratory_tract_infection" title="Upper respiratory tract infection">Upper respiratory tract infection</a> </td> <td>6 </td> <td>4 </td> <td>5 </td></tr> <tr> <td><a href="/wiki/Nasopharyngitis" class="mw-redirect" title="Nasopharyngitis">Nasopharyngitis</a> </td> <td>6 </td> <td>6 </td> <td>4 </td></tr> <tr> <td><a href="/wiki/Sinusitis" title="Sinusitis">Sinusitis</a> </td> <td>5 </td> <td>6 </td> <td>4 </td></tr> <tr> <td><a href="/wiki/Arthralgia" title="Arthralgia">Arthralgia</a> </td> <td>3 </td> <td>5 </td> <td>3 </td></tr> <tr> <td>>8% <a href="/wiki/Osteoporosis" title="Osteoporosis"><abbr title="bone mineral density">BMD</abbr> decrease</a> (6 months) </td> <td><1–2 </td> <td>6–7 </td> <td><1 </td></tr> <tr> <td>>8% <a href="/wiki/Osteoporosis" title="Osteoporosis"><abbr title="bone mineral density">BMD</abbr> decrease</a> (12 months) </td> <td>2–8 </td> <td>21 </td> <td><1 </td></tr> <tr> <td><a href="/wiki/Elevated_liver_enzymes" class="mw-redirect" title="Elevated liver enzymes">Elevated liver enzymes</a>a </td> <td>0.2 (n=1) </td> <td>1.1 (n=5) </td> <td>0.1 (n=1) </td></tr> <tr> <td><a href="/wiki/Suicidal_ideation" title="Suicidal ideation">Suicidal ideation</a> </td> <td>0.2 (n=1) </td> <td>0.2 (n=1) </td> <td>0 </td></tr> <tr> <td><a href="/wiki/Suicide" title="Suicide">Suicide</a> </td> <td>0.2 (n=1) </td> <td>0 </td> <td>0 </td></tr> <tr class="sortbottom"> <td colspan="4" style="width: 1px; background-color:#eaecf0; text-align: center;">Notes: Side effects reported in ≥3% but <5% included <a href="/wiki/Diarrhea" title="Diarrhea">diarrhea</a>, <a href="/wiki/Abdominal_pain" title="Abdominal pain">abdominal pain</a>, <a href="/wiki/Constipation" title="Constipation">constipation</a>, <a href="/wiki/Weight_gain" title="Weight gain">weight gain</a>, <a href="/wiki/Dizziness" title="Dizziness">dizziness</a>, <a href="/wiki/Irritability" title="Irritability">irritability</a>, and <a href="/wiki/Decreased_libido" class="mw-redirect" title="Decreased libido">decreased libido</a>. Footnotes: a = Asymptomatic; <a href="/wiki/Alanine_transaminase" title="Alanine transaminase"><abbr title="alanine transaminase">ALT</abbr></a><span class="sr-only" style="border: 0; clip: rect(0, 0, 0, 0); clip-path: polygon(0px 0px, 0px 0px, 0px 0px); height: 1px; margin: -1px; overflow: hidden; padding: 0; position: absolute; width: 1px; white-space: nowrap;">Tooltip alanine transaminase >3 times upper limit. </td></tr></tbody></table> The <a href="/wiki/Side_effect" title="Side effect">side effects</a> of elagolix are in general similar to <a href="/wiki/Menopausal_symptoms" class="mw-redirect" title="Menopausal symptoms">menopausal symptoms</a>.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> The most common side effects of elagolix (incidence ≥10%) are <a href="/wiki/Hot_flash" title="Hot flash">hot flashes</a>, <a href="/wiki/Night_sweat" class="mw-redirect" title="Night sweat">night sweats</a>, <a href="/wiki/Headache" title="Headache">headaches</a>, <a href="/wiki/Nausea" title="Nausea">nausea</a>, and <a href="/wiki/Amenorrhea" title="Amenorrhea">amenorrhea</a> (cessation of <a href="/wiki/Menstruation" title="Menstruation">menstruation</a>).<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a><a href="#cite_note-Orilissa_CA_PI-2">[2]</a><a href="#cite_note-OrillisaLabelCa-3">[3]</a> The next most frequent side effects of elagolix (incidence ≥5%) are <a href="/wiki/Insomnia" title="Insomnia">insomnia</a>, <a href="/wiki/Anxiety" title="Anxiety">anxiety</a>, <a href="/wiki/Arthralgia" title="Arthralgia">arthralgia</a> (joint pain), <a href="/wiki/Depression_(mood)" title="Depression (mood)">depression</a>, and <a href="/wiki/Mood_(psychology)" title="Mood (psychology)">mood</a> changes.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a><a href="#cite_note-Orilissa_CA_PI-2">[2]</a><a href="#cite_note-OrillisaLabelCa-3">[3]</a><a href="#cite_note-pmid29889764-16">[16]</a> Less common side effects of elagolix (incidence ≥3% and <5%) include <a href="/wiki/Decreased_sex_drive" class="mw-redirect" title="Decreased sex drive">decreased sex drive</a>, <a href="/wiki/Diarrhea" title="Diarrhea">diarrhea</a>, <a href="/wiki/Abdominal_pain" title="Abdominal pain">abdominal pain</a>, <a href="/wiki/Weight_gain" title="Weight gain">weight gain</a>, <a href="/wiki/Dizziness" title="Dizziness">dizziness</a>, <a href="/wiki/Constipation" title="Constipation">constipation</a>, and <a href="/wiki/Irritability" title="Irritability">irritability</a>.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Other common side effects of elagolix include decreased <a href="/wiki/Bone_mineral_density" class="mw-redirect" title="Bone mineral density">bone mineral density</a> (BMD) and changes in the <a href="/wiki/Blood_lipids" title="Blood lipids">blood lipid</a> <a href="/wiki/Lipid_profile" title="Lipid profile">profile</a>.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a><a href="#cite_note-pmid29889764-16">[16]</a> Rare but serious adverse effects that were observed during elagolix therapy in clinical trials included <a href="/wiki/Appendicitis" title="Appendicitis">appendicitis</a> (0.3%), abdominal pain (0.2%), and <a href="/wiki/Back_pain" title="Back pain">back pain</a> (0.2%), though it is unknown if these were due to elagolix.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a><a href="#cite_note-pmid29889764-16">[16]</a> Other serious adverse effects of elagolix may include <a href="/wiki/Osteoporosis" title="Osteoporosis">bone loss</a>, <a href="/wiki/Miscarriage" title="Miscarriage">miscarriage</a>, <a href="/wiki/Suicidality" class="mw-redirect" title="Suicidality">suicidality</a>, and <a href="/wiki/Elevated_liver_enzymes" class="mw-redirect" title="Elevated liver enzymes">elevated liver enzymes</a>.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Elagolix was discontinued due to side effects by 5 to 10% of women in clinical trials, with the most common reasons being hot flashes or night sweats, nausea, and decreased BMD.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Elagolix dose- and duration-dependently decreases BMD in <a href="/wiki/Premenopause" class="mw-redirect" title="Premenopause">premenopausal</a> women with long-term therapy.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> After 6 months of treatment with elagolix, <a href="/wiki/Lumbar_spine" class="mw-redirect" title="Lumbar spine">lumbar spine</a> BMD was decreased by 0.3 to 1.3% with 150 mg once per day and by 2.5 to 3.1% with 200 mg twice per day.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> The decrease in BMD during elagolix therapy may not be fully reversible with discontinuation, as only partial recovery was observed 12 months after discontinuation of therapy.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> The cause of the decrease in BMD with elagolix is <a href="/wiki/Estrogen_deficiency" class="mw-redirect" title="Estrogen deficiency">estrogen deficiency</a>, and is analogous to that associated with <a href="/wiki/Postmenopause" class="mw-redirect" title="Postmenopause">postmenopause</a>.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> The consequences of the effects of elagolix on BMD are unknown, but may be an increase in the risk of <a href="/wiki/Osteoporosis" title="Osteoporosis">bone loss</a> and <a href="/wiki/Bone_fracture" title="Bone fracture">fractures</a>.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> This is why the duration of use of elagolix should be limited.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> In women with risk factors for bone loss and osteoporosis, such as a history of low-trauma fracture, assessment of BMD may be considered.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Elagolix should not be used in premenopausal women with known osteoporosis.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Supplementation with <a href="/wiki/Calcium" title="Calcium">calcium</a> and/or <a href="/wiki/Vitamin_D" title="Vitamin D">vitamin D</a> during treatment with elagolix has not been studied, but may be beneficial for helping to maintain bone health.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Elagolix decreases the amount, intensity, and duration of <a href="/wiki/Menstrual_bleeding" class="mw-redirect" title="Menstrual bleeding">menstrual bleeding</a>.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Amenorrhea, the cessation of menstruation, was observed in 4 to 17% of women with 150 mg once per day and in 7 to 57% of women with 200 mg twice per day, compared to less than 1% of women given placebo.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> The decreased menstrual bleeding caused by elagolix may impede the ability to recognize <a href="/wiki/Pregnancy" title="Pregnancy">pregnancy</a> in a timely manner.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Based on its mechanism of action, elagolix may increase the risk of <a href="/wiki/Miscarriage" title="Miscarriage">miscarriage</a> in early pregnancy, and so should be discontinued if pregnancy occurs.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a><a href="#cite_note-pmid23012318-21">[21]</a> If pregnancy is suspected, <a href="/wiki/Pregnancy_testing" class="mw-redirect" title="Pregnancy testing">pregnancy testing</a> can be performed.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Elagolix decreases the rate of <a href="/wiki/Ovulation" title="Ovulation">ovulation</a> and thereby decreases the likelihood of pregnancy, but has not been shown to be a fully effective <a href="/wiki/Hormonal_contraception" title="Hormonal contraception">contraceptive</a> and should not be relied on to prevent pregnancy.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> The incidence of depression and mood changes in clinical trials with elagolix was increased in premenopausal women taking elagolix relative to placebo.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Mood- and depression-type side effects such as altered mood, <a href="/wiki/Mood_swing" title="Mood swing">mood swings</a>, depressed mood, depression, depressive symptoms, and <a href="/wiki/Tearfulness" class="mw-redirect" title="Tearfulness">tearfulness</a> occurred in 3 to 6% of women with 150 mg per day and in 5 to 6% of women with 200 mg twice per day, compared to 2 to 3% in women given <a href="/wiki/Placebo" title="Placebo">placebo</a>.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> <a href="/wiki/Suicidality" class="mw-redirect" title="Suicidality">Suicidal ideation and behavior</a> occurred in a few women (0.2–0.4%), with one suicide observed.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> People taking elagolix with new or existing depressive symptoms should be promptly evaluated to determine whether the benefits of treatment outweigh the risks.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> In those with new or existing depressive symptoms, referral to a <a href="/wiki/Mental_health_professional" title="Mental health professional">mental health professional</a>, as appropriate, may be warranted.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Immediate medical attention should be sought for those with suicidal ideation and behavior.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Elagolix dose-dependently produced <a href="/wiki/Elevated_liver_enzymes" class="mw-redirect" title="Elevated liver enzymes">elevated liver enzymes</a>, including elevations of <a href="/wiki/Blood_serum" class="mw-redirect" title="Blood serum">serum</a> <a href="/wiki/Alanine_aminotransferase" class="mw-redirect" title="Alanine aminotransferase">alanine aminotransferase</a> of at least 3-fold the upper limit, in clinical trials.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> This was observed in one woman (0.2%) with 150 mg once per day and in five women (1.1%) with 200 mg twice per day, compared to one woman (0.1%) given placebo.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Medical attention should be sought if signs or symptoms of <a href="/wiki/Liver_injury" title="Liver injury">liver injury</a>, such as <a href="/wiki/Jaundice" title="Jaundice">jaundice</a>, are noticed.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> The lowest effective dosage of elagolix may be used to minimize the risk of liver problems, and in those who develop elevated liver enzymes during elagolix therapy, prompt evaluation should be done to determine whether the benefits of treatment outweigh the risks.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> <div class="mw-heading mw-heading2"><h2 id="Overdose">Overdose</h2>[<a href="/w/index.php?title=Elagolix&action=edit&section=5" title="Edit section: Overdose">edit</a>]</div> In the event of an <a href="/wiki/Overdose" class="mw-redirect" title="Overdose">overdose</a> of elagolix, the person should be monitored for any signs or symptoms of <a href="/wiki/Adverse_reaction" class="mw-redirect" title="Adverse reaction">adverse reactions</a> and should be treated on a symptomatic basis as needed.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Elagolix has been assessed in clinical studies at a dose as high as a single administration of 1,200 mg, which resulted in concentrations of the medication that were 17 times higher than with the typical high clinical dosage of 200 mg twice per day.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> No adverse effects were mentioned.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Chronic overdosage of elagolix may result in greater suppression of estradiol levels and a consequent increased risk of bone loss with long-term therapy.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> <div class="mw-heading mw-heading2"><h2 id="Interactions">Interactions</h2>[<a href="/w/index.php?title=Elagolix&action=edit&section=6" title="Edit section: Interactions">edit</a>]</div> Elagolix has a number of potential <a href="/wiki/Drug_interaction" title="Drug interaction">drug interactions</a> with other medications.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Elagolix is a <a href="/wiki/Substrate_(biochemistry)" class="mw-redirect" title="Substrate (biochemistry)">substrate</a> of the <a href="/wiki/Cytochrome_P450" title="Cytochrome P450">cytochrome P450</a> (CYP450) <a href="/wiki/Enzyme" title="Enzyme">enzyme</a> <a href="/wiki/CYP3A" title="CYP3A">CYP3A</a>, and <a href="/wiki/Enzyme_inhibitor" title="Enzyme inhibitor">inhibitors</a> and <a href="/wiki/Enzyme_inducer" title="Enzyme inducer">inducers</a> of <a href="/wiki/CYP3A4" title="CYP3A4">CYP3A4</a> may alter the <a href="/wiki/Metabolism" title="Metabolism">metabolism</a> of elagolix and increase or decrease its circulating levels.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> The strong CYP3A4 inhibitor <a href="/wiki/Ketoconazole" title="Ketoconazole">ketoconazole</a> has been found to increase peak levels of and total exposure to a single 150 mg dose of elagolix by about 2-fold.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Paradoxically, <a href="/wiki/Rifampin" class="mw-redirect" title="Rifampin">rifampin</a>, a strong inducer of CYP3A4 and other CYP450 enzymes, increased peak levels of and total exposure to a single 150 mg dose of elagolix as well.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> A single dose of rifampin increased peak levels of elagolix by 4.4-fold and total exposure by 5.6-fold, whereas continuous rifampin therapy increased peak levels of elagolix by 2-fold and total exposure by 1.7-fold.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> The use of elagolix at 200 mg twice per day concomitantly with rifampin is not recommended, whereas the concomitant use of elagolix at 150 mg once per day with rifampin should be limited to 6 months.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> No significant changes in exposure to elagolix were observed with concomitant administration of <a href="/wiki/Rosuvastatin" title="Rosuvastatin">rosuvastatin</a> (a <a href="/wiki/Substrate_(biochemistry)" class="mw-redirect" title="Substrate (biochemistry)">substrate</a> of <a href="/wiki/OATP1B1" class="mw-redirect" title="OATP1B1">OATP1B1</a>, <a href="/wiki/OATP1B3" class="mw-redirect" title="OATP1B3">OATP1B3</a>, and <a href="/wiki/ABCG2" title="ABCG2">BCRP</a>), <a href="/wiki/Sertraline" title="Sertraline">sertraline</a> (a moderate inhibitor of <a href="/wiki/CYP2D6" title="CYP2D6">CYP2D6</a> and <a href="/wiki/CYP2B6" title="CYP2B6">CYP2B6</a>), or <a href="/wiki/Fluconazole" title="Fluconazole">fluconazole</a> (a strong inhibitor of CYP2C19 and a moderate inhibitor of CYP2C9 and CYP3A4).<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a><a href="#cite_note-FDADrugDev-22">[22]</a> Elagolix is a substrate of the hepatic <a href="/wiki/OATP1B1" class="mw-redirect" title="OATP1B1">OATP1B1</a> transporter.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Levels of elagolix have been found to be increased by 78% in people with a <a href="/wiki/Genotype" title="Genotype">genotype</a> characterized by reduced OATP1B1 transporter function.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> The concomitant use of elagolix with medications that inhibit OATP1B1 may increase elagolix levels, and the use of elagolix with strong OATP1B1 inhibitors like <a href="/wiki/Ciclosporin" title="Ciclosporin">ciclosporin</a> and <a href="/wiki/Gemfibrozil" title="Gemfibrozil">gemfibrozil</a>, which may markedly increase elagolix exposure, is contraindicated.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Elagolix is a weak to moderate <a href="/wiki/Enzyme_inducer" title="Enzyme inducer">inducer</a> of CYP3A, and may decrease levels of medications that are substrates of CYP3A4.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> In addition, elagolix is an inhibitor of <a href="/wiki/P-glycoprotein" title="P-glycoprotein">P-glycoprotein</a>, and may increase levels of medications that are substrates of P-glycoprotein, such as <a href="/wiki/Digoxin" title="Digoxin">digoxin</a>.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Elagolix has been found to increase exposure to digoxin and <a href="/wiki/Ethinylestradiol" title="Ethinylestradiol">ethinylestradiol</a>, whereas it has been found to decrease exposure to <a href="/wiki/Rosuvastatin" title="Rosuvastatin">rosuvastatin</a>, <a href="/wiki/Midazolam" title="Midazolam">midazolam</a>, <a href="/wiki/Norethisterone" title="Norethisterone">norethisterone</a>, <a href="/wiki/Norelgestromin" title="Norelgestromin">norelgestromin</a>, and <a href="/wiki/Norgestrel" title="Norgestrel">norgestrel</a>.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Because <a href="/wiki/Combined_birth_control_pill" class="mw-redirect" title="Combined birth control pill">combined birth control pills</a> and other forms of <a href="/wiki/Combined_birth_control" class="mw-redirect" title="Combined birth control">combined birth control</a> contain an estrogen, and because elagolix treats endometriosis by decreasing estrogen levels in the endometrium, these form of <a href="/wiki/Hormonal_birth_control" class="mw-redirect" title="Hormonal birth control">hormonal birth control</a> are likely and expected to decrease the effectiveness of elagolix in the treatment of this condition.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> The effect of <a href="/wiki/Progestogen-only_birth_control" class="mw-redirect" title="Progestogen-only birth control">progestogen-only birth control</a> on the effectiveness of elagolix in endometriosis is unknown.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> However, progestogens are <a href="/wiki/Antiestrogenic" class="mw-redirect" title="Antiestrogenic">antiestrogenic</a> in the <a href="/wiki/Uterus" title="Uterus">uterus</a>, and high-dose <a href="/wiki/Progestin" class="mw-redirect" title="Progestin">progestin</a> therapy is known to be effective in the treatment of endometriosis similarly to GnRH antagonists.<a href="#cite_note-Becker2001-23">[23]</a><a href="#cite_note-pmid26389558-24">[24]</a> On the basis of limited clinical research, combined birth control pills have also been found to be effective in the treatment of endometriosis, but are likely not as effective as GnRH modulator monotherapy.<a href="#cite_note-Becker2001-23">[23]</a> It is advised that women use non-hormonal methods of <a href="/wiki/Birth_control" title="Birth control">birth control</a> during elagolix therapy and for one week following discontinuation of elagolix.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> <div class="mw-heading mw-heading2"><h2 id="Pharmacology">Pharmacology</h2>[<a href="/w/index.php?title=Elagolix&action=edit&section=7" title="Edit section: Pharmacology">edit</a>]</div> <div class="mw-heading mw-heading3"><h3 id="Pharmacodynamics">Pharmacodynamics</h3>[<a href="/w/index.php?title=Elagolix&action=edit&section=8" title="Edit section: Pharmacodynamics">edit</a>]</div> Elagolix acts as a <a href="/wiki/Potency_(pharmacology)" title="Potency (pharmacology)">potent</a> and <a href="/wiki/Binding_selectivity" title="Binding selectivity">selective</a> <a href="/wiki/Competitive_antagonist" class="mw-redirect" title="Competitive antagonist">competitive antagonist</a> of the <a href="/wiki/Gonadotropin-releasing_hormone_receptor" title="Gonadotropin-releasing hormone receptor">gonadotropin-releasing hormone receptor</a> (GnRHR), the <a href="/wiki/Biological_target" title="Biological target">biological target</a> of the <a href="/wiki/Hypothalamus" title="Hypothalamus">hypothalamic</a> <a href="/wiki/Peptide_hormone" title="Peptide hormone">peptide hormone</a> <a href="/wiki/Gonadotropin-releasing_hormone" title="Gonadotropin-releasing hormone">gonadotropin-releasing hormone</a> (GnRH).<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> As such, it is a <a href="/wiki/GnRH_antagonist" class="mw-redirect" title="GnRH antagonist">GnRH antagonist</a>.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> The <a href="/wiki/Affinity_(pharmacology)" class="mw-redirect" title="Affinity (pharmacology)">affinity</a> (KD) of elagolix for the GnRHR is 54 pM.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a><a href="#cite_note-pmid19006286-10">[10]</a><a href="#cite_note-LemkeWilliams2012-25">[25]</a> By blocking the GnRHR in the <a href="/wiki/Pituitary_gland" title="Pituitary gland">pituitary gland</a>, elagolix suppresses the GnRH-induced <a href="/wiki/Secretion" title="Secretion">secretion</a> of the <a href="/wiki/Gonadotropin" title="Gonadotropin">gonadotropins</a> <a href="/wiki/Luteinizing_hormone" title="Luteinizing hormone">luteinizing hormone</a> (LH) and <a href="/wiki/Follicle-stimulating_hormone" title="Follicle-stimulating hormone">follicle-stimulating hormone</a> (FSH) from the <a href="/wiki/Anterior_pituitary" title="Anterior pituitary">anterior pituitary</a>, and thereby decreases the <a href="/wiki/Biosynthesis" title="Biosynthesis">production</a> of <a href="/wiki/Sex_hormone" title="Sex hormone">sex hormones</a> by the <a href="/wiki/Gonad" title="Gonad">gonads</a>.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a><a href="#cite_note-pmid28323948-26">[26]</a> In women, elagolix dose-dependently suppresses the production of <a href="/wiki/Ovary" title="Ovary">ovarian</a> hormones including <a href="/wiki/Estradiol" title="Estradiol">estradiol</a>, <a href="/wiki/Progesterone" title="Progesterone">progesterone</a>, and <a href="/wiki/Testosterone" title="Testosterone">testosterone</a>, and thereby decreases the circulating levels of these hormones.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a><a href="#cite_note-pmid28323948-26">[26]</a> In men, GnRH modulators suppress the <a href="/wiki/Testicle" title="Testicle">testicular</a> production of testosterone and estradiol, decreasing the circulating levels of these hormones similarly.<a href="#cite_note-Melmed2016-27">[27]</a> Unlike previous <a href="/wiki/GnRH_agonist" class="mw-redirect" title="GnRH agonist">GnRH agonists</a> and antagonists, referred to collectively as <a href="/wiki/GnRH_analogue" class="mw-redirect" title="GnRH analogue">GnRH analogues</a>, elagolix is a <a href="/wiki/Non-peptide" class="mw-redirect" title="Non-peptide">non-peptide</a> and <a href="/wiki/Small-molecule" class="mw-redirect" title="Small-molecule">small-molecule</a> <a href="/wiki/Chemical_compound" title="Chemical compound">compound</a> that can be taken <a href="/wiki/Oral_administration" title="Oral administration">orally</a>.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a><a href="#cite_note-pmid29559388-8">[8]</a> <a href="/wiki/Estrogen" title="Estrogen">Estrogens</a> like estradiol stimulate the <a href="/wiki/Cell_growth" title="Cell growth">growth</a> of the <a href="/wiki/Endometrium" title="Endometrium">endometrium</a>, and thereby aggravate <a href="/wiki/Symptom" class="mw-redirect" title="Symptom">symptoms</a> of <a href="/wiki/Endometriosis" title="Endometriosis">endometriosis</a>.<a href="#cite_note-pmid29559388-8">[8]</a> By suppressing estrogen production and levels, elagolix decreases the growth of the endometrium and decreases endometriosis symptoms such as pelvic pain.<a href="#cite_note-pmid29559388-8">[8]</a><a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Elagolix is a short-acting GnRH antagonist, with a <a href="/wiki/Terminal_half-life" class="mw-redirect" title="Terminal half-life">terminal half-life</a> of typically about 4 to 6 hours.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a><a href="#cite_note-pmid28323948-26">[26]</a><a href="#cite_note-pmid29559388-8">[8]</a> Because of the short <a href="/wiki/Duration_of_action" class="mw-redirect" title="Duration of action">duration</a> of elagolix in the body, the activation of the GnRHR by GnRH is not fully blocked throughout the day with once-daily administration of elagolix.<a href="#cite_note-EzzatiCarr2015-6">[6]</a><a href="#cite_note-pmid19033369-5">[5]</a> As a result, gonadotropin and sex hormone levels are only partially suppressed when elagolix is taken once per day.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a><a href="#cite_note-EzzatiCarr2015-6">[6]</a><a href="#cite_note-pmid19033369-5">[5]</a> In addition, the degree of suppression can be dose-dependently adjusted as needed, for instance with higher-dose twice-daily administration to achieve greater hormonal suppression.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a><a href="#cite_note-EzzatiCarr2015-6">[6]</a><a href="#cite_note-pmid19033369-5">[5]</a> Because of its short duration in the body, the effects of elagolix are rapidly reversible upon discontinuation.<a href="#cite_note-EzzatiCarr2015-6">[6]</a><a href="#cite_note-pmid19033369-5">[5]</a> In addition, due to its partial and incomplete suppression of estradiol levels, the side effects of elagolix, such as hot flashes and decreased BMD, are lower than with first-generation GnRH modulators.<a href="#cite_note-EzzatiCarr2015-6">[6]</a><a href="#cite_note-pmid19033369-5">[5]</a><a href="#cite_note-pmid23885105-28">[28]</a><a href="#cite_note-pmid25249568-29">[29]</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1257001546"><table class="infobox" style="width: 250px; clear: right; float:right;margin:0 0 1.5em 1.5em"><tbody><tr><th colspan="2" class="infobox-above" style="font-size:115%">External images</th></tr><tr><td colspan="2" class="infobox-full-data" style="text-align: left"><img alt="image icon" src="//upload.wikimedia.org/wikipedia/en/thumb/6/61/Searchtool.svg/16px-Searchtool.svg.png" decoding="async" width="16" height="16" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/6/61/Searchtool.svg/24px-Searchtool.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/61/Searchtool.svg/32px-Searchtool.svg.png 2x" data-file-width="512" data-file-height="512" /> <a rel="nofollow" class="external text" href="https://academic.oup.com/view-large/figure/81683830/jc.2016-3845f2.tif">Levels of LH, FSH, estradiol, and progesterone over a 21-day period with elagolix in premenopausal women</a><a href="#cite_note-pmid28323948-26">[26]</a></td></tr><tr><td colspan="2" class="infobox-full-data" style="text-align: left"><img alt="image icon" src="//upload.wikimedia.org/wikipedia/en/thumb/6/61/Searchtool.svg/16px-Searchtool.svg.png" decoding="async" width="16" height="16" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/6/61/Searchtool.svg/24px-Searchtool.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/61/Searchtool.svg/32px-Searchtool.svg.png 2x" data-file-width="512" data-file-height="512" /> <a rel="nofollow" class="external text" href="https://academic.oup.com/view-large/figure/81683832/jc.2016-3845f3.tif">Levels of LH, FSH, estradiol, and progesterone after the first dose on day 1 and after the last dose on day 21 with elagolix in premenopausal women</a><a href="#cite_note-pmid28323948-26">[26]</a></td></tr></tbody></table> In clinical trials, elagolix produced dose-dependent decreases in gonadotropin, estradiol, and progesterone levels in women.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a><a href="#cite_note-pmid28323948-26">[26]</a><a href="#cite_note-pmid19033369-5">[5]</a> Median levels of estradiol were partially suppressed to 42 pg/mL (<a href="/wiki/Follicular_phase" title="Follicular phase">follicular phase</a> levels) with 150 mg once daily and were fully or near-fully suppressed to 12 pg/mL (<a href="/wiki/Postmenopause" class="mw-redirect" title="Postmenopause">postmenopausal</a> levels) with 200 mg twice daily.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> In a 21-day study in premenopausal women, the effects of elagolix on FSH levels were found to be maximal at a dosage of 300 mg twice per day or above, whereas its effects on LH and estradiol levels were maximal at a dosage of 200 mg twice per day or above.<a href="#cite_note-pmid28323948-26">[26]</a> Levels of progesterone were maintained at <a href="/wiki/Anovulatory" class="mw-redirect" title="Anovulatory">anovulatory</a> levels (<2 ng/mL) across the 21-day study period at dosages of elagolix of 100 mg twice per day and above.<a href="#cite_note-pmid28323948-26">[26]</a> A dosage of elagolix of 400 mg twice per day appears to produce no greater suppression in gonadotropin or estradiol levels than a dosage of 300 mg twice per day in premenopausal women.<a href="#cite_note-pmid28323948-26">[26]</a> Suppression of gonadotropin and sex hormone levels with elagolix occurs rapidly, within hours, and upon discontinuation of elagolix, gonadotropin and sex hormone levels remain suppressed for at least 12 hours, but show recovery within 24 to 48 hours.<a href="#cite_note-pmid28323948-26">[26]</a> As a consequence of its suppression of gonadotropin and sex hormone levels, elagolix inhibits <a href="/wiki/Ovulation" title="Ovulation">ovulation</a> in women.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Over the course of three <a href="/wiki/Menstrual_cycle" title="Menstrual cycle">menstrual cycles</a>, the ovulation rate with elagolix was 50% at 150 mg once daily and 32% at 200 mg twice daily.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Because ovulation is triggered by a surge in estradiol levels at <a href="/wiki/Mid-cycle" class="mw-redirect" title="Mid-cycle">mid-cycle</a>, estrogen exposure during elagolix therapy might be greater around this time in some women.<a href="#cite_note-StraussIII2013-30">[30]</a> In addition to its activity as a GnRH antagonist, elagolix is a weak to moderate <a href="/wiki/Enzyme_inducer" title="Enzyme inducer">inducer</a> of <a href="/wiki/CYP3A" title="CYP3A">CYP3A</a> and an <a href="/wiki/Transporter_inhibitor" class="mw-redirect" title="Transporter inhibitor">inhibitor</a> of <a href="/wiki/P-glycoprotein" title="P-glycoprotein">P-glycoprotein</a>.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> As a result, elagolix may affect the <a href="/wiki/Metabolism" title="Metabolism">metabolism</a> and/or <a href="/wiki/Active_transport" title="Active transport">transport</a> of other medications, and this may contribute to <a href="/wiki/Drug_interaction" title="Drug interaction">drug interactions</a> with elagolix.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> <div class="mw-heading mw-heading3"><h3 id="Pharmacokinetics">Pharmacokinetics</h3>[<a href="/w/index.php?title=Elagolix&action=edit&section=9" title="Edit section: Pharmacokinetics">edit</a>]</div> <figure class="mw-halign-right" typeof="mw:File/Thumb"><a href="/wiki/File:Levels_of_elagolix_following_a_single_oral_dose_of_different_doses_of_elagolix_in_women.png" class="mw-file-description"><img src="//upload.wikimedia.org/wikipedia/commons/thumb/9/92/Levels_of_elagolix_following_a_single_oral_dose_of_different_doses_of_elagolix_in_women.png/325px-Levels_of_elagolix_following_a_single_oral_dose_of_different_doses_of_elagolix_in_women.png" decoding="async" width="325" height="292" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/9/92/Levels_of_elagolix_following_a_single_oral_dose_of_different_doses_of_elagolix_in_women.png/488px-Levels_of_elagolix_following_a_single_oral_dose_of_different_doses_of_elagolix_in_women.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/9/92/Levels_of_elagolix_following_a_single_oral_dose_of_different_doses_of_elagolix_in_women.png/650px-Levels_of_elagolix_following_a_single_oral_dose_of_different_doses_of_elagolix_in_women.png 2x" data-file-width="1247" data-file-height="1120" /></a><figcaption>Levels of elagolix following a single oral dose of different doses of elagolix in women.<a href="#cite_note-pmid19033369-5">[5]</a></figcaption></figure> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1257001546"><table class="infobox" style="width: 250px; clear: right; float:right;margin:0 0 1.5em 1.5em"><tbody><tr><th colspan="2" class="infobox-above" style="font-size:115%">External image</th></tr><tr><td colspan="2" class="infobox-full-data" style="text-align: left"><img alt="image icon" src="//upload.wikimedia.org/wikipedia/en/thumb/6/61/Searchtool.svg/16px-Searchtool.svg.png" decoding="async" width="16" height="16" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/6/61/Searchtool.svg/24px-Searchtool.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/61/Searchtool.svg/32px-Searchtool.svg.png 2x" data-file-width="512" data-file-height="512" /> <a rel="nofollow" class="external text" href="https://academic.oup.com/view-large/figure/81683826/jc.2016-3845f1.tif">Levels of elagolix over 12- or 24-hour dosing intervals on days 1 and 21 with elagolix in premenopausal women</a><a href="#cite_note-pmid28323948-26">[26]</a></td></tr></tbody></table> Elagolix is taken by the <a href="/wiki/Oral_administration" title="Oral administration">oral</a> <a href="/wiki/Route_of_administration" title="Route of administration">route of administration</a>, in contrast to other GnRH modulators.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a><a href="#cite_note-pmid28323948-26">[26]</a><a href="#cite_note-pmid29559388-8">[8]</a><a href="#cite_note-EzzatiCarr2015-6">[6]</a> The oral <a href="/wiki/Bioavailability" title="Bioavailability">bioavailability</a> of elagolix in humans is not described in the <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA) <a href="/wiki/Medication_package_insert" title="Medication package insert">label</a> for the medication, but in <a href="/wiki/Animal_research" class="mw-redirect" title="Animal research">animal research</a> elagolix showed a low oral bioavailability of 5.8% in rats and 11% in monkeys.<a href="#cite_note-pmid29232843-4">[4]</a> Following administration, elagolix is rapidly <a href="/wiki/Absorption_(pharmacokinetics)" class="mw-redirect" title="Absorption (pharmacokinetics)">absorbed</a>, with <a href="/wiki/Cmax_(pharmacology)" title="Cmax (pharmacology)">peak concentrations</a> occurring after 0.5 to 1.5 hours.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a><a href="#cite_note-pmid28323948-26">[26]</a> The <a href="/wiki/Drug_accumulation_ratio" title="Drug accumulation ratio">drug accumulation ratio</a> of elagolix at 150 mg once per day is 0.98 and at 200 mg twice per day is 0.89, indicating that it is not accumulated in the body with continuous administration.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a><a href="#cite_note-pmid28323948-26">[26]</a><a href="#cite_note-pmid19033369-5">[5]</a> At <a href="/wiki/Steady_state_(pharmacokinetics)" class="mw-redirect" title="Steady state (pharmacokinetics)">steady state</a>, peak levels of elagolix at 150 mg once per day are 574 ng/mL and at 200 mg twice per day are 774 ng/mL while <a href="/wiki/Area-under-the-curve_levels" class="mw-redirect" title="Area-under-the-curve levels">area-under-the-curve levels</a> of elagolix at 150 mg once per day are 1,292 ng•hour/mL and at 200 mg twice per day are 1,725 ng•hour/mL.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> A <a href="/wiki/Toxicology" title="Toxicology">toxicology</a> study found that levels of elagolix in women after a single dose of 1,200 mg were 17 times higher than in women taking 200 mg twice daily.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Taking elagolix with a high-<a href="/wiki/Fat" title="Fat">fat</a> <a href="/wiki/Food" title="Food">meal</a> has been found to decrease its peak levels by 36% and its area-under-the-curve levels by 24%.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> In terms of <a href="/wiki/Distribution_(pharmacology)" title="Distribution (pharmacology)">distribution</a>, the <a href="/wiki/Plasma_protein_binding" title="Plasma protein binding">plasma protein binding</a> of elagolix is 80% and its <a href="/wiki/Blood-to-plasma_ratio" class="mw-redirect" title="Blood-to-plasma ratio">blood-to-plasma ratio</a> is 0.6.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> The <a href="/wiki/Volume_of_distribution" title="Volume of distribution">volume of distribution</a> at <a href="/wiki/Steady_state_(pharmacokinetics)" class="mw-redirect" title="Steady state (pharmacokinetics)">steady state</a> is 1,674 L at 150 mg once per day and 881 L at 200 mg twice per day.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Elagolix is <a href="/wiki/Metabolism" title="Metabolism">metabolized</a> in the <a href="/wiki/Liver" title="Liver">liver</a>, with the major <a href="/wiki/Metabolic_pathway" title="Metabolic pathway">pathway</a> being by <a href="/wiki/CYP3A" title="CYP3A">CYP3A</a> and minor pathways including by <a href="/wiki/CYP2D6" title="CYP2D6">CYP2D6</a>, <a href="/wiki/CYP2C8" title="CYP2C8">CYP2C8</a>, and <a href="/wiki/UDP-glucuronosyltransferase" class="mw-redirect" title="UDP-glucuronosyltransferase"><abbr title="uridine 5'-diphosphate">UDP</abbr>-glucuronosyltransferases</a>.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> The <a href="/wiki/Terminal_half-life" class="mw-redirect" title="Terminal half-life">terminal half-life</a> of elagolix is typically about 4 to 6 hours.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a><a href="#cite_note-pmid28323948-26">[26]</a> A study found that its half-life was 2.4 to 6.3 hours with a single dose and was 2.2 to 10.8 hours with continuous administration.<a href="#cite_note-pmid19033369-5">[5]</a><a href="#cite_note-EzzatiCarr2015-6">[6]</a> The oral <a href="/wiki/Clearance_(pharmacology)" title="Clearance (pharmacology)">clearance</a> of elagolix is 123 L/hour at 150 mg once per day and 144 L/hour at 200 mg twice per day.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> The major pathway of <a href="/wiki/Elimination_(pharmacology)" title="Elimination (pharmacology)">elimination</a> of elagolix is hepatic metabolism.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Elagolix is taken up from the <a href="/wiki/Circulatory_system" title="Circulatory system">circulation</a> into the liver by the hepatic <a href="/wiki/OATP1B1" class="mw-redirect" title="OATP1B1">OATP1B1</a> carrier.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> In people with two reduced function <a href="/wiki/Allele" title="Allele">alleles</a> of the <a href="/wiki/Gene" title="Gene">gene</a> that <a href="/wiki/Genetic_code" title="Genetic code">encodes</a> OATP1B1 (SLCO1B1 521T>C; SLCO1B1 521 C/C <a href="/wiki/Genotype" title="Genotype">genotype</a>), <a href="/wiki/Blood_plasma" title="Blood plasma">plasma</a> levels of elagolix have been found to be increased by 78% relative to in people with normal OATP1B1 function (SLCO1B1 521T/T genotype).<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> The frequency of this reduced function OATP1B1 <a href="/wiki/Genotype" title="Genotype">genotype</a> is generally less than 5% in most <a href="/wiki/Race_(human_categorization)" title="Race (human categorization)">racial</a> and <a href="/wiki/Ethnicity" title="Ethnicity">ethnic</a> groups.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Elagolix is <a href="/wiki/Excretion" title="Excretion">excreted</a> less than 3% in <a href="/wiki/Urine" title="Urine">urine</a> and 90% in <a href="/wiki/Feces" title="Feces">feces</a>.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Exposure to elagolix is not affected by <a href="/wiki/Renal_impairment" class="mw-redirect" title="Renal impairment">renal impairment</a> or mild <a href="/wiki/Hepatic_impairment" class="mw-redirect" title="Hepatic impairment">hepatic impairment</a>, but is increased by approximately 3-fold in women with moderate hepatic impairment and by approximately 7-fold in women with severe hepatic impairment.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> There were no differences in the <a href="/wiki/Pharmacokinetics" title="Pharmacokinetics">pharmacokinetics</a> of elagolix between individuals of different racial and ethnic groups.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Similarly, the pharmacokinetics of elagolix were unaffected by <a href="/wiki/Body_weight" class="mw-redirect" title="Body weight">body weight</a> and <a href="/wiki/Body_mass_index" title="Body mass index">body mass index</a>.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Peak and area-under-the-curve levels of elagolix have been shown to be altered by <a href="/wiki/CYP3A4" title="CYP3A4">CYP3A4</a> <a href="/wiki/Enzyme_inhibitor" title="Enzyme inhibitor">inhibitors</a> like <a href="/wiki/Ketoconazole" title="Ketoconazole">ketoconazole</a> and CYP3A4 <a href="/wiki/Enzyme_inducer" title="Enzyme inducer">inducers</a> like <a href="/wiki/Rifampin" class="mw-redirect" title="Rifampin">rifampin</a>.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Inhibitors of OATP1B1 may increase circulating levels of elagolix, and elagolix is considered to be contraindicated in combination with strong OATP1B1 inhibitors.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Elagolix is a <a href="/wiki/Substrate_(biochemistry)" class="mw-redirect" title="Substrate (biochemistry)">substrate</a> of <a href="/wiki/P-glycoprotein" title="P-glycoprotein">P-glycoprotein</a>, but the effect of inhibitors and inducers of P-glycoprotein on the pharmacokinetics of elagolix is unknown.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> Elagolix itself is an inhibitor of P-glycoprotein.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> <div class="mw-heading mw-heading2"><h2 id="Chemistry">Chemistry</h2>[<a href="/w/index.php?title=Elagolix&action=edit&section=10" title="Edit section: Chemistry">edit</a>]</div> <style data-mw-deduplicate="TemplateStyles:r1236090951">.mw-parser-output .hatnote{font-style:italic}.mw-parser-output div.hatnote{padding-left:1.6em;margin-bottom:0.5em}.mw-parser-output .hatnote i{font-style:normal}.mw-parser-output .hatnote+link+.hatnote{margin-top:-0.5em}@media print{body.ns-0 .mw-parser-output .hatnote{display:none!important}}</style><div role="note" class="hatnote navigation-not-searchable">See also: <a href="/wiki/Gonadotropin-releasing_hormone_receptor#Antagonists" title="Gonadotropin-releasing hormone receptor">Gonadotropin-releasing hormone receptor § Antagonists</a></div> Elagolix is a <a href="/wiki/Small-molecule" class="mw-redirect" title="Small-molecule">small-molecule</a> and <a href="/wiki/Non-peptide" class="mw-redirect" title="Non-peptide">non-peptide</a> <a href="/wiki/Chemical_compound" title="Chemical compound">compound</a>.<a href="#cite_note-AdisInsight-9">[9]</a><a href="#cite_note-ChemIDplus-31">[31]</a><a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> This is in contrast to <a href="/wiki/GnRH_analogue" class="mw-redirect" title="GnRH analogue">GnRH analogues</a> such as <a href="/wiki/Leuprorelin" title="Leuprorelin">leuprorelin</a> and <a href="/wiki/Cetrorelix" title="Cetrorelix">cetrorelix</a>, which are <a href="/wiki/Peptide" title="Peptide">peptides</a> and <a href="/wiki/Structural_analog" title="Structural analog">analogues</a> of GnRH.<a href="#cite_note-EzzatiCarr2015-6">[6]</a><a href="#cite_note-AdisInsight-9">[9]</a> Other small-molecule and non-peptide orally active GnRH antagonists besides elagolix include <a href="/wiki/Linzagolix" title="Linzagolix">linzagolix</a>, <a href="/wiki/Opigolix" title="Opigolix">opigolix</a>, <a href="/wiki/Relugolix" title="Relugolix">relugolix</a>, and <a href="/wiki/Sufugolix" title="Sufugolix">sufugolix</a>, although none of these compounds have been introduced for medical use at this time.<a href="#cite_note-DrugInfoPortal@NLM-32">[32]</a> Elagolix is used as elagolix sodium, the <a href="/wiki/Sodium" title="Sodium">sodium</a> <a href="/wiki/Salt_(chemistry)" title="Salt (chemistry)">salt</a> of elagolix.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> It is a white to off white to light yellow <a href="/wiki/Powder" title="Powder">powder</a>.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> The compound is freely <a href="/wiki/Solubility" title="Solubility">soluble</a> in <a href="/wiki/Water" title="Water">water</a>.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> The <a href="/wiki/Chemical_name" class="mw-redirect" title="Chemical name">chemical name</a> of elagolix sodium is sodium 4-({(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}-4-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl]-1-phenylethyl}amino)butanoate.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> It has a <a href="/wiki/Molecular_formula" class="mw-redirect" title="Molecular formula">molecular formula</a> of C32H29F5N3O5Na and a <a href="/wiki/Molecular_weight" class="mw-redirect" title="Molecular weight">molecular weight</a> of 653.58 g/mol.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> The <a href="/wiki/Free_acid" class="mw-redirect" title="Free acid">free acid</a> form of elagolix has a molecular formula of C32H29F5N3O5 and a molecular weight of 631.60 g/mol.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> <div class="mw-heading mw-heading2"><h2 id="History">History</h2>[<a href="/w/index.php?title=Elagolix&action=edit&section=11" title="Edit section: History">edit</a>]</div> Elagolix was first described in the literature in 2005.<a href="#cite_note-US7056927-33">[33]</a><a href="#cite_note-pmid15715483-34">[34]</a><a href="#cite_note-pmid19006286-10">[10]</a> It was originally developed by the <a href="/wiki/Pharmaceutical_company" class="mw-redirect" title="Pharmaceutical company">pharmaceutical company</a> <a href="/wiki/Neurocrine_Biosciences" title="Neurocrine Biosciences">Neurocrine Biosciences</a>, and was later developed together by Neurocrine Biosciences and <a href="/wiki/AbbVie" title="AbbVie">AbbVie</a> (previously <a href="/wiki/Abbott_Laboratories" title="Abbott Laboratories">Abbott Laboratories</a>).<a href="#cite_note-AdisInsight-9">[9]</a><a href="#cite_note-pmid19006286-10">[10]</a><a href="#cite_note-LemkeWilliams2012-25">[25]</a> In June 2010, Neurocrine Biosciences and Abbott announced a global agreement to develop and commercialize elagolix for the treatment of endometriosis.<a href="#cite_note-FierceBiotech2010-35">[35]</a> The medication completed <a href="/wiki/Phases_of_clinical_research#Phase_III" title="Phases of clinical research">phase III</a> <a href="/wiki/Clinical_trial" title="Clinical trial">clinical trials</a> for endometriosis in November 2016.<a href="#cite_note-pmid29232843-4">[4]</a> Two phase III clinical trials, the Elaris Endometriosis I and II (EM-I and EM-II) studies, were conducted.<a href="#cite_note-pmid29559388-8">[8]</a><a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> The studies included almost 1,700 women, about 950 of whom were treated with elagolix.<a href="#cite_note-pmid29559388-8">[8]</a><a href="#cite_note-Orilissa_FDA_Label-1">[1]</a><a href="#cite_note-UPI2018-14">[14]</a> In September 2017, AbbVie filed a <a href="/wiki/New_Drug_Application" title="New Drug Application">New Drug Application</a> (NDA) for elagolix for the treatment of pain associated with endometriosis in the <a href="/wiki/United_States" title="United States">United States</a>.<a href="#cite_note-pmid29232843-4">[4]</a> The medication was approved by the FDA for the treatment of endometriosis-associated pain in the United States on 23 July 2018.<a href="#cite_note-AdisInsight-9">[9]</a><a href="#cite_note-Drugs.com-2-36">[36]</a> It was the first new medication to be approved by the FDA for the treatment of endometriosis in more than a decade.<a href="#cite_note-Time2018-37">[37]</a><a href="#cite_note-Vox2018-38">[38]</a> Elagolix was the first member of a new class of <a href="/wiki/GnRH_modulator" class="mw-redirect" title="GnRH modulator">GnRH modulators</a> described as "second-generation" due to their <a href="/wiki/Non-peptide" class="mw-redirect" title="Non-peptide">non-peptide</a> and <a href="/wiki/Small-molecule" class="mw-redirect" title="Small-molecule">small-molecule</a> nature and <a href="/wiki/Oral_administration" title="Oral administration">oral activity</a> to be marketed.<a href="#cite_note-pmid29232843-4">[4]</a><a href="#cite_note-EzzatiCarr2015-6">[6]</a> A second member of this group, <a href="/wiki/Relugolix" title="Relugolix">relugolix</a> (brand name Relumina), was introduced in <a href="/wiki/Japan" title="Japan">Japan</a> in January 2019.<a href="#cite_note-AdisInsight-Relugolix-11">[11]</a> In addition to endometriosis, elagolix is under development for the treatment of uterine fibroids and menorrhagia.<a href="#cite_note-AdisInsight-9">[9]</a> It is in phase III clinical trials for these indications.<a href="#cite_note-AdisInsight-9">[9]</a> <div class="mw-heading mw-heading2"><h2 id="Society_and_culture">Society and culture</h2>[<a href="/w/index.php?title=Elagolix&action=edit&section=12" title="Edit section: Society and culture">edit</a>]</div> <div class="mw-heading mw-heading3"><h3 id="Generic_names">Generic names</h3>[<a href="/w/index.php?title=Elagolix&action=edit&section=13" title="Edit section: Generic names">edit</a>]</div> Elagolix is the <a href="/wiki/Generic_term" class="mw-redirect" title="Generic term">generic name</a> of the drug and its <a href="/wiki/International_Nonproprietary_Name" class="mw-redirect" title="International Nonproprietary Name"><abbr title="International Nonproprietary Name">INN</abbr></a><span class="sr-only" style="border: 0; clip: rect(0, 0, 0, 0); clip-path: polygon(0px 0px, 0px 0px, 0px 0px); height: 1px; margin: -1px; overflow: hidden; padding: 0; position: absolute; width: 1px; white-space: nowrap;">Tooltip International Nonproprietary Name and <a href="/wiki/United_States_Adopted_Name" title="United States Adopted Name"><abbr title="United States Adopted Name">USAN</abbr></a><span class="sr-only" style="border: 0; clip: rect(0, 0, 0, 0); clip-path: polygon(0px 0px, 0px 0px, 0px 0px); height: 1px; margin: -1px; overflow: hidden; padding: 0; position: absolute; width: 1px; white-space: nowrap;">Tooltip United States Adopted Name.<a href="#cite_note-ChemIDplus-31">[31]</a> It is also known by its former developmental code names NBI-56418 and ABT-620.<a href="#cite_note-AdisInsight-9">[9]</a><a href="#cite_note-ChemIDplus-31">[31]</a> <div class="mw-heading mw-heading3"><h3 id="Brand_names">Brand names</h3>[<a href="/w/index.php?title=Elagolix&action=edit&section=14" title="Edit section: Brand names">edit</a>]</div> Elagolix is marketed under the brand name Orilissa.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a> <div class="mw-heading mw-heading3"><h3 id="Availability">Availability</h3>[<a href="/w/index.php?title=Elagolix&action=edit&section=15" title="Edit section: Availability">edit</a>]</div> Elagolix is available in the United States and Canada.<a href="#cite_note-Orilissa_FDA_Label-1">[1]</a><a href="#cite_note-Orilissa_CA_PI-2">[2]</a><a href="#cite_note-OrillisaLabelCa-3">[3]</a> A similar medication, <a href="/wiki/Relugolix" title="Relugolix">relugolix</a>, is available in Japan.<a href="#cite_note-AdisInsight-Relugolix-11">[11]</a> <div class="mw-heading mw-heading3"><h3 id="Economics">Economics</h3>[<a href="/w/index.php?title=Elagolix&action=edit&section=16" title="Edit section: Economics">edit</a>]</div> Prior to its introduction, elagolix was estimated to cost about US$850 per month.<a href="#cite_note-UPI2018-14">[14]</a> It is not available as a <a href="/wiki/Generic_medication" class="mw-redirect" title="Generic medication">generic medication</a>.[<a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed">citation needed</a>] <div class="mw-heading mw-heading2"><h2 id="Research">Research</h2>[<a href="/w/index.php?title=Elagolix&action=edit&section=17" title="Edit section: Research">edit</a>]</div> As of November 2018<a class="external text" href="https://en.wikipedia.org/w/index.php?title=Elagolix&action=edit">[update]</a>, elagolix in <a href="/wiki/Phases_of_clinical_research#Phase_III" title="Phases of clinical research">phase III</a> <a href="/wiki/Clinical_trial" title="Clinical trial">clinical trials</a> for the treatment of <a href="/wiki/Uterine_fibroid" title="Uterine fibroid">uterine fibroids</a> (uterine leiomyoma) and <a href="/wiki/Menorrhagia" class="mw-redirect" title="Menorrhagia">menorrhagia</a> (abnormally heavy bleeding during <a href="/wiki/Menstruation" title="Menstruation">menstruation</a>) in women.<a href="#cite_note-EzzatiCarr2015-6">[6]</a><a href="#cite_note-AdisInsight-9">[9]</a> An <a href="/wiki/Efficacy" title="Efficacy">efficacy</a> and <a href="/wiki/Drug_safety" class="mw-redirect" title="Drug safety">safety</a> study of elagolix in combination with add-back <a href="/wiki/Estradiol_(medication)" title="Estradiol (medication)">estradiol</a>, an <a href="/wiki/Estrogen_(medication)" title="Estrogen (medication)">estrogen</a>, and <a href="/wiki/Norethisterone_acetate" title="Norethisterone acetate">norethisterone acetate</a>, a <a href="/wiki/Progestin" class="mw-redirect" title="Progestin">progestin</a>, for the treatment of menorrhagia associated with uterine fibroids in premenopausal women has been published.<a href="#cite_note-pmid29232843-4">[4]</a> The medication was also under investigation for the treatment of <a href="/wiki/Prostate_cancer" title="Prostate cancer">prostate cancer</a> and <a href="/wiki/Benign_prostatic_hyperplasia" title="Benign prostatic hyperplasia">benign prostatic hyperplasia</a> (enlarged prostate) in men, but development for these indications was discontinued.<a href="#cite_note-AdisInsight-9">[9]</a> <div class="mw-heading mw-heading2"><h2 id="References">References</h2>[<a href="/w/index.php?title=Elagolix&action=edit&section=18" title="Edit section: References">edit</a>]</div> <style data-mw-deduplicate="TemplateStyles:r1239543626">.mw-parser-output .reflist{margin-bottom:0.5em;list-style-type:decimal}@media screen{.mw-parser-output .reflist{font-size:90%}}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}</style><div class="reflist"> <div class="mw-references-wrap mw-references-columns"><ol class="references"> <li id="cite_note-Orilissa_FDA_Label-1">^ <a href="#cite_ref-Orilissa_FDA_Label_1-0">a</a> <a href="#cite_ref-Orilissa_FDA_Label_1-1">b</a> <a href="#cite_ref-Orilissa_FDA_Label_1-2">c</a> <a href="#cite_ref-Orilissa_FDA_Label_1-3">d</a> <a href="#cite_ref-Orilissa_FDA_Label_1-4">e</a> <a href="#cite_ref-Orilissa_FDA_Label_1-5">f</a> <a href="#cite_ref-Orilissa_FDA_Label_1-6">g</a> <a href="#cite_ref-Orilissa_FDA_Label_1-7">h</a> <a href="#cite_ref-Orilissa_FDA_Label_1-8">i</a> <a href="#cite_ref-Orilissa_FDA_Label_1-9">j</a> <a href="#cite_ref-Orilissa_FDA_Label_1-10">k</a> <a href="#cite_ref-Orilissa_FDA_Label_1-11">l</a> <a href="#cite_ref-Orilissa_FDA_Label_1-12">m</a> <a href="#cite_ref-Orilissa_FDA_Label_1-13">n</a> <a href="#cite_ref-Orilissa_FDA_Label_1-14">o</a> <a href="#cite_ref-Orilissa_FDA_Label_1-15">p</a> <a href="#cite_ref-Orilissa_FDA_Label_1-16">q</a> <a href="#cite_ref-Orilissa_FDA_Label_1-17">r</a> <a href="#cite_ref-Orilissa_FDA_Label_1-18">s</a> <a href="#cite_ref-Orilissa_FDA_Label_1-19">t</a> <a href="#cite_ref-Orilissa_FDA_Label_1-20">u</a> <a href="#cite_ref-Orilissa_FDA_Label_1-21">v</a> <a href="#cite_ref-Orilissa_FDA_Label_1-22">w</a> <a href="#cite_ref-Orilissa_FDA_Label_1-23">x</a> <a href="#cite_ref-Orilissa_FDA_Label_1-24">y</a> <a href="#cite_ref-Orilissa_FDA_Label_1-25">z</a> <a href="#cite_ref-Orilissa_FDA_Label_1-26">aa</a> <a href="#cite_ref-Orilissa_FDA_Label_1-27">ab</a> <a href="#cite_ref-Orilissa_FDA_Label_1-28">ac</a> <a href="#cite_ref-Orilissa_FDA_Label_1-29">ad</a> <a href="#cite_ref-Orilissa_FDA_Label_1-30">ae</a> <a href="#cite_ref-Orilissa_FDA_Label_1-31">af</a> <a href="#cite_ref-Orilissa_FDA_Label_1-32">ag</a> <a href="#cite_ref-Orilissa_FDA_Label_1-33">ah</a> <a href="#cite_ref-Orilissa_FDA_Label_1-34">ai</a> <a href="#cite_ref-Orilissa_FDA_Label_1-35">aj</a> <a href="#cite_ref-Orilissa_FDA_Label_1-36">ak</a> <a href="#cite_ref-Orilissa_FDA_Label_1-37">al</a> <a href="#cite_ref-Orilissa_FDA_Label_1-38">am</a> <a href="#cite_ref-Orilissa_FDA_Label_1-39">an</a> <a href="#cite_ref-Orilissa_FDA_Label_1-40">ao</a> <a href="#cite_ref-Orilissa_FDA_Label_1-41">ap</a> <a href="#cite_ref-Orilissa_FDA_Label_1-42">aq</a> <a href="#cite_ref-Orilissa_FDA_Label_1-43">ar</a> <a href="#cite_ref-Orilissa_FDA_Label_1-44">as</a> <a href="#cite_ref-Orilissa_FDA_Label_1-45">at</a> <a href="#cite_ref-Orilissa_FDA_Label_1-46">au</a> <a href="#cite_ref-Orilissa_FDA_Label_1-47">av</a> <a href="#cite_ref-Orilissa_FDA_Label_1-48">aw</a> <a href="#cite_ref-Orilissa_FDA_Label_1-49">ax</a> <a href="#cite_ref-Orilissa_FDA_Label_1-50">ay</a> <a href="#cite_ref-Orilissa_FDA_Label_1-51">az</a> <a href="#cite_ref-Orilissa_FDA_Label_1-52">ba</a> <a href="#cite_ref-Orilissa_FDA_Label_1-53">bb</a> <a href="#cite_ref-Orilissa_FDA_Label_1-54">bc</a> <a href="#cite_ref-Orilissa_FDA_Label_1-55">bd</a> <a href="#cite_ref-Orilissa_FDA_Label_1-56">be</a> <a href="#cite_ref-Orilissa_FDA_Label_1-57">bf</a> <a href="#cite_ref-Orilissa_FDA_Label_1-58">bg</a> <a href="#cite_ref-Orilissa_FDA_Label_1-59">bh</a> <a href="#cite_ref-Orilissa_FDA_Label_1-60">bi</a> <a href="#cite_ref-Orilissa_FDA_Label_1-61">bj</a> <a href="#cite_ref-Orilissa_FDA_Label_1-62">bk</a> <a href="#cite_ref-Orilissa_FDA_Label_1-63">bl</a> <a href="#cite_ref-Orilissa_FDA_Label_1-64">bm</a> <a href="#cite_ref-Orilissa_FDA_Label_1-65">bn</a> <a href="#cite_ref-Orilissa_FDA_Label_1-66">bo</a> <a href="#cite_ref-Orilissa_FDA_Label_1-67">bp</a> <a href="#cite_ref-Orilissa_FDA_Label_1-68">bq</a> <a href="#cite_ref-Orilissa_FDA_Label_1-69">br</a> <a href="#cite_ref-Orilissa_FDA_Label_1-70">bs</a> <a href="#cite_ref-Orilissa_FDA_Label_1-71">bt</a> <a href="#cite_ref-Orilissa_FDA_Label_1-72">bu</a> <a href="#cite_ref-Orilissa_FDA_Label_1-73">bv</a> <a href="#cite_ref-Orilissa_FDA_Label_1-74">bw</a> <a href="#cite_ref-Orilissa_FDA_Label_1-75">bx</a> <a href="#cite_ref-Orilissa_FDA_Label_1-76">by</a> <a href="#cite_ref-Orilissa_FDA_Label_1-77">bz</a> <a href="#cite_ref-Orilissa_FDA_Label_1-78">ca</a> <a href="#cite_ref-Orilissa_FDA_Label_1-79">cb</a> <a href="#cite_ref-Orilissa_FDA_Label_1-80">cc</a> <a href="#cite_ref-Orilissa_FDA_Label_1-81">cd</a> <a href="#cite_ref-Orilissa_FDA_Label_1-82">ce</a> <a href="#cite_ref-Orilissa_FDA_Label_1-83">cf</a> <a href="#cite_ref-Orilissa_FDA_Label_1-84">cg</a> <a href="#cite_ref-Orilissa_FDA_Label_1-85">ch</a> <a href="#cite_ref-Orilissa_FDA_Label_1-86">ci</a> <a href="#cite_ref-Orilissa_FDA_Label_1-87">cj</a> <a href="#cite_ref-Orilissa_FDA_Label_1-88">ck</a> <a href="#cite_ref-Orilissa_FDA_Label_1-89">cl</a> <a href="#cite_ref-Orilissa_FDA_Label_1-90">cm</a> <a href="#cite_ref-Orilissa_FDA_Label_1-91">cn</a> <a href="#cite_ref-Orilissa_FDA_Label_1-92">co</a> <a href="#cite_ref-Orilissa_FDA_Label_1-93">cp</a> <a href="#cite_ref-Orilissa_FDA_Label_1-94">cq</a> <a href="#cite_ref-Orilissa_FDA_Label_1-95">cr</a> <a href="#cite_ref-Orilissa_FDA_Label_1-96">cs</a> <a href="#cite_ref-Orilissa_FDA_Label_1-97">ct</a> <a href="#cite_ref-Orilissa_FDA_Label_1-98">cu</a> <a href="#cite_ref-Orilissa_FDA_Label_1-99">cv</a> <a href="#cite_ref-Orilissa_FDA_Label_1-100">cw</a> <a href="#cite_ref-Orilissa_FDA_Label_1-101">cx</a> <a href="#cite_ref-Orilissa_FDA_Label_1-102">cy</a> <a href="#cite_ref-Orilissa_FDA_Label_1-103">cz</a> <a href="#cite_ref-Orilissa_FDA_Label_1-104">da</a> <a href="#cite_ref-Orilissa_FDA_Label_1-105">db</a> <a href="#cite_ref-Orilissa_FDA_Label_1-106">dc</a> <a href="#cite_ref-Orilissa_FDA_Label_1-107">dd</a> <a href="#cite_ref-Orilissa_FDA_Label_1-108">de</a> <a href="#cite_ref-Orilissa_FDA_Label_1-109">df</a> <a href="#cite_ref-Orilissa_FDA_Label_1-110">dg</a> <a href="#cite_ref-Orilissa_FDA_Label_1-111">dh</a> <a href="#cite_ref-Orilissa_FDA_Label_1-112">di</a> <a href="#cite_ref-Orilissa_FDA_Label_1-113">dj</a> <a href="#cite_ref-Orilissa_FDA_Label_1-114">dk</a> <a href="#cite_ref-Orilissa_FDA_Label_1-115">dl</a> <a href="#cite_ref-Orilissa_FDA_Label_1-116">dm</a> <a href="#cite_ref-Orilissa_FDA_Label_1-117">dn</a> <a href="#cite_ref-Orilissa_FDA_Label_1-118">do</a> <a href="#cite_ref-Orilissa_FDA_Label_1-119">dp</a> <a href="#cite_ref-Orilissa_FDA_Label_1-120">dq</a> <a href="#cite_ref-Orilissa_FDA_Label_1-121">dr</a> <a href="#cite_ref-Orilissa_FDA_Label_1-122">ds</a> <a href="#cite_ref-Orilissa_FDA_Label_1-123">dt</a> <a href="#cite_ref-Orilissa_FDA_Label_1-124">du</a> <a href="#cite_ref-Orilissa_FDA_Label_1-125">dv</a> <a href="#cite_ref-Orilissa_FDA_Label_1-126">dw</a> <a href="#cite_ref-Orilissa_FDA_Label_1-127">dx</a> <a href="#cite_ref-Orilissa_FDA_Label_1-128">dy</a> <a href="#cite_ref-Orilissa_FDA_Label_1-129">dz</a> <a href="#cite_ref-Orilissa_FDA_Label_1-130">ea</a> <a href="#cite_ref-Orilissa_FDA_Label_1-131">eb</a> <a href="#cite_ref-Orilissa_FDA_Label_1-132">ec</a> <a href="#cite_ref-Orilissa_FDA_Label_1-133">ed</a> <a href="#cite_ref-Orilissa_FDA_Label_1-134">ee</a> <a href="#cite_ref-Orilissa_FDA_Label_1-135">ef</a> <a href="#cite_ref-Orilissa_FDA_Label_1-136">eg</a> <a href="#cite_ref-Orilissa_FDA_Label_1-137">eh</a> <a href="#cite_ref-Orilissa_FDA_Label_1-138">ei</a> <a href="#cite_ref-Orilissa_FDA_Label_1-139">ej</a> <a href="#cite_ref-Orilissa_FDA_Label_1-140">ek</a> <style data-mw-deduplicate="TemplateStyles:r1238218222">.mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free.id-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited.id-lock-limited a,.mw-parser-output .id-lock-registration.id-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription.id-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-free a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-limited a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-registration a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-subscription a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .cs1-ws-icon a{background-size:contain;padding:0 1em 0 0}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:var(--color-error,#d33)}.mw-parser-output .cs1-visible-error{color:var(--color-error,#d33)}.mw-parser-output .cs1-maint{display:none;color:#085;margin-left:0.3em}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}@media screen{.mw-parser-output .cs1-format{font-size:95%}html.skin-theme-clientpref-night .mw-parser-output .cs1-maint{color:#18911f}}@media screen and (prefers-color-scheme:dark){html.skin-theme-clientpref-os .mw-parser-output .cs1-maint{color:#18911f}}</style><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a86757b3-09c5-fd3b-1223-244e94f50a66">"Orilissa- elagolix tablet, film coated"</a>. DailyMed. 5 May 2020. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20200924152922/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a86757b3-09c5-fd3b-1223-244e94f50a66">Archived</a> from the original on 24 September 2020. Retrieved 30 May 2020.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=DailyMed&rft.atitle=Orilissa-+elagolix+tablet%2C+film+coated&rft.date=2020-05-05&rft_id=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3Da86757b3-09c5-fd3b-1223-244e94f50a66&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-Orilissa_CA_PI-2">^ <a href="#cite_ref-Orilissa_CA_PI_2-0">a</a> <a href="#cite_ref-Orilissa_CA_PI_2-1">b</a> <a href="#cite_ref-Orilissa_CA_PI_2-2">c</a> <a href="#cite_ref-Orilissa_CA_PI_2-3">d</a> <a href="#cite_ref-Orilissa_CA_PI_2-4">e</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97182">"Orilissa Product information"</a>. <a href="/wiki/Health_Canada" title="Health Canada">Health Canada</a>. 25 April 2012. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20220601033508/https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97182">Archived</a> from the original on 1 June 2022. Retrieved 31 May 2022.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=Health+Canada&rft.atitle=Orilissa+Product+information&rft.date=2012-04-25&rft_id=https%3A%2F%2Fhealth-products.canada.ca%2Fdpd-bdpp%2Finfo.do%3Flang%3Den%26code%3D97182&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-OrillisaLabelCa-3">^ <a href="#cite_ref-OrillisaLabelCa_3-0">a</a> <a href="#cite_ref-OrillisaLabelCa_3-1">b</a> <a href="#cite_ref-OrillisaLabelCa_3-2">c</a> <a href="#cite_ref-OrillisaLabelCa_3-3">d</a> <a href="#cite_ref-OrillisaLabelCa_3-4">e</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="http://www.abbvie.ca/content/dam/abbviecorp/ca/en/docs/ORILISSA_PM_EN.PDF">"Orilissa (elagolix) Health Canada Product Monograph"</a> (PDF). 4 October 2018. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20190216153435/http://www.abbvie.ca/content/dam/abbviecorp/ca/en/docs/ORILISSA_PM_EN.PDF">Archived</a> (PDF) from the original on 16 February 2019. Retrieved 15 February 2019.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=Orilissa+%28elagolix%29+Health+Canada+Product+Monograph&rft.date=2018-10-04&rft_id=http%3A%2F%2Fwww.abbvie.ca%2Fcontent%2Fdam%2Fabbviecorp%2Fca%2Fen%2Fdocs%2FORILISSA_PM_EN.PDF&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-pmid29232843-4">^ <a href="#cite_ref-pmid29232843_4-0">a</a> <a href="#cite_ref-pmid29232843_4-1">b</a> <a href="#cite_ref-pmid29232843_4-2">c</a> <a href="#cite_ref-pmid29232843_4-3">d</a> <a href="#cite_ref-pmid29232843_4-4">e</a> <a href="#cite_ref-pmid29232843_4-5">f</a> <a href="#cite_ref-pmid29232843_4-6">g</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFTukunOlbergRissHaraldsen2017" class="citation journal cs1">Tukun FL, Olberg DE, Riss PJ, Haraldsen I, Kaass A, Klaveness J (December 2017). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149776">"Recent Development of Non-Peptide GnRH Antagonists"</a>. Molecules. 22 (12): 2188. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.3390%2Fmolecules22122188">10.3390/molecules22122188</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a> <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149776">6149776</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/29232843">29232843</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Molecules&rft.atitle=Recent+Development+of+Non-Peptide+GnRH+Antagonists&rft.volume=22&rft.issue=12&rft.pages=2188&rft.date=2017-12&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6149776%23id-name%3DPMC&rft_id=info%3Apmid%2F29232843&rft_id=info%3Adoi%2F10.3390%2Fmolecules22122188&rft.aulast=Tukun&rft.aufirst=FL&rft.au=Olberg%2C+DE&rft.au=Riss%2C+PJ&rft.au=Haraldsen%2C+I&rft.au=Kaass%2C+A&rft.au=Klaveness%2C+J&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6149776&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-pmid19033369-5">^ <a href="#cite_ref-pmid19033369_5-0">a</a> <a href="#cite_ref-pmid19033369_5-1">b</a> <a href="#cite_ref-pmid19033369_5-2">c</a> <a href="#cite_ref-pmid19033369_5-3">d</a> <a href="#cite_ref-pmid19033369_5-4">e</a> <a href="#cite_ref-pmid19033369_5-5">f</a> <a href="#cite_ref-pmid19033369_5-6">g</a> <a href="#cite_ref-pmid19033369_5-7">h</a> <a href="#cite_ref-pmid19033369_5-8">i</a> <a href="#cite_ref-pmid19033369_5-9">j</a> <a href="#cite_ref-pmid19033369_5-10">k</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFStruthersNichollsGrundyChen2009" class="citation journal cs1">Struthers RS, Nicholls AJ, Grundy J, Chen T, Jimenez R, Yen SS, Bozigian HP (February 2009). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646513">"Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix"</a>. J. Clin. Endocrinol. Metab. 94 (2): 545–51. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1210%2Fjc.2008-1695">10.1210/jc.2008-1695</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a> <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646513">2646513</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/19033369">19033369</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=J.+Clin.+Endocrinol.+Metab.&rft.atitle=Suppression+of+gonadotropins+and+estradiol+in+premenopausal+women+by+oral+administration+of+the+nonpeptide+gonadotropin-releasing+hormone+antagonist+elagolix&rft.volume=94&rft.issue=2&rft.pages=545-51&rft.date=2009-02&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2646513%23id-name%3DPMC&rft_id=info%3Apmid%2F19033369&rft_id=info%3Adoi%2F10.1210%2Fjc.2008-1695&rft.aulast=Struthers&rft.aufirst=RS&rft.au=Nicholls%2C+AJ&rft.au=Grundy%2C+J&rft.au=Chen%2C+T&rft.au=Jimenez%2C+R&rft.au=Yen%2C+SS&rft.au=Bozigian%2C+HP&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2646513&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-EzzatiCarr2015-6">^ <a href="#cite_ref-EzzatiCarr2015_6-0">a</a> <a href="#cite_ref-EzzatiCarr2015_6-1">b</a> <a href="#cite_ref-EzzatiCarr2015_6-2">c</a> <a href="#cite_ref-EzzatiCarr2015_6-3">d</a> <a href="#cite_ref-EzzatiCarr2015_6-4">e</a> <a href="#cite_ref-EzzatiCarr2015_6-5">f</a> <a href="#cite_ref-EzzatiCarr2015_6-6">g</a> <a href="#cite_ref-EzzatiCarr2015_6-7">h</a> <a href="#cite_ref-EzzatiCarr2015_6-8">i</a> <a href="#cite_ref-EzzatiCarr2015_6-9">j</a> <a href="#cite_ref-EzzatiCarr2015_6-10">k</a> <a href="#cite_ref-EzzatiCarr2015_6-11">l</a> <a href="#cite_ref-EzzatiCarr2015_6-12">m</a> <a href="#cite_ref-EzzatiCarr2015_6-13">n</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFEzzatiCarr2015" class="citation journal cs1">Ezzati M, Carr BR (January 2015). <a rel="nofollow" class="external text" href="https://doi.org/10.2217%2Fwhe.14.68">"Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain"</a>. Women's Health. 11 (1): 19–28. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.2217%2Fwhe.14.68">10.2217/whe.14.68</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/25581052">25581052</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Women%27s+Health&rft.atitle=Elagolix%2C+a+novel%2C+orally+bioavailable+GnRH+antagonist+under+investigation+for+the+treatment+of+endometriosis-related+pain&rft.volume=11&rft.issue=1&rft.pages=19-28&rft.date=2015-01&rft_id=info%3Adoi%2F10.2217%2Fwhe.14.68&rft_id=info%3Apmid%2F25581052&rft.aulast=Ezzati&rft.aufirst=M&rft.au=Carr%2C+BR&rft_id=https%3A%2F%2Fdoi.org%2F10.2217%252Fwhe.14.68&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-pmid30194661-7"><a href="#cite_ref-pmid30194661_7-0">^</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFLamb2018" class="citation journal cs1">Lamb YN (September 2018). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244606">"Elagolix: First Global Approval"</a>. Drugs. 78 (14): 1501–1508. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1007%2Fs40265-018-0977-4">10.1007/s40265-018-0977-4</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a> <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244606">6244606</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/30194661">30194661</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Drugs&rft.atitle=Elagolix%3A+First+Global+Approval&rft.volume=78&rft.issue=14&rft.pages=1501-1508&rft.date=2018-09&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6244606%23id-name%3DPMC&rft_id=info%3Apmid%2F30194661&rft_id=info%3Adoi%2F10.1007%2Fs40265-018-0977-4&rft.aulast=Lamb&rft.aufirst=YN&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6244606&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-pmid29559388-8">^ <a href="#cite_ref-pmid29559388_8-0">a</a> <a href="#cite_ref-pmid29559388_8-1">b</a> <a href="#cite_ref-pmid29559388_8-2">c</a> <a href="#cite_ref-pmid29559388_8-3">d</a> <a href="#cite_ref-pmid29559388_8-4">e</a> <a href="#cite_ref-pmid29559388_8-5">f</a> <a href="#cite_ref-pmid29559388_8-6">g</a> <a href="#cite_ref-pmid29559388_8-7">h</a> <a href="#cite_ref-pmid29559388_8-8">i</a> <a href="#cite_ref-pmid29559388_8-9">j</a> <a href="#cite_ref-pmid29559388_8-10">k</a> <a href="#cite_ref-pmid29559388_8-11">l</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFClemenzaSorbiNociCapezzuoli2018" class="citation journal cs1">Clemenza S, Sorbi F, Noci I, Capezzuoli T, Turrini I, Carriero C, Buffi N, Fambrini M, Petraglia F (February 2018). "From pathogenesis to clinical practice: Emerging medical treatments for endometriosis". Best Pract Res Clin Obstet Gynaecol. 51: 92–101. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.bpobgyn.2018.01.021">10.1016/j.bpobgyn.2018.01.021</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/29559388">29559388</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a> <a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:3952054">3952054</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Best+Pract+Res+Clin+Obstet+Gynaecol&rft.atitle=From+pathogenesis+to+clinical+practice%3A+Emerging+medical+treatments+for+endometriosis&rft.volume=51&rft.pages=92-101&rft.date=2018-02&rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A3952054%23id-name%3DS2CID&rft_id=info%3Apmid%2F29559388&rft_id=info%3Adoi%2F10.1016%2Fj.bpobgyn.2018.01.021&rft.aulast=Clemenza&rft.aufirst=S&rft.au=Sorbi%2C+F&rft.au=Noci%2C+I&rft.au=Capezzuoli%2C+T&rft.au=Turrini%2C+I&rft.au=Carriero%2C+C&rft.au=Buffi%2C+N&rft.au=Fambrini%2C+M&rft.au=Petraglia%2C+F&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-AdisInsight-9">^ <a href="#cite_ref-AdisInsight_9-0">a</a> <a href="#cite_ref-AdisInsight_9-1">b</a> <a href="#cite_ref-AdisInsight_9-2">c</a> <a href="#cite_ref-AdisInsight_9-3">d</a> <a href="#cite_ref-AdisInsight_9-4">e</a> <a href="#cite_ref-AdisInsight_9-5">f</a> <a href="#cite_ref-AdisInsight_9-6">g</a> <a href="#cite_ref-AdisInsight_9-7">h</a> <a href="#cite_ref-AdisInsight_9-8">i</a> <a href="#cite_ref-AdisInsight_9-9">j</a> <a href="#cite_ref-AdisInsight_9-10">k</a> <a href="#cite_ref-AdisInsight_9-11">l</a> <a href="#cite_ref-AdisInsight_9-12">m</a> <a href="#cite_ref-AdisInsight_9-13">n</a> <a href="#cite_ref-AdisInsight_9-14">o</a> <a href="#cite_ref-AdisInsight_9-15">p</a> <a href="#cite_ref-AdisInsight_9-16">q</a> AdisInsight: <a rel="nofollow" class="external text" href="http://adisinsight.springer.com/drugs/800020238">Elagolix</a> <a rel="nofollow" class="external text" href="https://web.archive.org/web/20161220031105/http://adisinsight.springer.com/drugs/800020238">Archived</a> 2016-12-20 at the <a href="/wiki/Wayback_Machine" title="Wayback Machine">Wayback Machine</a>. </li> <li id="cite_note-pmid19006286-10">^ <a href="#cite_ref-pmid19006286_10-0">a</a> <a href="#cite_ref-pmid19006286_10-1">b</a> <a href="#cite_ref-pmid19006286_10-2">c</a> <a href="#cite_ref-pmid19006286_10-3">d</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFChenWuGuoXie2008" class="citation journal cs1">Chen C, Wu D, Guo Z, Xie Q, Reinhart GJ, Madan A, Wen J, Chen T, Huang CQ, Chen M, Chen Y, Tucci FC, Rowbottom M, Pontillo J, Zhu YF, Wade W, Saunders J, Bozigian H, Struthers RS (December 2008). "Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor". J. Med. Chem. 51 (23): 7478–85. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1021%2Fjm8006454">10.1021/jm8006454</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/19006286">19006286</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=J.+Med.+Chem.&rft.atitle=Discovery+of+sodium+R-%28%2B%29-4-%7B2-%5B5-%282-fluoro-3-methoxyphenyl%29-3-%282-fluoro-6-%5Btrifluoromethyl%5Dbenzyl%29-4-methyl-2%2C6-dioxo-3%2C6-dihydro-2H-pyrimidin-1-yl%5D-1-phenylethylamino%7D%7Dbutyrate+%28elagolix%29%2C+a+potent+and+orally+available+nonpeptide+antagonist+of+the+human+gonadotropin-releasing+hormone+receptor&rft.volume=51&rft.issue=23&rft.pages=7478-85&rft.date=2008-12&rft_id=info%3Adoi%2F10.1021%2Fjm8006454&rft_id=info%3Apmid%2F19006286&rft.aulast=Chen&rft.aufirst=C&rft.au=Wu%2C+D&rft.au=Guo%2C+Z&rft.au=Xie%2C+Q&rft.au=Reinhart%2C+GJ&rft.au=Madan%2C+A&rft.au=Wen%2C+J&rft.au=Chen%2C+T&rft.au=Huang%2C+CQ&rft.au=Chen%2C+M&rft.au=Chen%2C+Y&rft.au=Tucci%2C+FC&rft.au=Rowbottom%2C+M&rft.au=Pontillo%2C+J&rft.au=Zhu%2C+YF&rft.au=Wade%2C+W&rft.au=Saunders%2C+J&rft.au=Bozigian%2C+H&rft.au=Struthers%2C+RS&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-AdisInsight-Relugolix-11">^ <a href="#cite_ref-AdisInsight-Relugolix_11-0">a</a> <a href="#cite_ref-AdisInsight-Relugolix_11-1">b</a> <a href="#cite_ref-AdisInsight-Relugolix_11-2">c</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="http://adisinsight.springer.com/drugs/800028257">"Relugolix - Myovant/Takeda - AdisInsight"</a>. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20180920132414/https://adisinsight.springer.com/drugs/800028257">Archived</a> from the original on 2018-09-20. Retrieved 2019-02-16.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=Relugolix+-+Myovant%2FTakeda+-+AdisInsight&rft_id=http%3A%2F%2Fadisinsight.springer.com%2Fdrugs%2F800028257&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-12"><a href="#cite_ref-12">^</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation report cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/media/120357/download">New Drug Therapy Approvals 2018</a> (PDF). U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA) (Report). January 2019. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20200917055627/https://www.fda.gov/media/120357/download">Archived</a> from the original on 17 September 2020. Retrieved 16 September 2020.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=report&rft.btitle=New+Drug+Therapy+Approvals+2018&rft.date=2019-01&rft_id=https%3A%2F%2Fwww.fda.gov%2Fmedia%2F120357%2Fdownload&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-pmid20574791-13">^ <a href="#cite_ref-pmid20574791_13-0">a</a> <a href="#cite_ref-pmid20574791_13-1">b</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFBullettiCocciaBattistoniBorini2010" class="citation journal cs1">Bulletti C, Coccia ME, Battistoni S, Borini A (August 2010). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2941592">"Endometriosis and infertility"</a>. J. Assist. Reprod. Genet. 27 (8): 441–7. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1007%2Fs10815-010-9436-1">10.1007/s10815-010-9436-1</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a> <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2941592">2941592</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/20574791">20574791</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=J.+Assist.+Reprod.+Genet.&rft.atitle=Endometriosis+and+infertility&rft.volume=27&rft.issue=8&rft.pages=441-7&rft.date=2010-08&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2941592%23id-name%3DPMC&rft_id=info%3Apmid%2F20574791&rft_id=info%3Adoi%2F10.1007%2Fs10815-010-9436-1&rft.aulast=Bulletti&rft.aufirst=C&rft.au=Coccia%2C+ME&rft.au=Battistoni%2C+S&rft.au=Borini%2C+A&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2941592&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-UPI2018-14">^ <a href="#cite_ref-UPI2018_14-0">a</a> <a href="#cite_ref-UPI2018_14-1">b</a> <a href="#cite_ref-UPI2018_14-2">c</a> <a href="#cite_ref-UPI2018_14-3">d</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFCone2018" class="citation web cs1">Cone A (25 July 2018). <a rel="nofollow" class="external text" href="https://www.upi.com/Health_News/2018/07/25/FDA-approves-drug-to-control-endometriosis-pain/8731532534650/">"FDA approves drug to control endometriosis pain"</a>. UPI. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20220425102755/https://www.upi.com/Health_News/2018/07/25/FDA-approves-drug-to-control-endometriosis-pain/8731532534650/">Archived</a> from the original on 25 April 2022. Retrieved 31 July 2018.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=FDA+approves+drug+to+control+endometriosis+pain&rft.pub=UPI&rft.date=2018-07-25&rft.aulast=Cone&rft.aufirst=A&rft_id=https%3A%2F%2Fwww.upi.com%2FHealth_News%2F2018%2F07%2F25%2FFDA-approves-drug-to-control-endometriosis-pain%2F8731532534650%2F&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-pmid28525302-15">^ <a href="#cite_ref-pmid28525302_15-0">a</a> <a href="#cite_ref-pmid28525302_15-1">b</a> <a href="#cite_ref-pmid28525302_15-2">c</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFTaylorGiudiceLesseyAbrao2017" class="citation journal cs1">Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, Diamond MP, Surrey E, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Rowan JP, Duan WR, Ng J, Schwefel B, Thomas JW, Jain RI, Chwalisz K (July 2017). <a rel="nofollow" class="external text" href="http://www.escholarship.org/uc/item/3pw94370">"Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist"</a>. N. Engl. J. Med. 377 (1): 28–40. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1056%2FNEJMoa1700089">10.1056/NEJMoa1700089</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/28525302">28525302</a>. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20200612185535/https://escholarship.org/uc/item/3pw94370">Archived</a> from the original on 2020-06-12. Retrieved 2018-11-07.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=N.+Engl.+J.+Med.&rft.atitle=Treatment+of+Endometriosis-Associated+Pain+with+Elagolix%2C+an+Oral+GnRH+Antagonist&rft.volume=377&rft.issue=1&rft.pages=28-40&rft.date=2017-07&rft_id=info%3Adoi%2F10.1056%2FNEJMoa1700089&rft_id=info%3Apmid%2F28525302&rft.aulast=Taylor&rft.aufirst=HS&rft.au=Giudice%2C+LC&rft.au=Lessey%2C+BA&rft.au=Abrao%2C+MS&rft.au=Kotarski%2C+J&rft.au=Archer%2C+DF&rft.au=Diamond%2C+MP&rft.au=Surrey%2C+E&rft.au=Johnson%2C+NP&rft.au=Watts%2C+NB&rft.au=Gallagher%2C+JC&rft.au=Simon%2C+JA&rft.au=Carr%2C+BR&rft.au=Dmowski%2C+WP&rft.au=Leyland%2C+N&rft.au=Rowan%2C+JP&rft.au=Duan%2C+WR&rft.au=Ng%2C+J&rft.au=Schwefel%2C+B&rft.au=Thomas%2C+JW&rft.au=Jain%2C+RI&rft.au=Chwalisz%2C+K&rft_id=http%3A%2F%2Fwww.escholarship.org%2Fuc%2Fitem%2F3pw94370&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-pmid29889764-16">^ <a href="#cite_ref-pmid29889764_16-0">a</a> <a href="#cite_ref-pmid29889764_16-1">b</a> <a href="#cite_ref-pmid29889764_16-2">c</a> <a href="#cite_ref-pmid29889764_16-3">d</a> <a href="#cite_ref-pmid29889764_16-4">e</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFSurreyTaylorGiudiceLessey2018" class="citation journal cs1">Surrey E, Taylor HS, Giudice L, Lessey BA, Abrao MS, Archer DF, Diamond MP, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Singh SS, Rechberger T, Agarwal SK, Duan WR, Schwefel B, Thomas JW, Peloso PM, Ng J, Soliman AM, Chwalisz K (July 2018). <a rel="nofollow" class="external text" href="https://doi.org/10.1097%2FAOG.0000000000002675">"Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies"</a>. Obstet Gynecol. 132 (1): 147–160. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1097%2FAOG.0000000000002675">10.1097/AOG.0000000000002675</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/29889764">29889764</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Obstet+Gynecol&rft.atitle=Long-Term+Outcomes+of+Elagolix+in+Women+With+Endometriosis%3A+Results+From+Two+Extension+Studies&rft.volume=132&rft.issue=1&rft.pages=147-160&rft.date=2018-07&rft_id=info%3Adoi%2F10.1097%2FAOG.0000000000002675&rft_id=info%3Apmid%2F29889764&rft.aulast=Surrey&rft.aufirst=E&rft.au=Taylor%2C+HS&rft.au=Giudice%2C+L&rft.au=Lessey%2C+BA&rft.au=Abrao%2C+MS&rft.au=Archer%2C+DF&rft.au=Diamond%2C+MP&rft.au=Johnson%2C+NP&rft.au=Watts%2C+NB&rft.au=Gallagher%2C+JC&rft.au=Simon%2C+JA&rft.au=Carr%2C+BR&rft.au=Dmowski%2C+WP&rft.au=Leyland%2C+N&rft.au=Singh%2C+SS&rft.au=Rechberger%2C+T&rft.au=Agarwal%2C+SK&rft.au=Duan%2C+WR&rft.au=Schwefel%2C+B&rft.au=Thomas%2C+JW&rft.au=Peloso%2C+PM&rft.au=Ng%2C+J&rft.au=Soliman%2C+AM&rft.au=Chwalisz%2C+K&rft_id=https%3A%2F%2Fdoi.org%2F10.1097%252FAOG.0000000000002675&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-pmid11734258-17"><a href="#cite_ref-pmid11734258_17-0">^</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFHuirneLambalk2001" class="citation journal cs1">Huirne JA, Lambalk CB (November 2001). "Gonadotropin-releasing-hormone-receptor antagonists". Lancet. 358 (9295): 1793–803. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2FS0140-6736%2801%2906797-6">10.1016/S0140-6736(01)06797-6</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/11734258">11734258</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a> <a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:34316585">34316585</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Lancet&rft.atitle=Gonadotropin-releasing-hormone-receptor+antagonists&rft.volume=358&rft.issue=9295&rft.pages=1793-803&rft.date=2001-11&rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A34316585%23id-name%3DS2CID&rft_id=info%3Apmid%2F11734258&rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2801%2906797-6&rft.aulast=Huirne&rft.aufirst=JA&rft.au=Lambalk%2C+CB&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-pmid19509099-18"><a href="#cite_ref-pmid19509099_18-0">^</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFHembreeCohen-KettenisDelemarre-van_de_WaalGooren2009" class="citation journal cs1">Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, Gooren LJ, Meyer WJ, Spack NP, Tangpricha V, Montori VM (September 2009). <a rel="nofollow" class="external text" href="https://doi.org/10.1210%2Fjc.2009-0345">"Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline"</a>. J. Clin. Endocrinol. Metab. 94 (9): 3132–54. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1210%2Fjc.2009-0345">10.1210/jc.2009-0345</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/19509099">19509099</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=J.+Clin.+Endocrinol.+Metab.&rft.atitle=Endocrine+treatment+of+transsexual+persons%3A+an+Endocrine+Society+clinical+practice+guideline&rft.volume=94&rft.issue=9&rft.pages=3132-54&rft.date=2009-09&rft_id=info%3Adoi%2F10.1210%2Fjc.2009-0345&rft_id=info%3Apmid%2F19509099&rft.aulast=Hembree&rft.aufirst=WC&rft.au=Cohen-Kettenis%2C+P&rft.au=Delemarre-van+de+Waal%2C+HA&rft.au=Gooren%2C+LJ&rft.au=Meyer%2C+WJ&rft.au=Spack%2C+NP&rft.au=Tangpricha%2C+V&rft.au=Montori%2C+VM&rft_id=https%3A%2F%2Fdoi.org%2F10.1210%252Fjc.2009-0345&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-Orilissa_Canada_Label-19"><a href="#cite_ref-Orilissa_Canada_Label_19-0">^</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/ORILISSA_PM_EN.PDF">"Orilissa Product Monograph Including Patient Information"</a> (PDF). <a href="/wiki/AbbVie" title="AbbVie">AbbVie</a>. 29 October 2021. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20211019130502/https://www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/ORILISSA_PM_EN.PDF">Archived</a> (PDF) from the original on 19 October 2021. Retrieved 17 May 2022.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=Orilissa+Product+Monograph+Including+Patient+Information&rft.pub=AbbVie&rft.date=2021-10-29&rft_id=https%3A%2F%2Fwww.abbvie.ca%2Fcontent%2Fdam%2Fabbvie-dotcom%2Fca%2Fen%2Fdocuments%2Fproducts%2FORILISSA_PM_EN.PDF&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-Orilissa-AbbVie-Leaflet-20"><a href="#cite_ref-Orilissa-AbbVie-Leaflet_20-0">^</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="http://www.fasgo.org.ar/images/OBGYN1119_Ezine.pdf">"Orilissa AbbVie Leaflet"</a> (PDF). Contemporary OB/GYN. pp. 2–6. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20211019133102/http://www.fasgo.org.ar/images/OBGYN1119_Ezine.pdf">Archived</a> (PDF) from the original on 19 October 2021. Retrieved 17 May 2022.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=Orilissa+AbbVie+Leaflet&rft.pages=2-6&rft.pub=Contemporary+OB%2FGYN&rft_id=http%3A%2F%2Fwww.fasgo.org.ar%2Fimages%2FOBGYN1119_Ezine.pdf&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-pmid23012318-21"><a href="#cite_ref-pmid23012318_21-0">^</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFTanCarrBeshayBukulmez2013" class="citation journal cs1">Tan O, Carr BR, Beshay VE, Bukulmez O (January 2013). "The extrapituitary effects of GnRH antagonists and their potential clinical implications: a narrated review". Reprod Sci. 20 (1): 16–25. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1177%2F1933719112459244">10.1177/1933719112459244</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/23012318">23012318</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a> <a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:21376889">21376889</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Reprod+Sci&rft.atitle=The+extrapituitary+effects+of+GnRH+antagonists+and+their+potential+clinical+implications%3A+a+narrated+review&rft.volume=20&rft.issue=1&rft.pages=16-25&rft.date=2013-01&rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A21376889%23id-name%3DS2CID&rft_id=info%3Apmid%2F23012318&rft_id=info%3Adoi%2F10.1177%2F1933719112459244&rft.aulast=Tan&rft.aufirst=O&rft.au=Carr%2C+BR&rft.au=Beshay%2C+VE&rft.au=Bukulmez%2C+O&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-FDADrugDev-22"><a href="#cite_ref-FDADrugDev_22-0">^</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm">"Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers"</a>. FDA. 14 November 2017. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20160510152158/https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm">Archived</a> from the original on 10 May 2016. Retrieved 31 July 2018.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=Drug+Development+and+Drug+Interactions%3A+Table+of+Substrates%2C+Inhibitors+and+Inducers&rft.pub=FDA&rft.date=2017-11-14&rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdevelopmentapprovalprocess%2Fdevelopmentresources%2Fdruginteractionslabeling%2Fucm093664.htm&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-Becker2001-23">^ <a href="#cite_ref-Becker2001_23-0">a</a> <a href="#cite_ref-Becker2001_23-1">b</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFBecker2001" class="citation book cs1">Becker KL (2001). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=FVfzRvaucq8C&pg=PA975">"Endometriosis"</a>. Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 975–. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a> <a href="/wiki/Special:BookSources/978-0-7817-1750-2" title="Special:BookSources/978-0-7817-1750-2"><bdi>978-0-7817-1750-2</bdi></a>. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20220610024605/https://books.google.com/books?id=FVfzRvaucq8C&pg=PA975">Archived</a> from the original on 2022-06-10. Retrieved 2018-07-26.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=bookitem&rft.atitle=Endometriosis&rft.btitle=Principles+and+Practice+of+Endocrinology+and+Metabolism&rft.pages=975-&rft.pub=Lippincott+Williams+%26+Wilkins&rft.date=2001&rft.isbn=978-0-7817-1750-2&rft.aulast=Becker&rft.aufirst=KL&rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DFVfzRvaucq8C%26pg%3DPA975&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-pmid26389558-24"><a href="#cite_ref-pmid26389558_24-0">^</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFGezerOral2015" class="citation journal cs1">Gezer A, Oral E (August 2015). <a rel="nofollow" class="external text" href="https://doi.org/10.2217%2Fwhe.15.42">"Progestin therapy in endometriosis"</a>. Women's Health. 11 (5): 643–52. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.2217%2Fwhe.15.42">10.2217/whe.15.42</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/26389558">26389558</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Women%27s+Health&rft.atitle=Progestin+therapy+in+endometriosis&rft.volume=11&rft.issue=5&rft.pages=643-52&rft.date=2015-08&rft_id=info%3Adoi%2F10.2217%2Fwhe.15.42&rft_id=info%3Apmid%2F26389558&rft.aulast=Gezer&rft.aufirst=A&rft.au=Oral%2C+E&rft_id=https%3A%2F%2Fdoi.org%2F10.2217%252Fwhe.15.42&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-LemkeWilliams2012-25">^ <a href="#cite_ref-LemkeWilliams2012_25-0">a</a> <a href="#cite_ref-LemkeWilliams2012_25-1">b</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFLemkeWilliams2012" class="citation book cs1">Lemke TL, Williams DA (24 January 2012). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA1411">"Womens Health"</a>. Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 1411–. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a> <a href="/wiki/Special:BookSources/978-1-60913-345-0" title="Special:BookSources/978-1-60913-345-0"><bdi>978-1-60913-345-0</bdi></a>. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20161221030214/https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA1411">Archived</a> from the original on 21 December 2016. Retrieved 24 October 2016.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=bookitem&rft.atitle=Womens+Health&rft.btitle=Foye%27s+Principles+of+Medicinal+Chemistry&rft.pages=1411-&rft.pub=Lippincott+Williams+%26+Wilkins&rft.date=2012-01-24&rft.isbn=978-1-60913-345-0&rft.aulast=Lemke&rft.aufirst=TL&rft.au=Williams%2C+DA&rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DSd6ot9ul-bUC%26pg%3DPA1411&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-pmid28323948-26">^ <a href="#cite_ref-pmid28323948_26-0">a</a> <a href="#cite_ref-pmid28323948_26-1">b</a> <a href="#cite_ref-pmid28323948_26-2">c</a> <a href="#cite_ref-pmid28323948_26-3">d</a> <a href="#cite_ref-pmid28323948_26-4">e</a> <a href="#cite_ref-pmid28323948_26-5">f</a> <a href="#cite_ref-pmid28323948_26-6">g</a> <a href="#cite_ref-pmid28323948_26-7">h</a> <a href="#cite_ref-pmid28323948_26-8">i</a> <a href="#cite_ref-pmid28323948_26-9">j</a> <a href="#cite_ref-pmid28323948_26-10">k</a> <a href="#cite_ref-pmid28323948_26-11">l</a> <a href="#cite_ref-pmid28323948_26-12">m</a> <a href="#cite_ref-pmid28323948_26-13">n</a> <a href="#cite_ref-pmid28323948_26-14">o</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFNgChwaliszCarterKlein2017" class="citation journal cs1">Ng J, Chwalisz K, Carter DC, Klein CE (May 2017). <a rel="nofollow" class="external text" href="https://doi.org/10.1210%2Fjc.2016-3845">"Dose-Dependent Suppression of Gonadotropins and Ovarian Hormones by Elagolix in Healthy Premenopausal Women"</a>. J. Clin. Endocrinol. Metab. 102 (5): 1683–1691. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1210%2Fjc.2016-3845">10.1210/jc.2016-3845</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/28323948">28323948</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=J.+Clin.+Endocrinol.+Metab.&rft.atitle=Dose-Dependent+Suppression+of+Gonadotropins+and+Ovarian+Hormones+by+Elagolix+in+Healthy+Premenopausal+Women&rft.volume=102&rft.issue=5&rft.pages=1683-1691&rft.date=2017-05&rft_id=info%3Adoi%2F10.1210%2Fjc.2016-3845&rft_id=info%3Apmid%2F28323948&rft.aulast=Ng&rft.aufirst=J&rft.au=Chwalisz%2C+K&rft.au=Carter%2C+DC&rft.au=Klein%2C+CE&rft_id=https%3A%2F%2Fdoi.org%2F10.1210%252Fjc.2016-3845&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-Melmed2016-27"><a href="#cite_ref-Melmed2016_27-0">^</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFMatsumotoBremmer2016" class="citation book cs1">Matsumoto AM, Bremmer WJ (1 January 2016). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=YZ8_CwAAQBAJ&pg=PA752">"Testicular Disorders"</a>. In Melmed S (ed.). Williams Textbook of Endocrinology. Elsevier Health Sciences. pp. 752–. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a> <a href="/wiki/Special:BookSources/978-0-323-29738-7" title="Special:BookSources/978-0-323-29738-7"><bdi>978-0-323-29738-7</bdi></a>. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20200727104231/https://books.google.com/books?id=YZ8_CwAAQBAJ&pg=PA752">Archived</a> from the original on 27 July 2020. Retrieved 26 July 2018.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=bookitem&rft.atitle=Testicular+Disorders&rft.btitle=Williams+Textbook+of+Endocrinology&rft.pages=752-&rft.pub=Elsevier+Health+Sciences&rft.date=2016-01-01&rft.isbn=978-0-323-29738-7&rft.aulast=Matsumoto&rft.aufirst=AM&rft.au=Bremmer%2C+WJ&rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DYZ8_CwAAQBAJ%26pg%3DPA752&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-pmid23885105-28"><a href="#cite_ref-pmid23885105_28-0">^</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFDiamondCarrDmowskiKoltun2014" class="citation journal cs1">Diamond MP, Carr B, Dmowski WP, Koltun W, O'Brien C, Jiang P, Burke J, Jimenez R, Garner E, Chwalisz K (2014). "Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study". Reprod Sci. 21 (3): 363–71. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1177%2F1933719113497292">10.1177/1933719113497292</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/23885105">23885105</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a> <a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:9607500">9607500</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Reprod+Sci&rft.atitle=Elagolix+treatment+for+endometriosis-associated+pain%3A+results+from+a+phase+2%2C+randomized%2C+double-blind%2C+placebo-controlled+study&rft.volume=21&rft.issue=3&rft.pages=363-71&rft.date=2014&rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A9607500%23id-name%3DS2CID&rft_id=info%3Apmid%2F23885105&rft_id=info%3Adoi%2F10.1177%2F1933719113497292&rft.aulast=Diamond&rft.aufirst=MP&rft.au=Carr%2C+B&rft.au=Dmowski%2C+WP&rft.au=Koltun%2C+W&rft.au=O%27Brien%2C+C&rft.au=Jiang%2C+P&rft.au=Burke%2C+J&rft.au=Jimenez%2C+R&rft.au=Garner%2C+E&rft.au=Chwalisz%2C+K&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-pmid25249568-29"><a href="#cite_ref-pmid25249568_29-0">^</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFCarrDmowskiO'BrienJiang2014" class="citation journal cs1">Carr B, Dmowski WP, O'Brien C, Jiang P, Burke J, Jimenez R, Garner E, Chwalisz K (2014). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4212335">"Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density"</a>. Reprod Sci. 21 (11): 1341–51. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1177%2F1933719114549848">10.1177/1933719114549848</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a> <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4212335">4212335</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/25249568">25249568</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Reprod+Sci&rft.atitle=Elagolix%2C+an+oral+GnRH+antagonist%2C+versus+subcutaneous+depot+medroxyprogesterone+acetate+for+the+treatment+of+endometriosis%3A+effects+on+bone+mineral+density&rft.volume=21&rft.issue=11&rft.pages=1341-51&rft.date=2014&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4212335%23id-name%3DPMC&rft_id=info%3Apmid%2F25249568&rft_id=info%3Adoi%2F10.1177%2F1933719114549848&rft.aulast=Carr&rft.aufirst=B&rft.au=Dmowski%2C+WP&rft.au=O%27Brien%2C+C&rft.au=Jiang%2C+P&rft.au=Burke%2C+J&rft.au=Jimenez%2C+R&rft.au=Garner%2C+E&rft.au=Chwalisz%2C+K&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4212335&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-StraussIII2013-30"><a href="#cite_ref-StraussIII2013_30-0">^</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFMcCartneyMarshall2013" class="citation book cs1">McCartney CR, Marshall JC (13 September 2013). <a rel="nofollow" class="external text" href="https://books.google.com/books?id=KZ95AAAAQBAJ&pg=PA19">"Endocrinology of Reproduction"</a>. In Strauss III JF, Barbieri RL (eds.). Yen and Jaffe's Reproductive Endocrinology. Elsevier Health Sciences. pp. 19–. <a href="/wiki/ISBN_(identifier)" class="mw-redirect" title="ISBN (identifier)">ISBN</a> <a href="/wiki/Special:BookSources/978-1-4557-2758-2" title="Special:BookSources/978-1-4557-2758-2"><bdi>978-1-4557-2758-2</bdi></a>. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20220610024605/https://books.google.com/books?id=KZ95AAAAQBAJ&pg=PA19">Archived</a> from the original on 10 June 2022. Retrieved 26 July 2018.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=bookitem&rft.atitle=Endocrinology+of+Reproduction&rft.btitle=Yen+and+Jaffe%27s+Reproductive+Endocrinology&rft.pages=19-&rft.pub=Elsevier+Health+Sciences&rft.date=2013-09-13&rft.isbn=978-1-4557-2758-2&rft.aulast=McCartney&rft.aufirst=CR&rft.au=Marshall%2C+JC&rft_id=https%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DKZ95AAAAQBAJ%26pg%3DPA19&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-ChemIDplus-31">^ <a href="#cite_ref-ChemIDplus_31-0">a</a> <a href="#cite_ref-ChemIDplus_31-1">b</a> <a href="#cite_ref-ChemIDplus_31-2">c</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://chem.nlm.nih.gov/chemidplus/rn/834153-87-6">"ChemIDplus - 834153-87-6 - HEAUOKZIVMZVQL-VWLOTQADSA-N - Elagolix [USAN:INN]"</a>. ChemIDplus. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20180726103709/https://chem.nlm.nih.gov/chemidplus/rn/834153-87-6">Archived</a> from the original on 26 July 2018. Retrieved 31 July 2018.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=ChemIDplus+-+834153-87-6+-+HEAUOKZIVMZVQL-VWLOTQADSA-N+-+Elagolix+%5BUSAN%3AINN%5D&rft.pub=ChemIDplus&rft_id=https%3A%2F%2Fchem.nlm.nih.gov%2Fchemidplus%2Frn%2F834153-87-6&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-DrugInfoPortal@NLM-32"><a href="#cite_ref-DrugInfoPortal@NLM_32-0">^</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation cs2"><a rel="nofollow" class="external text" href="https://druginfo.nlm.nih.gov/drugportal/name/endswith/golix">Search Drug Information Portal - Ends with "*golix"</a>, U.S. National Library of Medicine, <a rel="nofollow" class="external text" href="https://web.archive.org/web/20180726104132/https://druginfo.nlm.nih.gov/drugportal/name/endswith/golix">archived</a> from the original on 26 July 2018, retrieved 31 July 2018</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=book&rft.btitle=Search+Drug+Information+Portal+-+Ends+with+%22%2Agolix%22&rft.pub=U.S.+National+Library+of+Medicine&rft_id=https%3A%2F%2Fdruginfo.nlm.nih.gov%2Fdrugportal%2Fname%2Fendswith%2Fgolix&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-US7056927-33"><a href="#cite_ref-US7056927_33-0">^</a> <style data-mw-deduplicate="TemplateStyles:r1041539562">.mw-parser-output .citation{word-wrap:break-word}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}</style><a rel="nofollow" class="external text" href="https://patents.google.com/patent/US7056927">US patent 7056927</a>, Zhiqiang Guo, Yongsheng Chen, Dongpei Wu, Chen Chen, Warren Wade, Wesley J. Dwight, Charles Q. Huang, Fabio C. Tucci, "Gonadotropin-releasing hormone receptor antagonists and methods relating thereto", published 2006-06-06<span class="Z3988" title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.number=7056927&rft.cc=US&rft.title=Gonadotropin-releasing+hormone+receptor+antagonists+and+methods+relating+thereto&rft.inventor=Zhiqiang+Guo%2C+Yongsheng+Chen%2C+Dongpei+Wu%2C+Chen+Chen%2C+Warren+Wade%2C+Wesley+J.+Dwight%2C+Charles+Q.+Huang%2C+Fabio+C.+Tucci&rft.appldate=2004-07-06&rft.pubdate=2006-06-06&rft.prioritydate=2003-07-07">  <a rel="nofollow" class="external text" href="https://web.archive.org/web/20201127124352/https://patents.google.com/patent/US7056927">Archived</a> 2020-11-27 at the <a href="/wiki/Wayback_Machine" title="Wayback Machine">Wayback Machine</a> </li> <li id="cite_note-pmid15715483-34"><a href="#cite_ref-pmid15715483_34-0">^</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFTucciZhuStruthersGuo2005" class="citation journal cs1">Tucci FC, Zhu YF, Struthers RS, Guo Z, Gross TD, Rowbottom MW, Acevedo O, Gao Y, Saunders J, Xie Q, Reinhart GJ, Liu XJ, Ling N, Bonneville AK, Chen T, Bozigian H, Chen C (February 2005). "3-[(2R)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)- 6-methylpyrimidin-2,4-dione (NBI 42902) as a potent and orally active antagonist of the human gonadotropin-releasing hormone receptor. Design, synthesis, and in vitro and in vivo characterization". J. Med. Chem. 48 (4): 1169–78. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1021%2Fjm049218c">10.1021/jm049218c</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/15715483">15715483</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=J.+Med.+Chem.&rft.atitle=3-%5B%282R%29-Amino-2-phenylethyl%5D-1-%282%2C6-difluorobenzyl%29-5-%282-fluoro-3-methoxyphenyl%29-+6-methylpyrimidin-2%2C4-dione+%28NBI+42902%29+as+a+potent+and+orally+active+antagonist+of+the+human+gonadotropin-releasing+hormone+receptor.+Design%2C+synthesis%2C+and+in+vitro+and+in+vivo+characterization&rft.volume=48&rft.issue=4&rft.pages=1169-78&rft.date=2005-02&rft_id=info%3Adoi%2F10.1021%2Fjm049218c&rft_id=info%3Apmid%2F15715483&rft.aulast=Tucci&rft.aufirst=FC&rft.au=Zhu%2C+YF&rft.au=Struthers%2C+RS&rft.au=Guo%2C+Z&rft.au=Gross%2C+TD&rft.au=Rowbottom%2C+MW&rft.au=Acevedo%2C+O&rft.au=Gao%2C+Y&rft.au=Saunders%2C+J&rft.au=Xie%2C+Q&rft.au=Reinhart%2C+GJ&rft.au=Liu%2C+XJ&rft.au=Ling%2C+N&rft.au=Bonneville%2C+AK&rft.au=Chen%2C+T&rft.au=Bozigian%2C+H&rft.au=Chen%2C+C&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-FierceBiotech2010-35"><a href="#cite_ref-FierceBiotech2010_35-0">^</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.fiercebiotech.com/biotech/abbott-and-neurocrine-announce-global-agreement-to-develop-and-commercialize-elagolix-for">"Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis"</a>. FierceBiotech. 16 June 2010. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20180702204705/https://www.fiercebiotech.com/biotech/abbott-and-neurocrine-announce-global-agreement-to-develop-and-commercialize-elagolix-for">Archived</a> from the original on 2 July 2018. Retrieved 31 July 2018.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=Abbott+and+Neurocrine+Announce+Global+Agreement+to+Develop+and+Commercialize+Elagolix+for+the+Treatment+of+Endometriosis&rft.pub=FierceBiotech&rft.date=2010-06-16&rft_id=https%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Fabbott-and-neurocrine-announce-global-agreement-to-develop-and-commercialize-elagolix-for&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-Drugs.com-2-36"><a href="#cite_ref-Drugs.com-2_36-0">^</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.drugs.com/orilissa.html">"Orilissa (elagolix) Medication Guide"</a>. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20180816194427/https://www.drugs.com/orilissa.html">Archived</a> from the original on 2018-08-16. Retrieved 2018-08-16.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=Orilissa+%28elagolix%29+Medication+Guide&rft_id=https%3A%2F%2Fwww.drugs.com%2Forilissa.html&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-Time2018-37"><a href="#cite_ref-Time2018_37-0">^</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFDucharme2018" class="citation web cs1">Ducharme J (25 July 2018). <a rel="nofollow" class="external text" href="https://time.com/5348119/orilissa-endometriosis-fda/">"The FDA Approved the First New Endometriosis Treatment In a Decade"</a>. Time. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20180731031443/http://time.com/5348119/orilissa-endometriosis-fda/">Archived</a> from the original on 31 July 2018. Retrieved 31 July 2018.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=The+FDA+Approved+the+First+New+Endometriosis+Treatment+In+a+Decade&rft.pub=Time&rft.date=2018-07-25&rft.aulast=Ducharme&rft.aufirst=J&rft_id=https%3A%2F%2Ftime.com%2F5348119%2Forilissa-endometriosis-fda%2F&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> <li id="cite_note-Vox2018-38"><a href="#cite_ref-Vox2018_38-0">^</a> <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFBelluz2018" class="citation web cs1">Belluz J (26 July 2018). <a rel="nofollow" class="external text" href="https://www.vox.com/2018/7/24/17608984/endometriosis-pain-symptoms-treatments-elagolix-orilissa">"Endometriosis treatment: elagolix could help the painful uterus disorder: Women with endometriosis experience terrible pain. There's finally a new treatment"</a>. Vox. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20180726201624/https://www.vox.com/2018/7/24/17608984/endometriosis-pain-symptoms-treatments-elagolix-orilissa">Archived</a> from the original on 26 July 2018. Retrieved 31 July 2018.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=Endometriosis+treatment%3A+elagolix+could+help+the+painful+uterus+disorder%3A+Women+with+endometriosis+experience+terrible+pain.+There%27s+finally+a+new+treatment.&rft.pub=Vox&rft.date=2018-07-26&rft.aulast=Belluz&rft.aufirst=J&rft_id=https%3A%2F%2Fwww.vox.com%2F2018%2F7%2F24%2F17608984%2Fendometriosis-pain-symptoms-treatments-elagolix-orilissa&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"> </li> </ol></div></div> <div class="mw-heading mw-heading2"><h2 id="Further_reading">Further reading</h2>[<a href="/w/index.php?title=Elagolix&action=edit&section=19" title="Edit section: Further reading">edit</a>]</div> <ul><li><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFEzzatiCarr2015" class="citation journal cs1">Ezzati M, Carr BR (January 2015). <a rel="nofollow" class="external text" href="https://doi.org/10.2217%2Fwhe.14.68">"Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain"</a>. Women's Health. 11 (1): 19–28. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.2217%2Fwhe.14.68">10.2217/whe.14.68</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/25581052">25581052</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Women%27s+Health&rft.atitle=Elagolix%2C+a+novel%2C+orally+bioavailable+GnRH+antagonist+under+investigation+for+the+treatment+of+endometriosis-related+pain&rft.volume=11&rft.issue=1&rft.pages=19-28&rft.date=2015-01&rft_id=info%3Adoi%2F10.2217%2Fwhe.14.68&rft_id=info%3Apmid%2F25581052&rft.aulast=Ezzati&rft.aufirst=M&rft.au=Carr%2C+BR&rft_id=https%3A%2F%2Fdoi.org%2F10.2217%252Fwhe.14.68&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"></li> <li><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFMelisNeriCordaMalune2016" class="citation journal cs1">Melis GB, Neri M, Corda V, Malune ME, Piras B, Pirarba S, Guerriero S, Orrù M, D'Alterio MN, Angioni S, Paoletti AM (May 2016). "Overview of elagolix for the treatment of endometriosis". Expert Opin Drug Metab Toxicol. 12 (5): 581–8. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1517%2F17425255.2016.1171316">10.1517/17425255.2016.1171316</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/27021205">27021205</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a> <a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:28684228">28684228</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Expert+Opin+Drug+Metab+Toxicol&rft.atitle=Overview+of+elagolix+for+the+treatment+of+endometriosis&rft.volume=12&rft.issue=5&rft.pages=581-8&rft.date=2016-05&rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A28684228%23id-name%3DS2CID&rft_id=info%3Apmid%2F27021205&rft_id=info%3Adoi%2F10.1517%2F17425255.2016.1171316&rft.aulast=Melis&rft.aufirst=GB&rft.au=Neri%2C+M&rft.au=Corda%2C+V&rft.au=Malune%2C+ME&rft.au=Piras%2C+B&rft.au=Pirarba%2C+S&rft.au=Guerriero%2C+S&rft.au=Orr%C3%B9%2C+M&rft.au=D%27Alterio%2C+MN&rft.au=Angioni%2C+S&rft.au=Paoletti%2C+AM&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"></li> <li><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFAlessandroLuigiFeliceMaria2017" class="citation journal cs1">Alessandro P, Luigi N, Felice S, Maria PA, Benedetto MG, Stefano A (April 2017). "Research development of a new GnRH antagonist (Elagolix) for the treatment of endometriosis: a review of the literature". Arch. Gynecol. Obstet. 295 (4): 827–832. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1007%2Fs00404-017-4328-6">10.1007/s00404-017-4328-6</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/28255765">28255765</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a> <a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:26422467">26422467</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Arch.+Gynecol.+Obstet.&rft.atitle=Research+development+of+a+new+GnRH+antagonist+%28Elagolix%29+for+the+treatment+of+endometriosis%3A+a+review+of+the+literature&rft.volume=295&rft.issue=4&rft.pages=827-832&rft.date=2017-04&rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A26422467%23id-name%3DS2CID&rft_id=info%3Apmid%2F28255765&rft_id=info%3Adoi%2F10.1007%2Fs00404-017-4328-6&rft.aulast=Alessandro&rft.aufirst=P&rft.au=Luigi%2C+N&rft.au=Felice%2C+S&rft.au=Maria%2C+PA&rft.au=Benedetto%2C+MG&rft.au=Stefano%2C+A&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"></li> <li><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFPerricosWenzl2017" class="citation journal cs1">Perricos A, Wenzl R (September 2017). "Efficacy of elagolix in the treatment of endometriosis". Expert Opin Pharmacother. 18 (13): 1391–1397. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1080%2F14656566.2017.1359258">10.1080/14656566.2017.1359258</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/28737050">28737050</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a> <a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:32467159">32467159</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Expert+Opin+Pharmacother&rft.atitle=Efficacy+of+elagolix+in+the+treatment+of+endometriosis&rft.volume=18&rft.issue=13&rft.pages=1391-1397&rft.date=2017-09&rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A32467159%23id-name%3DS2CID&rft_id=info%3Apmid%2F28737050&rft_id=info%3Adoi%2F10.1080%2F14656566.2017.1359258&rft.aulast=Perricos&rft.aufirst=A&rft.au=Wenzl%2C+R&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"></li> <li><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFSurreyTaylorGiudiceLessey2018" class="citation journal cs1">Surrey E, Taylor HS, Giudice L, Lessey BA, Abrao MS, Archer DF, Diamond MP, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Singh SS, Rechberger T, Agarwal SK, Duan WR, Schwefel B, Thomas JW, Peloso PM, Ng J, Soliman AM, Chwalisz K (July 2018). <a rel="nofollow" class="external text" href="https://doi.org/10.1097%2FAOG.0000000000002675">"Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies"</a>. Obstet Gynecol. 132 (1): 147–160. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1097%2FAOG.0000000000002675">10.1097/AOG.0000000000002675</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/29889764">29889764</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Obstet+Gynecol&rft.atitle=Long-Term+Outcomes+of+Elagolix+in+Women+With+Endometriosis%3A+Results+From+Two+Extension+Studies&rft.volume=132&rft.issue=1&rft.pages=147-160&rft.date=2018-07&rft_id=info%3Adoi%2F10.1097%2FAOG.0000000000002675&rft_id=info%3Apmid%2F29889764&rft.aulast=Surrey&rft.aufirst=E&rft.au=Taylor%2C+HS&rft.au=Giudice%2C+L&rft.au=Lessey%2C+BA&rft.au=Abrao%2C+MS&rft.au=Archer%2C+DF&rft.au=Diamond%2C+MP&rft.au=Johnson%2C+NP&rft.au=Watts%2C+NB&rft.au=Gallagher%2C+JC&rft.au=Simon%2C+JA&rft.au=Carr%2C+BR&rft.au=Dmowski%2C+WP&rft.au=Leyland%2C+N&rft.au=Singh%2C+SS&rft.au=Rechberger%2C+T&rft.au=Agarwal%2C+SK&rft.au=Duan%2C+WR&rft.au=Schwefel%2C+B&rft.au=Thomas%2C+JW&rft.au=Peloso%2C+PM&rft.au=Ng%2C+J&rft.au=Soliman%2C+AM&rft.au=Chwalisz%2C+K&rft_id=https%3A%2F%2Fdoi.org%2F10.1097%252FAOG.0000000000002675&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"></li> <li><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFTaylor2018" class="citation journal cs1">Taylor HS (July 2018). <a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.jogc.2018.01.004">"Use of Elagolix in Gynaecology"</a>. J Obstet Gynaecol Can. 40 (7): 931–934. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.jogc.2018.01.004">10.1016/j.jogc.2018.01.004</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/29921430">29921430</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=J+Obstet+Gynaecol+Can&rft.atitle=Use+of+Elagolix+in+Gynaecology&rft.volume=40&rft.issue=7&rft.pages=931-934&rft.date=2018-07&rft_id=info%3Adoi%2F10.1016%2Fj.jogc.2018.01.004&rft_id=info%3Apmid%2F29921430&rft.aulast=Taylor&rft.aufirst=HS&rft_id=https%3A%2F%2Fdoi.org%2F10.1016%252Fj.jogc.2018.01.004&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"></li> <li><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFLamb2018" class="citation journal cs1">Lamb YN (September 2018). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244606">"Elagolix: First Global Approval"</a>. Drugs. 78 (14): 1501–1508. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1007%2Fs40265-018-0977-4">10.1007/s40265-018-0977-4</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a> <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244606">6244606</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/30194661">30194661</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Drugs&rft.atitle=Elagolix%3A+First+Global+Approval&rft.volume=78&rft.issue=14&rft.pages=1501-1508&rft.date=2018-09&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6244606%23id-name%3DPMC&rft_id=info%3Apmid%2F30194661&rft_id=info%3Adoi%2F10.1007%2Fs40265-018-0977-4&rft.aulast=Lamb&rft.aufirst=YN&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6244606&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"></li> <li><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFVercelliniViganòBarbaraBuggio2019" class="citation journal cs1">Vercellini P, Viganò P, Barbara G, Buggio L, Somigliana E (February 2019). <a rel="nofollow" class="external text" href="https://doi.org/10.1093%2Fhumrep%2Fdey368">"Elagolix for endometriosis: all that glitters is not gold"</a>. Hum. Reprod. 34 (2): 193–199. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1093%2Fhumrep%2Fdey368">10.1093/humrep/dey368</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/30551159">30551159</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Hum.+Reprod.&rft.atitle=Elagolix+for+endometriosis%3A+all+that+glitters+is+not+gold&rft.volume=34&rft.issue=2&rft.pages=193-199&rft.date=2019-02&rft_id=info%3Adoi%2F10.1093%2Fhumrep%2Fdey368&rft_id=info%3Apmid%2F30551159&rft.aulast=Vercellini&rft.aufirst=P&rft.au=Vigan%C3%B2%2C+P&rft.au=Barbara%2C+G&rft.au=Buggio%2C+L&rft.au=Somigliana%2C+E&rft_id=https%3A%2F%2Fdoi.org%2F10.1093%252Fhumrep%252Fdey368&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"></li> <li><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFBarraScalaFerrero2019" class="citation journal cs1">Barra F, Scala C, Ferrero S (April 2019). "Elagolix sodium for the treatment of women with moderate to severe endometriosis-associated pain". Drugs Today. 55 (4): 237–246. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1358%2Fdot.2019.55.4.2930713">10.1358/dot.2019.55.4.2930713</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/31050692">31050692</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a> <a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:143434963">143434963</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Drugs+Today&rft.atitle=Elagolix+sodium+for+the+treatment+of+women+with+moderate+to+severe+endometriosis-associated+pain&rft.volume=55&rft.issue=4&rft.pages=237-246&rft.date=2019-04&rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A143434963%23id-name%3DS2CID&rft_id=info%3Apmid%2F31050692&rft_id=info%3Adoi%2F10.1358%2Fdot.2019.55.4.2930713&rft.aulast=Barra&rft.aufirst=F&rft.au=Scala%2C+C&rft.au=Ferrero%2C+S&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"></li></ul> <div class="mw-heading mw-heading2"><h2 id="External_links">External links</h2>[<a href="/w/index.php?title=Elagolix&action=edit&section=20" title="Edit section: External links">edit</a>]</div> <ul><li><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://druginfo.nlm.nih.gov/drugportal/name/elagolix">"Elagolix"</a>. Drug Information Portal. U.S. National Library of Medicine.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=Drug+Information+Portal&rft.atitle=Elagolix&rft_id=https%3A%2F%2Fdruginfo.nlm.nih.gov%2Fdrugportal%2Fname%2Felagolix&rfr_id=info%3Asid%2Fen.wikipedia.org%3AElagolix" class="Z3988"></li></ul> <div class="navbox-styles"><style data-mw-deduplicate="TemplateStyles:r1129693374">.mw-parser-output .hlist dl,.mw-parser-output .hlist ol,.mw-parser-output .hlist ul{margin:0;padding:0}.mw-parser-output .hlist dd,.mw-parser-output .hlist dt,.mw-parser-output .hlist li{margin:0;display:inline}.mw-parser-output .hlist.inline,.mw-parser-output .hlist.inline dl,.mw-parser-output .hlist.inline ol,.mw-parser-output .hlist.inline ul,.mw-parser-output .hlist dl dl,.mw-parser-output .hlist dl ol,.mw-parser-output .hlist dl ul,.mw-parser-output .hlist ol dl,.mw-parser-output .hlist ol ol,.mw-parser-output .hlist ol ul,.mw-parser-output .hlist ul dl,.mw-parser-output .hlist ul ol,.mw-parser-output .hlist ul ul{display:inline}.mw-parser-output .hlist .mw-empty-li{display:none}.mw-parser-output .hlist dt::after{content:": "}.mw-parser-output .hlist dd::after,.mw-parser-output .hlist li::after{content:" · ";font-weight:bold}.mw-parser-output .hlist dd:last-child::after,.mw-parser-output .hlist dt:last-child::after,.mw-parser-output .hlist li:last-child::after{content:none}.mw-parser-output .hlist dd dd:first-child::before,.mw-parser-output .hlist dd dt:first-child::before,.mw-parser-output .hlist dd li:first-child::before,.mw-parser-output .hlist dt dd:first-child::before,.mw-parser-output .hlist dt dt:first-child::before,.mw-parser-output .hlist dt li:first-child::before,.mw-parser-output .hlist li dd:first-child::before,.mw-parser-output .hlist li dt:first-child::before,.mw-parser-output .hlist li li:first-child::before{content:" (";font-weight:normal}.mw-parser-output .hlist dd dd:last-child::after,.mw-parser-output .hlist dd dt:last-child::after,.mw-parser-output .hlist dd li:last-child::after,.mw-parser-output .hlist dt dd:last-child::after,.mw-parser-output .hlist dt dt:last-child::after,.mw-parser-output .hlist dt li:last-child::after,.mw-parser-output .hlist li dd:last-child::after,.mw-parser-output .hlist li dt:last-child::after,.mw-parser-output .hlist li li:last-child::after{content:")";font-weight:normal}.mw-parser-output .hlist ol{counter-reset:listitem}.mw-parser-output .hlist ol>li{counter-increment:listitem}.mw-parser-output .hlist ol>li::before{content:" "counter(listitem)"\a0 "}.mw-parser-output .hlist dd ol>li:first-child::before,.mw-parser-output .hlist dt ol>li:first-child::before,.mw-parser-output .hlist li ol>li:first-child::before{content:" ("counter(listitem)"\a0 "}</style><style data-mw-deduplicate="TemplateStyles:r1236075235">.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}body.skin--responsive .mw-parser-output .navbox-image img{max-width:none!important}@media print{body.ns-0 .mw-parser-output .navbox{display:none!important}}</style></div><div role="navigation" class="navbox" aria-labelledby="Hypothalamic-pituitary_hormones_and_analogues_(H01)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1129693374"><style data-mw-deduplicate="TemplateStyles:r1239400231">.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}html.skin-theme-clientpref-night .mw-parser-output .navbar li a abbr{color:var(--color-base)!important}@media(prefers-color-scheme:dark){html.skin-theme-clientpref-os .mw-parser-output .navbar li a abbr{color:var(--color-base)!important}}@media print{.mw-parser-output .navbar{display:none!important}}</style><div class="navbar plainlinks hlist navbar-mini"><ul><li class="nv-view"><a href="/wiki/Template:Pituitary_and_hypothalamic_hormones_and_analogues" title="Template:Pituitary and hypothalamic hormones and analogues"><abbr title="View this template">v</abbr></a></li><li class="nv-talk"><a href="/wiki/Template_talk:Pituitary_and_hypothalamic_hormones_and_analogues" title="Template talk:Pituitary and hypothalamic hormones and analogues"><abbr title="Discuss this template">t</abbr></a></li><li class="nv-edit"><a href="/wiki/Special:EditPage/Template:Pituitary_and_hypothalamic_hormones_and_analogues" title="Special:EditPage/Template:Pituitary and hypothalamic hormones and analogues"><abbr title="Edit this template">e</abbr></a></li></ul></div><div id="Hypothalamic-pituitary_hormones_and_analogues_(H01)" style="font-size:114%;margin:0 4em"><a href="/wiki/Hypothalamic-pituitary_hormone" class="mw-redirect" title="Hypothalamic-pituitary hormone">Hypothalamic-pituitary hormones</a> and analogues (<a href="/wiki/ATC_code_H01" title="ATC code H01">H01</a>)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Hypothalamus" title="Hypothalamus">Hypothalamus</a></th><td class="navbox-list-with-group navbox-list navbox-odd hlist" style="width:100%;padding:0"><div style="padding:0 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Gonadotropin-releasing_hormone" title="Gonadotropin-releasing hormone">Gonadotropin-releasing hormone</a> (GnRH)</th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li>Agonists: <a href="/wiki/Gonadotropin-releasing_hormone" title="Gonadotropin-releasing hormone">Gonadorelin</a></li> <li><a href="/wiki/Nafarelin" title="Nafarelin">Nafarelin</a></li> <li><a href="/wiki/Histrelin" title="Histrelin">Histrelin</a> <a href="/wiki/Gonadotropin-releasing_hormone_antagonist" title="Gonadotropin-releasing hormone antagonist">Antagonists</a>: <a href="/wiki/Cetrorelix" title="Cetrorelix">Cetrorelix</a></li> <li><a class="mw-selflink selflink">Elagolix</a></li> <li><a href="/wiki/Ganirelix" title="Ganirelix">Ganirelix</a></li> <li><a href="/wiki/Relugolix" title="Relugolix">Relugolix</a> (<a href="/wiki/Relugolix/estradiol/norethisterone_acetate" title="Relugolix/estradiol/norethisterone acetate">+estradiol/norethisterone acetate</a>)</li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Somatostatin" title="Somatostatin">Somatostatin</a></th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li>Agonists: <a href="/wiki/Lanreotide" title="Lanreotide">Lanreotide</a></li> <li><a href="/wiki/Octreotide" title="Octreotide">Octreotide</a></li> <li><a href="/wiki/Pasireotide" title="Pasireotide">Pasireotide</a></li> <li><a href="/wiki/Vapreotide" title="Vapreotide">Vapreotide</a></li></ul> </div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Anterior_pituitary" title="Anterior pituitary">Anterior pituitary</a></th><td class="navbox-list-with-group navbox-list navbox-odd hlist" style="width:100%;padding:0"><div style="padding:0 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Adrenocorticotropic_hormone" title="Adrenocorticotropic hormone">Adrenocorticotropic hormone</a> (ACTH)</th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li>Agonists: <a href="/wiki/Corticotropin" class="mw-redirect" title="Corticotropin">Corticotropin</a></li> <li><a href="/wiki/Cosyntropin" class="mw-redirect" title="Cosyntropin">Cosyntropin</a></li> <li><a href="/wiki/Tetracosactide" class="mw-redirect" title="Tetracosactide">Tetracosactide</a></li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Growth_hormone" title="Growth hormone">Growth hormone</a> (GH)</th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li>Agonists: <a href="/wiki/Insulin-like_growth_factor_1" title="Insulin-like growth factor 1">Insulin-like growth factor 1</a> (IGF-1) (<a href="/wiki/Mecasermin" title="Mecasermin">Mecasermin</a>/<a href="/wiki/Mecasermin_rinfabate" title="Mecasermin rinfabate">Mecasermin rinfabate</a>)</li> <li><a href="/wiki/Somapacitan" title="Somapacitan">Somapacitan</a></li> <li><a href="/wiki/Somatrem" title="Somatrem">Somatrem</a></li> <li><a href="/wiki/Somatrogon" title="Somatrogon">Somatrogon</a></li></ul> Antagonists: <a href="/wiki/Pegvisomant" title="Pegvisomant">Pegvisomant</a> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Thyroid-stimulating_hormone" title="Thyroid-stimulating hormone">Thyroid-stimulating hormone</a> (TSH)</th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li>Agonists: <a href="/wiki/Thyrotropin" class="mw-redirect" title="Thyrotropin">Thyrotropin</a></li></ul> </div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Posterior_pituitary" title="Posterior pituitary">Posterior pituitary</a></th><td class="navbox-list-with-group navbox-list navbox-odd hlist" style="width:100%;padding:0"><div style="padding:0 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Oxytocin" title="Oxytocin">Oxytocin</a></th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li>Agonists: <a href="/wiki/Argiprestocin" class="mw-redirect" title="Argiprestocin">Argiprestocin</a></li> <li><a href="/wiki/Carbetocin" title="Carbetocin">Carbetocin</a></li> <li><a href="/w/index.php?title=Cargutocin&action=edit&redlink=1" class="new" title="Cargutocin (page does not exist)">Cargutocin</a></li> <li><a href="/wiki/Demoxytocin" title="Demoxytocin">Demoxytocin</a></li> <li><a href="/w/index.php?title=Nacartocin&action=edit&redlink=1" class="new" title="Nacartocin (page does not exist)">Nacartocin</a> Antagonists: <a href="/wiki/Atosiban" title="Atosiban">Atosiban</a></li> <li><a href="/wiki/Barusiban" title="Barusiban">Barusiban</a></li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Vasopressin" title="Vasopressin">Vasopressin</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Vasopressin_analogue" title="Vasopressin analogue">Agonists</a>: <a href="/wiki/Vasopressin" title="Vasopressin">Argipressin</a></li> <li><a href="/wiki/Desmopressin" title="Desmopressin">Desmopressin</a></li> <li><a href="/wiki/Felypressin" title="Felypressin">Felypressin</a></li> <li><a href="/wiki/Lypressin" class="mw-redirect" title="Lypressin">Lypressin</a></li> <li><a href="/wiki/Ornipressin" title="Ornipressin">Ornipressin</a></li> <li><a href="/wiki/Terlipressin" title="Terlipressin">Terlipressin</a> <a href="/wiki/Vasopressin_receptor_antagonist" title="Vasopressin receptor antagonist">Antagonists</a>: <a href="/wiki/Conivaptan" title="Conivaptan">Conivaptan</a></li> <li><a href="/wiki/Demeclocycline" title="Demeclocycline">Demeclocycline</a></li> <li><a href="/wiki/Lixivaptan" title="Lixivaptan">Lixivaptan</a></li> <li><a href="/wiki/Mozavaptan" title="Mozavaptan">Mozavaptan</a></li> <li><a href="/wiki/Nelivaptan" title="Nelivaptan">Nelivaptan</a></li> <li><a href="/wiki/Relcovaptan" title="Relcovaptan">Relcovaptan</a></li> <li><a href="/wiki/Satavaptan" title="Satavaptan">Satavaptan</a></li> <li><a href="/wiki/Tolvaptan" title="Tolvaptan">Tolvaptan</a></li></ul> </div></td></tr></tbody></table><div></div></td></tr></tbody></table></div> <div class="navbox-styles"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1129693374"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1236075235"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1129693374"></div><div role="navigation" class="navbox" aria-labelledby="GnRHTooltip_Gonadotropin-releasing_hormone_and_gonadotropins" style="padding:3px"><table class="nowraplinks mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1129693374"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1239400231"><div class="navbar plainlinks hlist navbar-mini"><ul><li class="nv-view"><a href="/wiki/Template:GnRH_and_gonadotropins" title="Template:GnRH and gonadotropins"><abbr title="View this template">v</abbr></a></li><li class="nv-talk"><a href="/wiki/Template_talk:GnRH_and_gonadotropins" title="Template talk:GnRH and gonadotropins"><abbr title="Discuss this template">t</abbr></a></li><li class="nv-edit"><a href="/wiki/Special:EditPage/Template:GnRH_and_gonadotropins" title="Special:EditPage/Template:GnRH and gonadotropins"><abbr title="Edit this template">e</abbr></a></li></ul></div><div id="GnRHTooltip_Gonadotropin-releasing_hormone_and_gonadotropins" style="font-size:114%;margin:0 4em"><a href="/wiki/Gonadotropin-releasing_hormone" title="Gonadotropin-releasing hormone"><abbr title="Gonadotropin-releasing hormone">GnRH</abbr></a><span class="sr-only" style="border: 0; clip: rect(0, 0, 0, 0); clip-path: polygon(0px 0px, 0px 0px, 0px 0px); height: 1px; margin: -1px; overflow: hidden; padding: 0; position: absolute; width: 1px; white-space: nowrap;">Tooltip Gonadotropin-releasing hormone and <a href="/wiki/Gonadotropin" title="Gonadotropin">gonadotropins</a></div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="/wiki/Gonadotropin-releasing_hormone_modulator" title="Gonadotropin-releasing hormone modulator"><abbr title="Gonadotropin-releasing hormone">GnRH</abbr> modulators</a> (incl. <a href="/wiki/Gonadotropin-releasing_hormone_analogue" class="mw-redirect" title="Gonadotropin-releasing hormone analogue">analogues</a>)</th><td class="navbox-list-with-group navbox-list navbox-odd hlist" style="width:100%;padding:0;background:#DDDDFF;"><div style="padding:0 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:9em;;text-align:center;"><a href="/wiki/Gonadotropin-releasing_hormone_agonist" title="Gonadotropin-releasing hormone agonist">Agonists</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="padding:0"><div style="padding:0 0.25em"> <ul><li>Peptide: <a href="/wiki/Azagly-nafarelin" title="Azagly-nafarelin">Azagly-nafarelin</a></li> <li><a href="/wiki/Buserelin" title="Buserelin">Buserelin</a></li> <li><a href="/wiki/Deslorelin" title="Deslorelin">Deslorelin</a></li> <li><a href="/wiki/Fertirelin" title="Fertirelin">Fertirelin</a></li> <li><a href="/wiki/Gonadorelin" title="Gonadorelin">Gonadorelin</a></li> <li><a href="/wiki/Goserelin" title="Goserelin">Goserelin</a></li> <li><a href="/wiki/Histrelin" title="Histrelin">Histrelin</a></li> <li><a href="/wiki/Lecirelin" title="Lecirelin">Lecirelin</a></li> <li><a href="/wiki/Leuprorelin" title="Leuprorelin">Leuprorelin (leuprolide)</a></li> <li><a href="/wiki/Nafarelin" title="Nafarelin">Nafarelin</a></li> <li><a href="/wiki/Peforelin" title="Peforelin">Peforelin</a></li> <li><a href="/wiki/Triptorelin" title="Triptorelin">Triptorelin</a></li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:9em;;text-align:center;"><a href="/wiki/Gonadotropin-releasing_hormone_antagonist" title="Gonadotropin-releasing hormone antagonist">Antagonists</a></th><td class="navbox-list-with-group navbox-list navbox-even" style="padding:0"><div style="padding:0 0.25em"> <ul><li>Peptide: <a href="/wiki/Abarelix" title="Abarelix">Abarelix</a></li> <li><a href="/wiki/Cetrorelix" title="Cetrorelix">Cetrorelix</a></li> <li><a href="/wiki/Degarelix" title="Degarelix">Degarelix</a></li> <li><a href="/wiki/Ganirelix" title="Ganirelix">Ganirelix</a></li></ul> <ul><li>Non-peptide: <a class="mw-selflink selflink">Elagolix</a></li> <li><a href="/wiki/Linzagolix" title="Linzagolix">Linzagolix</a>†</li> <li><a href="/wiki/Relugolix" title="Relugolix">Relugolix</a> (<a href="/wiki/Relugolix/estradiol/norethisterone_acetate" title="Relugolix/estradiol/norethisterone acetate">+estradiol/norethisterone acetate</a>)</li></ul> </div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="/wiki/Gonadotropin" title="Gonadotropin">Gonadotropins</a></th><td class="navbox-list-with-group navbox-list navbox-odd hlist" style="width:100%;padding:0;background:#DDDDFF;"><div style="padding:0 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th id="Preparations" scope="row" class="navbox-group" style="width:9em;;text-align:center;"><a href="/wiki/Gonadotropin_preparation" class="mw-redirect" title="Gonadotropin preparation">Preparations</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Follicle-stimulating_hormone" title="Follicle-stimulating hormone">Follicle-stimulating hormone</a></li> <li><a href="/wiki/Human_chorionic_gonadotropin" title="Human chorionic gonadotropin">Human chorionic gonadotropin</a></li> <li><a href="/wiki/Luteinizing_hormone" title="Luteinizing hormone">Luteinizing hormone</a></li> <li><a href="/wiki/Menotropin" title="Menotropin">Menotropin</a></li> <li><a href="/wiki/Urofollitropin" title="Urofollitropin">Urofollitropin</a></li></ul> </div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others (indirect)</th><td class="navbox-list-with-group navbox-list navbox-odd hlist" style="width:100%;padding:0;background:#DDDDFF;"><div style="padding:0 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:8em;;text-align:center;"><a href="/wiki/Progonadotropin" title="Progonadotropin">Progonadotropins</a></th><td class="navbox-list-with-group navbox-list navbox-even" style="padding:0"><div style="padding:0 0.25em"> <ul><li>Sex steroid antagonists (via disinhibition of the <a href="/wiki/Hypothalamic-pituitary-gonadal_axis" class="mw-redirect" title="Hypothalamic-pituitary-gonadal axis"><abbr title="hypothalamic–pituitary–gonadal">HPG</abbr> axis</a>): <a href="/wiki/Antiandrogen" title="Antiandrogen">Antiandrogens</a> (e.g., <a href="/wiki/Flutamide" title="Flutamide">flutamide</a>, <a href="/wiki/Bicalutamide" title="Bicalutamide">bicalutamide</a>, <a href="/wiki/Enzalutamide" title="Enzalutamide">enzalutamide</a>)</li> <li><a href="/wiki/Antiestrogen" title="Antiestrogen">Antiestrogens</a>/<a href="/wiki/Selective_estrogen_receptor_modulators" class="mw-redirect" title="Selective estrogen receptor modulators"><abbr title="Selective estrogen receptor modulators">SERMs</abbr></a><span class="sr-only" style="border: 0; clip: rect(0, 0, 0, 0); clip-path: polygon(0px 0px, 0px 0px, 0px 0px); height: 1px; margin: -1px; overflow: hidden; padding: 0; position: absolute; width: 1px; white-space: nowrap;">Tooltip Selective estrogen receptor modulators (e.g., <a href="/wiki/Tamoxifen" title="Tamoxifen">tamoxifen</a>, <a href="/wiki/Clomifene" title="Clomifene">clomifene</a>, <a href="/wiki/Enclomifene" title="Enclomifene">enclomifene</a>)</li> <li><a href="/wiki/Aromatase_inhibitor" title="Aromatase inhibitor">Aromatase inhibitors</a> (e.g., <a href="/wiki/Anastrozole" title="Anastrozole">anastrozole</a>)</li> <li><a href="/wiki/GnRH_agonist" class="mw-redirect" title="GnRH agonist"><abbr title="gonadotropin-releasing hormone">GnRH</abbr> agonists</a> (e.g., <a href="/wiki/Gonadotropin-releasing_hormone" title="Gonadotropin-releasing hormone"><abbr title="gonadotropin-releasing hormone">GnRH</abbr></a><span class="sr-only" style="border: 0; clip: rect(0, 0, 0, 0); clip-path: polygon(0px 0px, 0px 0px, 0px 0px); height: 1px; margin: -1px; overflow: hidden; padding: 0; position: absolute; width: 1px; white-space: nowrap;">Tooltip gonadotropin-releasing hormone)</li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:8em;;text-align:center;"><a href="/wiki/Antigonadotropin" title="Antigonadotropin">Antigonadotropins</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="padding:0"><div style="padding:0 0.25em"> <ul><li>Sex steroid agonists (via negative feedback on the <a href="/wiki/Hypothalamic-pituitary-gonadal_axis" class="mw-redirect" title="Hypothalamic-pituitary-gonadal axis"><abbr title="hypothalamic–pituitary–gonadal">HPG</abbr> axis</a>): <a href="/wiki/Androgen" title="Androgen">Androgens</a>/<a href="/wiki/Anabolic_steroid" title="Anabolic steroid">anabolic steroids</a> (e.g., <a href="/wiki/Testosterone_(medication)" title="Testosterone (medication)">testosterone</a>, <a href="/wiki/Nandrolone_ester" class="mw-redirect" title="Nandrolone ester">nandrolone esters</a>, <a href="/wiki/Oxandrolone" title="Oxandrolone">oxandrolone</a>)</li> <li><a href="/wiki/D2_receptor" class="mw-redirect" title="D2 receptor">D2 receptor</a> <a href="/wiki/Dopamine_antagonist" title="Dopamine antagonist">antagonists</a> (<a href="/wiki/Prolactin_releaser" class="mw-redirect" title="Prolactin releaser">prolactin releasers</a>) (incl., <a href="/wiki/Domperidone" title="Domperidone">domperidone</a>, <a href="/wiki/Metoclopramide" title="Metoclopramide">metoclopramide</a>, <a href="/wiki/Risperidone" title="Risperidone">risperidone</a>, <a href="/wiki/Haloperidol" title="Haloperidol">haloperidol</a>, <a href="/wiki/Chlorpromazine" title="Chlorpromazine">chlorpromazine</a>, <a href="/wiki/Sulpiride" title="Sulpiride">sulpiride</a>)</li> <li><a href="/wiki/Estrogen_(medication)" title="Estrogen (medication)">Estrogens</a> (incl., <a href="/wiki/Bifluranol" title="Bifluranol">bifluranol</a>, <a href="/wiki/Estradiol_(medication)" title="Estradiol (medication)">estradiol</a>, <a href="/wiki/Estradiol_ester" class="mw-redirect" title="Estradiol ester">estradiol esters</a>, <a href="/wiki/Ethinylestradiol" title="Ethinylestradiol">ethinylestradiol</a>, <a href="/wiki/Diethylstilbestrol" title="Diethylstilbestrol">diethylstilbestrol</a>, <a href="/wiki/Paroxypropione" title="Paroxypropione">paroxypropione</a>)</li> <li><a href="/wiki/Progestogen" title="Progestogen">Progestogens</a> (incl. <a href="/wiki/Progestin" class="mw-redirect" title="Progestin">progestins</a>, e.g., <a href="/wiki/Chlormadinone_acetate" title="Chlormadinone acetate">chlormadinone acetate</a>, <a href="/wiki/Cyproterone_acetate" title="Cyproterone acetate">cyproterone acetate</a>, <a href="/wiki/Hydroxyprogesterone_caproate" title="Hydroxyprogesterone caproate">hydroxyprogesterone caproate</a>, <a href="/wiki/Gestonorone_caproate" title="Gestonorone caproate">gestonorone caproate</a>, <a href="/wiki/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">medroxyprogesterone acetate</a>, <a href="/wiki/Megestrol_acetate" title="Megestrol acetate">megestrol acetate</a>)</li></ul> <ul><li>Others (mixed or unknown mechanism of action): <a href="/wiki/Danazol" title="Danazol">Danazol</a></li> <li><a href="/wiki/Gestrinone" title="Gestrinone">Gestrinone</a></li> <li><a href="/wiki/Metallibure" title="Metallibure">Metallibure</a></li></ul> </div></td></tr></tbody></table><div></div></td></tr><tr><td colspan="2" class="navbox-list navbox-even hlist" style="width:100%;padding:0;background:#DDDDFF;"><div style="padding:0 0.25em"><div class="hlist"> <ul><li>#<a href="/wiki/WHO_Model_List_of_Essential_Medicines" title="WHO Model List of Essential Medicines">WHO-EM</a></li> <li>‡<a href="/wiki/List_of_withdrawn_drugs" title="List of withdrawn drugs">Withdrawn</a> from market</li> <li><a href="/wiki/Clinical_trial" title="Clinical trial">Clinical trials</a>: <ul><li>†<a href="/wiki/Phases_of_clinical_research#Phase_III" title="Phases of clinical research">Phase III</a></li> <li>§Never to phase III</li></ul></li></ul> </div> <dl><dt>See also</dt> <dd><a href="/wiki/Template:GnRH_and_gonadotropin_receptor_modulators" title="Template:GnRH and gonadotropin receptor modulators"><abbr title="gonadotropin-releasing hormone">GnRH</abbr> and gonadotropin receptor modulators</a></dd> <dd><a href="/wiki/Template:Androgens_and_antiandrogens" title="Template:Androgens and antiandrogens">Androgens and antiandrogens</a></dd> <dd><a href="/wiki/Template:Estrogens_and_antiestrogens" title="Template:Estrogens and antiestrogens">Estrogens and antiestrogens</a></dd> <dd><a href="/wiki/Template:Progestogens_and_antiprogestogens" title="Template:Progestogens and antiprogestogens">Progestogens and antiprogestogens</a></dd></dl></div></td></tr></tbody></table></div> <div class="navbox-styles"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1129693374"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1236075235"></div><div role="navigation" class="navbox" aria-labelledby="GnRHTooltip_Gonadotropin-releasing_hormone_receptor_and_gonadotropin_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1129693374"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1239400231"><div class="navbar plainlinks hlist navbar-mini"><ul><li class="nv-view"><a href="/wiki/Template:GnRH_and_gonadotropin_receptor_modulators" title="Template:GnRH and gonadotropin receptor modulators"><abbr title="View this template">v</abbr></a></li><li class="nv-talk"><a href="/wiki/Template_talk:GnRH_and_gonadotropin_receptor_modulators" title="Template talk:GnRH and gonadotropin receptor modulators"><abbr title="Discuss this template">t</abbr></a></li><li class="nv-edit"><a href="/wiki/Special:EditPage/Template:GnRH_and_gonadotropin_receptor_modulators" title="Special:EditPage/Template:GnRH and gonadotropin receptor modulators"><abbr title="Edit this template">e</abbr></a></li></ul></div><div id="GnRHTooltip_Gonadotropin-releasing_hormone_receptor_and_gonadotropin_receptor_modulators" style="font-size:114%;margin:0 4em"><a href="/wiki/Gonadotropin-releasing_hormone_receptor" title="Gonadotropin-releasing hormone receptor"><abbr title="Gonadotropin-releasing hormone receptor">GnRH</abbr></a><span class="sr-only" style="border: 0; clip: rect(0, 0, 0, 0); clip-path: polygon(0px 0px, 0px 0px, 0px 0px); height: 1px; margin: -1px; overflow: hidden; padding: 0; position: absolute; width: 1px; white-space: nowrap;">Tooltip Gonadotropin-releasing hormone receptor and <a href="/wiki/Gonadotropin_receptor" title="Gonadotropin receptor">gonadotropin receptor</a> <a href="/wiki/Receptor_modulator" title="Receptor modulator">modulators</a></div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="/wiki/Gonadotropin-releasing_hormone_receptor" title="Gonadotropin-releasing hormone receptor"><abbr title="Gonadotropin-releasing hormone receptor">GnRH</abbr></a><span class="sr-only" style="border: 0; clip: rect(0, 0, 0, 0); clip-path: polygon(0px 0px, 0px 0px, 0px 0px); height: 1px; margin: -1px; overflow: hidden; padding: 0; position: absolute; width: 1px; white-space: nowrap;">Tooltip Gonadotropin-releasing hormone receptor</th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li>Agonists: Peptides: <a href="/w/index.php?title=Alarelin&action=edit&redlink=1" class="new" title="Alarelin (page does not exist)">Alarelin</a></li> <li><a href="/w/index.php?title=Avorelin&action=edit&redlink=1" class="new" title="Avorelin (page does not exist)">Avorelin</a></li> <li><a href="/wiki/Azagly-nafarelin" title="Azagly-nafarelin">Azagly-nafarelin</a></li> <li><a href="/wiki/Buserelin" title="Buserelin">Buserelin</a></li> <li><a href="/wiki/Deslorelin" title="Deslorelin">Deslorelin</a></li> <li><a href="/wiki/Fertirelin" title="Fertirelin">Fertirelin</a></li> <li><a href="/wiki/Gonadotropin-releasing_hormone" title="Gonadotropin-releasing hormone">GnRH</a></li> <li><a href="/wiki/Gonadorelin" title="Gonadorelin">Gonadorelin</a></li> <li><a href="/wiki/Goserelin" title="Goserelin">Goserelin</a></li> <li><a href="/wiki/Histrelin" title="Histrelin">Histrelin</a></li> <li><a href="/wiki/Leuprorelin" title="Leuprorelin">Leuprorelin (leuprolide)</a></li> <li><a href="/w/index.php?title=Lutrelin&action=edit&redlink=1" class="new" title="Lutrelin (page does not exist)">Lutrelin</a></li> <li><a href="/wiki/Nafarelin" title="Nafarelin">Nafarelin</a></li> <li><a href="/wiki/Peforelin" title="Peforelin">Peforelin</a></li> <li><a href="/w/index.php?title=Salmon_GnRH&action=edit&redlink=1" class="new" title="Salmon GnRH (page does not exist)">Salmon GnRH</a></li> <li><a href="/wiki/Triptorelin" title="Triptorelin">Triptorelin</a></li> <li><a href="/w/index.php?title=Zoptarelin&action=edit&redlink=1" class="new" title="Zoptarelin (page does not exist)">Zoptarelin</a></li> <li><a href="/wiki/Zoptarelin_doxorubicin" title="Zoptarelin doxorubicin">Zoptarelin doxorubicin</a></li></ul> <ul><li>Antagonists: Peptides: <a href="/wiki/Abarelix" title="Abarelix">Abarelix</a></li> <li><a href="/wiki/Acyline" title="Acyline">Acyline</a></li> <li><a href="/w/index.php?title=Azaline_B&action=edit&redlink=1" class="new" title="Azaline B (page does not exist)">Azaline B</a></li> <li><a href="/wiki/Cetrorelix" title="Cetrorelix">Cetrorelix</a></li> <li><a href="/wiki/Degarelix" title="Degarelix">Degarelix</a></li> <li><a href="/w/index.php?title=Detirelix&action=edit&redlink=1" class="new" title="Detirelix (page does not exist)">Detirelix</a></li> <li><a href="/wiki/Ganirelix" title="Ganirelix">Ganirelix</a></li> <li><a href="/w/index.php?title=Iturelix&action=edit&redlink=1" class="new" title="Iturelix (page does not exist)">Iturelix (antide)</a></li> <li><a href="/w/index.php?title=LXT-101&action=edit&redlink=1" class="new" title="LXT-101 (page does not exist)">LXT-101</a></li> <li><a href="/w/index.php?title=Ornirelix&action=edit&redlink=1" class="new" title="Ornirelix (page does not exist)">Ornirelix (ornitide)</a></li> <li><a href="/wiki/Ozarelix" title="Ozarelix">Ozarelix</a></li> <li><a href="/w/index.php?title=Prazarelix&action=edit&redlink=1" class="new" title="Prazarelix (page does not exist)">Prazarelix</a></li> <li><a href="/w/index.php?title=Ramorelix&action=edit&redlink=1" class="new" title="Ramorelix (page does not exist)">Ramorelix</a></li> <li><a href="/w/index.php?title=Teverelix&action=edit&redlink=1" class="new" title="Teverelix (page does not exist)">Teverelix (antarelix)</a>; Non-peptides: <a class="mw-selflink selflink">Elagolix</a></li> <li><a href="/wiki/Linzagolix" title="Linzagolix">Linzagolix</a></li> <li><a href="/wiki/Opigolix" title="Opigolix">Opigolix</a></li> <li><a href="/wiki/Relugolix" title="Relugolix">Relugolix</a></li> <li><a href="/wiki/Sufugolix" title="Sufugolix">Sufugolix</a></li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="/wiki/Gonadotropin_receptor" title="Gonadotropin receptor">Gonadotropin</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="/wiki/Luteinizing_hormone/choriogonadotropin_receptor" title="Luteinizing hormone/choriogonadotropin receptor"><abbr title="Luteinizing hormone/choriogonadotropin receptor">LH/hCG</abbr></a><span class="sr-only" style="border: 0; clip: rect(0, 0, 0, 0); clip-path: polygon(0px 0px, 0px 0px, 0px 0px); height: 1px; margin: -1px; overflow: hidden; padding: 0; position: absolute; width: 1px; white-space: nowrap;">Tooltip Luteinizing hormone/choriogonadotropin receptor</th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li>Agonists: Peptides: <a href="/wiki/Choriogonadotropin_alfa" class="mw-redirect" title="Choriogonadotropin alfa">Choriogonadotropin alfa</a></li> <li><a href="/wiki/Human_chorionic_gonadotropin" title="Human chorionic gonadotropin">Human chorionic gonadotropin</a></li> <li><a href="/wiki/Luteinizing_hormone" title="Luteinizing hormone">Luteinizing hormone</a></li> <li><a href="/wiki/Lutropin_alfa" class="mw-redirect" title="Lutropin alfa">Lutropin alfa</a></li> <li><a href="/wiki/Menotropin" title="Menotropin">Menotropin (human menopausal gonadotropin)</a></li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="/wiki/Follicle-stimulating_hormone_receptor" title="Follicle-stimulating hormone receptor"><abbr title="Follicle-stimulating hormone receptor">FSH</abbr></a><span class="sr-only" style="border: 0; clip: rect(0, 0, 0, 0); clip-path: polygon(0px 0px, 0px 0px, 0px 0px); height: 1px; margin: -1px; overflow: hidden; padding: 0; position: absolute; width: 1px; white-space: nowrap;">Tooltip Follicle-stimulating hormone receptor</th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li>Agonists: Peptides: <a href="/wiki/Corifollitropin_alfa" class="mw-redirect" title="Corifollitropin alfa">Corifollitropin alfa</a></li> <li><a href="/wiki/Follicle-stimulating_hormone" title="Follicle-stimulating hormone">Follicle-stimulating hormone</a></li> <li><a href="/wiki/Follitropin_alfa" class="mw-redirect" title="Follitropin alfa">Follitropin alfa</a></li> <li><a href="/wiki/Follitropin_beta" class="mw-redirect" title="Follitropin beta">Follitropin beta</a></li> <li><a href="/w/index.php?title=Follitropin_epsilon&action=edit&redlink=1" class="new" title="Follitropin epsilon (page does not exist)">Follitropin epsilon</a></li> <li><a href="/wiki/Menotropin" title="Menotropin">Menotropin (human menopausal gonadotropin)</a></li> <li><a href="/wiki/Urofollitropin" title="Urofollitropin">Urofollitropin</a></li> <li><a href="/w/index.php?title=Varfollitropin_alfa&action=edit&redlink=1" class="new" title="Varfollitropin alfa (page does not exist)">Varfollitropin alfa</a></li></ul> <ul><li><abbr title="negative allosteric modulators">NAMs</abbr>: Non-peptides: <a href="/w/index.php?title=ADX-61623&action=edit&redlink=1" class="new" title="ADX-61623 (page does not exist)">ADX-61623</a></li></ul> </div></td></tr></tbody></table><div></div></td></tr></tbody></table></div> <style data-mw-deduplicate="TemplateStyles:r1130092004">.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;justify-content:center;align-items:baseline}.mw-parser-output .portal-bar-bordered{padding:0 2em;background-color:#fdfdfd;border:1px solid #a2a9b1;clear:both;margin:1em auto 0}.mw-parser-output .portal-bar-related{font-size:100%;justify-content:flex-start}.mw-parser-output .portal-bar-unbordered{padding:0 1.7em;margin-left:0}.mw-parser-output .portal-bar-header{margin:0 1em 0 0.5em;flex:0 0 auto;min-height:24px}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;flex:0 1 auto;padding:0.15em 0;column-gap:1em;align-items:baseline;margin:0;list-style:none}.mw-parser-output .portal-bar-content-related{margin:0;list-style:none}.mw-parser-output .portal-bar-item{display:inline-block;margin:0.15em 0.2em;min-height:24px;line-height:24px}@media screen and (max-width:768px){.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;flex-flow:column wrap;align-items:baseline}.mw-parser-output .portal-bar-header{text-align:center;flex:0;padding-left:0.5em;margin:0 auto}.mw-parser-output .portal-bar-related{font-size:100%;align-items:flex-start}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:center;flex:0;column-gap:1em;border-top:1px solid #a2a9b1;margin:0 auto;list-style:none}.mw-parser-output .portal-bar-content-related{border-top:none;margin:0;list-style:none}}.mw-parser-output .navbox+link+.portal-bar,.mw-parser-output .navbox+style+.portal-bar,.mw-parser-output .navbox+link+.portal-bar-bordered,.mw-parser-output .navbox+style+.portal-bar-bordered,.mw-parser-output .sister-bar+link+.portal-bar,.mw-parser-output .sister-bar+style+.portal-bar,.mw-parser-output .portal-bar+.navbox-styles+.navbox,.mw-parser-output .portal-bar+.navbox-styles+.sister-bar{margin-top:-1px}</style><div class="portal-bar noprint metadata noviewer portal-bar-bordered" role="navigation" aria-label="Portals"><a href="/wiki/Wikipedia:Contents/Portals" title="Wikipedia:Contents/Portals">Portal</a>:<ul class="portal-bar-content"><li class="portal-bar-item"><img alt="icon" src="//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/WHO_Rod.svg/8px-WHO_Rod.svg.png" decoding="async" width="8" height="19" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/WHO_Rod.svg/12px-WHO_Rod.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/d/d6/WHO_Rod.svg/16px-WHO_Rod.svg.png 2x" data-file-width="107" data-file-height="250" /> <a href="/wiki/Portal:Medicine" title="Portal:Medicine">Medicine</a></li></ul></div>    </div><noscript><img src="https://login.wikimedia.org/wiki/Special:CentralAutoLogin/start?type=1x1" alt="" width="1" height="1" style="border: none; position: absolute;"></noscript> <div class="printfooter" data-nosnippet="">Retrieved from "<a dir="ltr" href="https://en.wikipedia.org/w/index.php?title=Elagolix&oldid=1257903058">https://en.wikipedia.org/w/index.php?title=Elagolix&oldid=1257903058</a>"</div></div> <div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/wiki/Help:Category" title="Help:Category">Categories</a>: <ul><li><a href="/wiki/Category:Drugs_developed_by_AbbVie" title="Category:Drugs developed by AbbVie">Drugs developed by AbbVie</a></li><li><a href="/wiki/Category:Amines" title="Category:Amines">Amines</a></li><li><a href="/wiki/Category:CYP3A4_inducers" title="Category:CYP3A4 inducers">CYP3A4 inducers</a></li><li><a href="/wiki/Category:Ethers" title="Category:Ethers">Ethers</a></li><li><a href="/wiki/Category:Fluoroarenes" title="Category:Fluoroarenes">Fluoroarenes</a></li><li><a href="/wiki/Category:GnRH_antagonists" title="Category:GnRH antagonists">GnRH antagonists</a></li><li><a href="/wiki/Category:Lactams" title="Category:Lactams">Lactams</a></li><li><a href="/wiki/Category:Pyrimidinediones" title="Category:Pyrimidinediones">Pyrimidinediones</a></li><li><a href="/wiki/Category:Trifluoromethyl_compounds" title="Category:Trifluoromethyl compounds">Trifluoromethyl compounds</a></li><li><a href="/wiki/Category:Triketones" title="Category:Triketones">Triketones</a></li><li><a href="/wiki/Category:Uracil_derivatives" title="Category:Uracil derivatives">Uracil derivatives</a></li></ul></div><div id="mw-hidden-catlinks" class="mw-hidden-catlinks mw-hidden-cats-hidden">Hidden categories: <ul><li><a href="/wiki/Category:Webarchive_template_wayback_links" title="Category:Webarchive template wayback links">Webarchive template wayback links</a></li><li><a href="/wiki/Category:Articles_with_short_description" title="Category:Articles with short description">Articles with short description</a></li><li><a href="/wiki/Category:Short_description_matches_Wikidata" title="Category:Short description matches Wikidata">Short description matches Wikidata</a></li><li><a href="/wiki/Category:ECHA_InfoCard_ID_from_Wikidata" title="Category:ECHA InfoCard ID from Wikidata">ECHA InfoCard ID from Wikidata</a></li><li><a href="/wiki/Category:Multiple_chemicals_in_Infobox_drug" title="Category:Multiple chemicals in Infobox drug">Multiple chemicals in Infobox drug</a></li><li><a href="/wiki/Category:Chemicals_using_indexlabels" title="Category:Chemicals using indexlabels">Chemicals using indexlabels</a></li><li><a href="/wiki/Category:Chemical_articles_with_multiple_CAS_registry_numbers" title="Category:Chemical articles with multiple CAS registry numbers">Chemical articles with multiple CAS registry numbers</a></li><li><a href="/wiki/Category:Articles_containing_unverified_chemical_infoboxes" title="Category:Articles containing unverified chemical infoboxes">Articles containing unverified chemical infoboxes</a></li><li><a href="/wiki/Category:All_articles_with_unsourced_statements" title="Category:All articles with unsourced statements">All articles with unsourced statements</a></li><li><a href="/wiki/Category:Articles_with_unsourced_statements_from_February_2019" title="Category:Articles with unsourced statements from February 2019">Articles with unsourced statements from February 2019</a></li><li><a href="/wiki/Category:Articles_containing_potentially_dated_statements_from_November_2018" title="Category:Articles containing potentially dated statements from November 2018">Articles containing potentially dated statements from November 2018</a></li><li><a href="/wiki/Category:All_articles_containing_potentially_dated_statements" title="Category:All articles containing potentially dated statements">All articles containing potentially dated statements</a></li></ul></div></div> </div> </main> </div> <div class="mw-footer-container"> <footer id="footer" class="mw-footer" > <ul id="footer-info"> <li id="footer-info-lastmod"> This page was last edited on 17 November 2024, at 05:02 (UTC).</li> <li id="footer-info-copyright">Text is available under the <a href="/wiki/Wikipedia:Text_of_the_Creative_Commons_Attribution-ShareAlike_4.0_International_License" title="Wikipedia:Text of the Creative Commons Attribution-ShareAlike 4.0 International License">Creative Commons Attribution-ShareAlike 4.0 License</a>; additional terms may apply. By using this site, you agree to the <a href="https://foundation.wikimedia.org/wiki/Special:MyLanguage/Policy:Terms_of_Use" class="extiw" title="foundation:Special:MyLanguage/Policy:Terms of Use">Terms of Use</a> and <a href="https://foundation.wikimedia.org/wiki/Special:MyLanguage/Policy:Privacy_policy" class="extiw" title="foundation:Special:MyLanguage/Policy:Privacy policy">Privacy Policy</a>. Wikipedia® is a registered trademark of the <a rel="nofollow" class="external text" href="https://wikimediafoundation.org/">Wikimedia Foundation, Inc.</a>, a non-profit organization.</li> </ul> <ul id="footer-places"> <li id="footer-places-privacy"><a href="https://foundation.wikimedia.org/wiki/Special:MyLanguage/Policy:Privacy_policy">Privacy policy</a></li> <li id="footer-places-about"><a href="/wiki/Wikipedia:About">About Wikipedia</a></li> <li id="footer-places-disclaimers"><a href="/wiki/Wikipedia:General_disclaimer">Disclaimers</a></li> <li id="footer-places-contact"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact Wikipedia</a></li> <li id="footer-places-wm-codeofconduct"><a href="https://foundation.wikimedia.org/wiki/Special:MyLanguage/Policy:Universal_Code_of_Conduct">Code of Conduct</a></li> <li id="footer-places-developers"><a href="https://developer.wikimedia.org">Developers</a></li> <li id="footer-places-statslink"><a href="https://stats.wikimedia.org/#/en.wikipedia.org">Statistics</a></li> <li id="footer-places-cookiestatement"><a href="https://foundation.wikimedia.org/wiki/Special:MyLanguage/Policy:Cookie_statement">Cookie statement</a></li> <li id="footer-places-mobileview"><a href="//en.m.wikipedia.org/w/index.php?title=Elagolix&mobileaction=toggle_view_mobile" class="noprint stopMobileRedirectToggle">Mobile view</a></li> </ul> <ul id="footer-icons" class="noprint"> <li id="footer-copyrightico"><a href="https://wikimediafoundation.org/" class="cdx-button cdx-button--fake-button cdx-button--size-large cdx-button--fake-button--enabled"><img src="/static/images/footer/wikimedia-button.svg" width="84" height="29" alt="Wikimedia Foundation" loading="lazy"></a></li> <li id="footer-poweredbyico"><a href="https://www.mediawiki.org/" class="cdx-button cdx-button--fake-button cdx-button--size-large cdx-button--fake-button--enabled"><img src="/w/resources/assets/poweredby_mediawiki.svg" alt="Powered by MediaWiki" width="88" height="31" loading="lazy"></a></li> </ul> </footer> </div> </div> </div> <div class="vector-settings" id="p-dock-bottom"> <ul></ul> </div><script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgHostname":"mw-web.codfw.main-f69cdc8f6-nv2q5","wgBackendResponseTime":161,"wgPageParseReport":{"limitreport":{"cputime":"1.109","walltime":"1.375","ppvisitednodes":{"value":12182,"limit":1000000},"postexpandincludesize":{"value":289068,"limit":2097152},"templateargumentsize":{"value":16855,"limit":2097152},"expansiondepth":{"value":22,"limit":100},"expensivefunctioncount":{"value":6,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":267997,"limit":5000000},"entityaccesscount":{"value":1,"limit":400},"timingprofile":["100.00% 1133.470 1 -total"," 29.71% 336.778 1 Template:Infobox_drug"," 28.20% 319.659 1 Template:Reflist"," 25.72% 291.525 3 Template:Infobox"," 11.46% 129.902 26 Template:Cite_journal"," 11.31% 128.249 14 Template:Cite_web"," 10.92% 123.768 10 Template:Navbox"," 7.73% 87.587 1 Template:Pituitary_and_hypothalamic_hormones_and_analogues"," 6.65% 75.429 1 Template:Short_description"," 5.96% 67.535 17 Template:Unbulleted_list"]},"scribunto":{"limitreport-timeusage":{"value":"0.515","limit":"10.000"},"limitreport-memusage":{"value":10455739,"limit":52428800}},"cachereport":{"origin":"mw-web.codfw.main-f69cdc8f6-gdkxt","timestamp":"20241122150320","ttl":2592000,"transientcontent":false}}});});</script> <script type="application/ld+json">{"@context":"https:\/\/schema.org","@type":"Article","name":"Elagolix","url":"https:\/\/en.wikipedia.org\/wiki\/Elagolix","sameAs":"http:\/\/www.wikidata.org\/entity\/Q21098999","mainEntity":"http:\/\/www.wikidata.org\/entity\/Q21098999","author":{"@type":"Organization","name":"Contributors to Wikimedia projects"},"publisher":{"@type":"Organization","name":"Wikimedia Foundation, Inc.","logo":{"@type":"ImageObject","url":"https:\/\/www.wikimedia.org\/static\/images\/wmf-hor-googpub.png"}},"datePublished":"2015-10-12T10:28:33Z","dateModified":"2024-11-17T05:02:38Z","image":"https:\/\/upload.wikimedia.org\/wikipedia\/commons\/6\/67\/Elagolix.svg","headline":"chemical compound"}</script> </body> </html>